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Levels of the enzyme α-methylacyl-CoA racemase (AMACR) are increased 
ca. 9-fold in prostate cancer cells. AMACR is a very promising novel drug 
target as reducing AMACR levels converts castrate-resistant prostate cancer 
cells to androgen-dependent cells which will respond to androgen-deprivation. 
Despite the importance of AMACR in prostate and other cancers, there are 
very limited numbers of AMACR inhibitors described to-date. This is mainly 
due to the absence of a high-throughput assay for the screening of inhibitors 
against AMACR. The active-site residues and catalytic mechanism of human 
AMACR are still unknown, which make the rational design of drugs targeting 
AMACR very difficult. A range of novel potential inhibitors were synthesised 
using a rational drug design approach to explore the structure-activity 
relationship (SAR) on the side-chains of AMACR inhibitors. Their potencies 
were assessed using the fluoride elimination assay based on 1H and 19F NMR. 
Potency, mode of binding and kinetic parameters of these inhibitors were 
assessed using the multi-well colorimetric assay, which is the first AMACR 
high-throughput continuous assay reported to-date. A site-directed 
mutagenesis study was carried out to identify the active-site residues and 
catalytic mechanism of human AMACR. His-122, Asp-152, Met-184 and Glu-
237 were identified as potential active-site residues, so the cDNA was mutated 
and expressed. The activity of wild-type and mutant AMACR enzymes were 
assessed using the deuterium wash-in, fluoride elimination and multi-well 
colorimetric assays. Results from these assays showed that human AMACR 
does not operate using a ‘two-base’ mechanism. Instead, it operates using a 
‘one-base’ mechanism, most likely via water molecules acting as 
intermediaries within the hydrogen-bondings network in the active site. The 
knowledge obtained from this research informs rational drug design for this 
castrate-resistant prostate cancer target. 
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Description of the AMACR ‘racemisation’ reaction  
Conventionally racemisation refers to the process of converting an 
enantiomerically pure compound to a racemic mixture of R- and S- 
compounds. AMACR is an enzyme that catalyses the conversion of a single 
chiral centre (at the 2-methyl position) of R- or S- configuration to a near 1:1 
mixture of ‘epimers’,1, 2 while all other chiral centres of the acyl-CoA moiety are 
unaffected. The conventional definition of racemisation would require 
production of a 1:1 mixture of all chiral centres, which is clearly not that case 
for AMACR. However, the AMACR catalysed reaction should not be called 
epimerisation either because even though only one chiral centre is involved, it 
is not converted to the opposite configuration (from R- to S- configuration or 
vice versa); rather the end product is a nearly 1:1 racemic mixture. Hence, the 
reaction performed by AMACR is referred to as ‘racemisation’,3 implying 
change of stereochemical configuration only at the centre bearing the 2-methyl 

















Syn- and anti- terminology 
The syn- and anti- terminology refer to the relative orientations of the fluorine 
atom and methyl group of 3-fluoro-2-methyldecanoyl-CoAs. Syn- refers to 
















1.1 The prostate  
The prostate is a tubulo-alveolar gland that belongs to the male reproductive 
system. Following the production of testosterone from the foetus’s testes at 
the 8th week of gestation, the prostate forms 2 weeks later. The prostate starts 
from solid outgrowths of the urethral epithelium upon signalling by 5α-
dihydrotestosterone (DHT).4 These solid outgrowths develop into specialised 
tissues with distinct functions in the prostate and continue developing during 
gestation. The prostate weighs a few grams at birth and continues to grow to 
approximately 20 g in a young male adult.5 
 
The prostate has a ‘walnut’ shape and is located at the neck of the bladder 
(Figure 1.1). The urethra runs from the bladder and goes through the centre 
of the prostate. During ejaculation, the prostate secretes its contents into the 
urethra which mixes with the sperm and secretions from the seminal vesicle.6 
 
 
Figure 1.1: The location of the prostate as part of the male reproductive system. This 
diagram is not to actual scale but an illustration of the approximate positions of the organs. 
 
1.2 Functions of the prostate 
The prostate plays an important role in facilitating fertility. It produces a range 
of molecules and enzymes including fibrinolysin and coagulase which are 
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involved in the coagulation of the ejaculate5 and proteases such as prostate-
specific antigen (PSA) which help to break down the seminal coagulum.6 As 
the seminal fluid is slightly alkaline, it neutralises the acidity of the urethra and 
vagina, and ensures the survival of spermatozoa.5 Glycoproteins in the 
seminal fluid have a lubricating property which could improve sperm motility.6 
The prostatic fluid also has a high zinc content which acts as an antibacterial 
agent. The acid phosphatase enzyme produced by the prostate is involved in 
the conversion of phosphorylcholine to choline, which is a nutrient source for 
spermatozoa.5 As the urethra passes through the prostate, it also plays a role 
in the transmission of seminal fluid and in controlling urine output (which can 
result in urinary problems with the enlargement of prostate). The prostate also 
has an endocrine function, where its 5α-reductase enzyme converts 
testosterone to DHT, a more potent hormone with a greater affinity for 
androgen receptors.5, 7 
 
1.3 Prostate conditions 
There are some common prostate problems, such as prostatitis, benign 
prostatic hyperplasia (BPH) and prostate cancer. 
 
1.3.1 Prostatitis 
Prostatitis refers to the inflammation of the prostate. This condition affects 
about 10% of the male population with the majority of those affected in their 
40s.8 Prostatitis can be classified into four categories, where category I is 
acute bacterial prostatitis; category II is chronic bacterial prostatitis; category 
III is chronic pelvic pain syndrome which is sub-divided into IIIa (inflammatory) 
and IIIb (non-inflammatory) and lastly category IV which is asymptomatic 
inflammatory prostatitis.9 Acute bacterial prostatitis can be easily treated with 
antibiotics.8, 9 The first line treatment for chronic prostatitis is an α-adrenergic 
antagonist such as tamsulosin and alfuzosin for patients with slow urinary 
flow.10 The choice of antibiotics will depend on the species of bacterial present 






1.3.2 Benign prostatic hyperplasia (BPH) 
BPH refers to the non-malignant enlargement of the prostate due to 
overgrowth of periurethral prostatic tissue.11, 12 As mentioned previously, the 
urethra runs through the prostate, so that when the surrounding tissue of the 
prostate overgrows, it exerts extra pressure on the urethra and causes 
resistance to urinary flow. This leads to lower urinary tract symptoms such as 
difficulty in urination, a frequent urge to urinate and nocturia.11 BPH is age-
related; only 8% of men in their 30s experience it but about 90% of those aged 
90 years do.11 It can be managed medically with α-adrenergic antagonists (e.g. 
tamsulosin) or 5-α-reductase inhibitors (e.g. finasteride).13 In severe cases, 
prostatectomy can be performed.13 
 
1.3.3 Prostate cancer  
Prostate cancer is the most common cancer in males in most developed 
countries including the U.K. and is the second most common cancer 
worldwide.14 Developed countries have a six times higher incidence of 
prostate cancer (56.2 cases per 100 000 population) in comparison to less 
developed countries (9.4 cases per 100 000 population).14 In 2012, over 1.11 
million men were diagnosed with prostate cancer worldwide and ca. 417 000 
new diagnoses were in Europe alone.15 After lung cancer, prostate cancer is 
the leading cause of cancer death in men.15, 16 It caused 92 300 deaths in 
Europe in 201215 and 29 480 deaths in the U.S.A. in 2014.16 Approximately 
one in six men will be diagnosed with prostate cancer in their lifetime.17 The 5-
year survival rate for men diagnosed with prostate cancer in England and 
Wales is 85% according to data from 2010-11.15 As prostate cancer is an age-
related condition, all men will eventually get histological prostate cancer if they 
live long enough.18 Older men (66 years old and above) with localised prostate 
cancer are more likely to die with prostate cancer rather than die from prostate 
cancer.19 
 
1.4 Risk factors of prostate cancer 
Risk factors of developing prostate cancer include age, ethnicity, family 




1.4.1 Age  
Prostate cancer is relatively rare in younger men, with the risk of 0.005% for 
those below 39 years old.20 The risk increases with age, from 2.2% (40-59 
years old) to 13.7% (60-79 years old).20 Most cases (~85%) are diagnosed in 
patients over 65 years old.21 
 
1.4.2 Ethnicity 
African Americans have the highest risk of developing prostate cancer. Their 
risk of having prostate cancer is 61% higher than Caucasians, 68% higher 
than Hispanics and 72% higher than Asians.22 African Americans are twice as 
likely to die from prostate cancer compared with Caucasians23 and 5 times as 
likely compared with Asians.22 It is not known whether the differences are 
purely due to an inherent difference from ethnicity, or whether cultural 
differences and socioeconomic status play a role.23 
 
1.4.3 Family history and genetics 
The risk of a man developing prostate cancer is increased by 2 times if one of 
his first-degree relatives (a father or brother) has a history of prostate 
cancer.22, 24 This risk increases with the increase in the number of affected 
first-degree relatives. The man will have 5 to 11 times higher risk if 2 or 3 of 
his first-degree relatives have been affected.24 Men also tend to develop 
prostate cancer at an earlier age (6-7 years earlier) when they have first-
degree relatives with a history of prostate cancer compared to those without 
such family history.22 
 
To determine whether genetics play a role, studies have been conducted to 
compare the concordance rates of prostate cancer (rates of both twins affected 
by prostate cancer) in monozygotic twins and dizygotic twins.25, 26 It has been 
found that monozygotic twins tend to have a higher concordance rate (~27%) 








Japanese Americans have a higher risk of prostate cancer compared to 
Japanese males who live in their native land due to the influence of their diet.22 
The Western diet with high red meat intake and high dairy product 
consumption increase their risk of developing prostate cancer.22 Red meats 
and dairy products are a rich source of branched-chain fatty acids and dietary 
levels are linked to the α-methylacyl-CoA racemase (AMACR) enzyme that is 
up-regulated in prostate cancer (vide infra).21, 22 It has also been hypothesised 
that the preparation and cooking of meat at a high temperature could result in 
the production of carcinogens such as heterocyclic amines, which may 
increase the risk of developing prostate cancer.21 
 
1.4.5 Hormones  
Androgens are a class of hormones that bind to androgen receptors and 
include testosterone and its more potent metabolite, dihydrotestosterone 
(DHT).27, 28 Androgen receptors are usually located at the cytoplasm.29 Upon 
binding with the androgen, the receptor translocates into the nucleus and binds 
to the promoter region of the target genes.29 The activation of the androgen 
receptor is important to allow cell proliferation during the growth of a normal 
prostate.30  
 
However, increased androgen receptor activity has been associated with 
prostate cancer.7, 29 It has been found that the receptor can bind to the 
promoter region of the TMPRSS2 gene.31 This causes the rearrangement of 
the chromosome where the promoter region of TMPRSS2 gene fuses with 
oncogenic genes (ERG or ETV1).31 The ERG and ETV1 transcription factors 
are over-expressed and lead to the progression of prostate cancer.32, 33 Animal 
models have also shown that testosterone and DHT can induce the growth of 
prostate cancer.21 The use of androgen-deprivation therapy supports the 
finding that prostate cancer cells are androgen-dependent in the early stages 
of the disease.23, 34 
 
Insulin-like growth factor 1 (IGF-1) also plays a role in cancer cell proliferation 
and differentiation.21  High levels have been associated with an increased risk 
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of prostate cancer.35, 36 The activation of the IGF-1 receptor alters the 
phosphorylation state of the androgen receptor.37 This assists the 
translocation of the androgen receptor from the cytoplasm into the nucleus for 
it to stimulate the growth of prostate cancer.37 
 
1.5 Screening and diagnosis of prostate cancer 
Initial examination of prostate cancer may involve the use of prostate cancer 
biomarkers and digital rectal examination.38 Imaging and biopsy will be used 
to diagnose prostate cancer, and the biopsy will be staged and graded.39, 40 
 
1.5.1 Prostate cancer biomarkers 
Prostate-specific antigen (PSA) is a serine protease secreted by epithelial cells 
of the prostate.6, 41 The function of PSA is to liquefy the seminal coagulum 
upon ejaculation.6 Together with digital rectal examination, PSA has been an 
approved screening tool for prostate cancer in the U.S.A since 1994.38 As PSA 
levels vary among men and change with age, there is no single PSA value that 
is considered to be the ‘normal’ value. As a rule of thumb, serum PSA levels 
that are below 4 ng mL-1 are considered as normal and elevated levels may 
indicate prostate cancer.38, 41 Even though PSA is still the most common 
biomarker for the detection of prostate cancer, it carries a few limitations. 
Some patients may have prostate cancer even though their serum PSA levels 
are below 4 ng mL-1. With PSA levels of 1.1-2.0 ng mL-1, patients have 17% 
prostate cancer risk, and this risk is increased to 24% with PSA levels of 2.1-
3.0 ng mL-1 and 27% with PSA levels of 3.1-4.0 ng mL-1.42, 43 Increased PSA 
levels are not specific to prostate cancer and may be raised in non-malignant 
conditions such as BPH and prostatitis.38 PSA levels are increased in only 
20% of prostate cancer cases but high levels are detected in 30-50% of BPH 
cases.38 To make the matter worse, a large proportion of prostate cancers 
detected are microscopic and may not result in a clinically significant 
condition.41 If treatment is merely based on raised PSA levels, it will result in 
over-diagnosis and unnecessary treatment. Routine screening of prostate 
cancer using PSA has been controversial as there has been a high number of 
over-diagnosed prostate cancer cases in Western countries, such as the 
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U.S.A.44, 45 PSA screening is currently not recommended in Europe as the 
risks outweigh the benefits.42 
 
Other potential prostate cancer markers include the urokinase plasminogen 
activator (a protein that is involved in metastasis by degrading the extracellular 
matrix),38 human kallikrein 2 (a serine protease that is closely related to PSA), 
transforming growth factor-beta 1 (a growth factor that is involved in the 
proliferation and differentiation of cancer cells) and interleukin-6 (a cytokine 
that is involved in immune responses).46 Even though these proteins have 
been shown to be involved in cancer mechanisms and could be potential 
biomarkers for prostate cancer, they have not been extensively validated and 
are not currently used in clinical settings.46 
 
Another very promising prostate cancer marker is the enzyme α-methylacyl-
CoA racemase (AMACR; P504S). AMACR levels are increased ca. 9-fold in 
prostate cancer cells compared to normal cells at both protein and mRNA 
levels.47-49 Immunocytochemical analysis conducted by Jiang et al. showed 
100% positive staining for P504S in prostate cancer cells and only 12% of 
benign prostate cells were stained positive for P504S.50 Honma et al. 
subsequently showed positive staining in ca. 70% of prostate cancer cells and 
negative staining in normal cells (Figure 1.2).51 As P504S is not raised in 
benign prostate conditions, it is a better prostate cancer biomarker compared 
to PSA.50, 51 It is highly sensitive and specific, and has been used clinically to 
help with prostate cancer diagnosis. Immunostaining of P504S on prostate 
needle biopsy (vide infra) can be used as an adjuvant diagnostic tool for 
ambiguous specimens, to differentiate between malignant prostate cancer 





Figure 1.2: Immunostaining performed by Honma et al.51: panel A was stained with anti-
AMACR antibody and positive staining was shown in cancerous cells (long arrows) but 
negative staining was shown in non-cancerous cells (short arrows). Panel B was the 
magnified picture for cancerous cells stained positive by anti-AMACR antibody. Panel C 
was stained with anti-PSA antibody and both cancerous cells (long arrows) and non-
cancerous cells (short arrows) were stained. 
 
1.5.2 Digital rectal examination (DRE) 
Examination of the prostate is carried out by inserting the index finger into the 
rectum and each lobe of prostate (anterior, posterior, medial and two lateral 
lobes) is physically examined for any irregularities.56 This method of detection 
is relatively insensitive as early-stage cancer is usually small and not easily 
palpated.56, 57 When DRE is combined with PSA, the detection rate improves.58 
However, the screening does not reduce the mortality rate from prostate 
cancer.42 
 
1.5.3 Imaging and biopsy 
If prostate cancer is suspected due to raised PSA levels and/or abnormal DRE 
results, a transrectal ultrasound (TRUS)-guided, systematic needle biopsy will 
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be performed.59 The TRUS-guided biopsy has been proven to be a superior 
biopsy method compared to digital-guided biopsy and it is currently the 
standard method for the diagnosis of prostate cancer.59 The procedure is 
performed under local anaesthetic and a set of systematic, laterally directed 
biopsy (at least 10-core biopsies) are taken and sent for analysis.42, 59 These 
samples will be graded and assigned a Gleason score (vide infra).42 A 10-core 
biopsy misses about 22% cases of cancer and a re-biopsy still misses about 
10% cases of cancer.59 The T2-weighted magnetic resonance imaging (T2WI) 
gives good anatomical images of the gland and improves the performance of 
prostate cancer examination.60 Dynamic contrast-enhanced imaging and 
diffusion-weighted imaging has been used to augment T2WI to give a more 
accurate diagnosis.60, 61 
 
1.6 Staging and grading  
The tumour, node, and metastasis (TNM) classification system by the 
American Joint Committee on Cancer (AJCC) is commonly used to stage 
prostate cancer.39 All three categories, T, N and M are given a score where 
the higher the score is, the more advanced the disease is. The T category is 
to determine the local extent of a prostate tumour: T1 is a tumour that is not 
detectable clinically or via imaging while T4 is a tumour that invades adjacent 
tissues.39, 41 The N category is to decide the involvement of regional lymph 
nodes: N0 is when regional lymph nodes are not involved and N3 is when 
metastasis occurs in a lymph node and is greater than 5 cm.39 The M category 
is to decide whether there is distant metastasis: M0 is when there is no distant 
metastasis and M1 is when a distant metastasis occurs.39 Most categories are 
divided into sub-categories (a, b and c) in order further classify the tumour.39 
It is essential to stage the disease in order to predict the prognosis of the 
disease and to decide the best treatment option for the patient.41 
 
Prostate cancer biopsy samples will be graded with Gleason score based on 
their histologic features examined under microscopes. Gleason scores range 
from 1 to 5, where 1 corresponds to uniform and very well differentiated 
cancerous cells and 5 corresponds to the most poorly differentiated cells.40 
Pattern 3 (moderately differentiated cancerous cells) is the most commonly 
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observed pattern.40 The most prevalent pattern in the biopsy will be graded as 
the primary pattern and the second most prevalent pattern will be graded as 
the secondary pattern. The primary and secondary pattern numbers will be 
combined to give a final Gleason score, which ranges from 2 to 10.40 If 
multiple-core needle biopsies show different scores, they are now reported 
separately and the highest score is used to decide the treatment option.62 The 
Gleason score correlates strongly with cancer survival where higher scores 
are associated with poorer prognosis.40, 63 
 
1.7 Management of prostate cancer 
The management of prostate cancer will be quite different, depending on the 
stage and prognosis of the cancer.  
 
1.7.1 Active survelliance 
Routine PSA screening has led to an increase in the number of prostate 
cancer cases detected. However, screening has also contributed to ca. 27-
56% incidences of over-detection, where the disease is clinically insignicant 
and patient will usually have no symptoms even the condition is left 
untreated.64 Elderly men that present a localised and low-grade tumour may 
be offered active survelliance instead of radical treatments.64 This will prevent 
unnecesary treatments that do not increase their survival but lead to side-
effects such as impotence and urinary incontinence.65 These patients will be 
actively monitored and treatments will be commenced if their tumours show 
signs of disease progression (when there are increases in PSA levels or 
changes in the Gleason scores of biopsy samples).64, 65 
 
1.7.2 Surgery 
Radical prostatectomy is a common surgery for localised tumours (grade 
≤T2c)66 and involved the removal of the prostate, the seminal vesical and the 
ampulla of the vas.41 High-risk prostate cancer patients will significantly benefit 
from radical prostatectomy as the 10-year cancer-specific mortality rate was 
only 5.2% after they have undergone the surgery.67 This rate was significantly 
lower than the observation cohort which has a 12.8% cancer-specific mortality 
rate.67 Modern technologies have reduced the mortality rate from the surgery 
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to as low as 0.3%.41 However, erectile dysfunction and urinary incontinence 
are very common side-effects, affecting 30-70% of patients.41 
 
1.7.3 Radiotherapy 
Radical radiotherapy which includes external beam radiotherapy (EBRT) and 
brachytherapy is an alternative to radical prostatectomy for localised prostate 
cancer.68 EBRT is effective for patients with prostate-confined disease but can 
also be used for patients with advanced disease (T3-T4) that has not 
metastasised.68 The success rate correlates with the tumour stage where 72% 
of T1 patients but only 22% of T2 b and c patients been tumour-free after 12-
year follow up.41 While conventional radiotherapy delivers 60-70 Gy doses to 
the prostate, seminal vesicle and surrounding tissues, higher doses (160 Gy) 
can be delivered via brachytherapy.41 Brachytherapy uses radioactive seeds 
(125I or 103Pd) which target prostate cancer cells directly and spare the 
surrounding normal tissues.68 Hormonal therapy can be used as an adjunct to 
radiotherapy in order to shrink the tumour before radiotherapy and minimise 
toxicity caused by high radiation dose.68 
 
1.7.4 Hormonal therapy 
Hormonal therapy, also known as androgen-deprivation therapy, is the main 
form of treatment for advanced stage prostate cancer.34 Orchiectomy is a 
surgical castration procedure where both testicles are removed to reduce the 
production of testesterone.34 Castration can also be performed chemically 
where drugs such as anti-androgens, luteinising hormone-releasing hormone 
(LHRH) agonists and gonadotrophin-releasing hormone (GnRH) antagonists 
are used.69 Anti-androgens are androgen receptor antagonists and they can 
be steroidal (such as cyproterone acetate) or non-steroidal (such as 
bicatulamide and flutamide).69 LHRH agonists reduce the release of pitutary 
hormones which in turn reduce the production of testesterone. Examples of 
LHRH agonists include buserelin, goserelin and triptorelin.69 They are usually 
given by subcutaneous or intramuscular injection every one to four months.69 
LHRH agonists can induce testosterone surges in the first two weeks of 
treatment and cause tumour flare.69, 70 GnRH antagonists, such as degarelix,71 
represents the newest drug class and has the advantage of not inducing 
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tumour flare.69 These treatments are not curative but they can induce 
remission in 80-90% cases of advanced stage prostate cancer.34 Prostate 
cancer will develop a castrate-resistant phenotype usually within 2 to 3 years 
of treatment.72 The prognosis of castrate-resistant prostate cancer is very poor 
and patients only live for 9 to 13 months if they have metastatic disease.73 
 
1.7.5 Treatments for castrate-resistant prostate cancer 
Chemotherapeutic agents such as docetaxel and cabazitaxel72 and newer 
agents such as Sipuleucel-T, a cell-based cancer vaccine74 are used for 
castrate-resistant prostate cancer. Drug resistance emerges rapidly and the 
condition will progress despite treatment.72 Two-third of patients are reported 
to receive palliative care instead of active treatments.73 Bisphosphonates, 
opioids and radiotherapy are used to manage skeletal-related pain.73 
  
1.8 AMACR as a drug target for castrate-resistant prostate cancer 
AMACR was identified as a drug target for castrate-resistant prostate cancer 
more than a decade ago.47, 75 AMACR levels are increased ca. 9-fold in 
prostate cancer compared to normal cells.47, 48 Increased levels of AMACR 
protein is associated with androgen-independent growth of prostate cancer but 
its exact mechanism is unknown.48 It has been postulated that AMACR is 
involved in lipid metabolism (vide infra) and hence provides an alternative 
energy source for the growth of prostate cancer.76 Another postulation is its 
role in peroxisomal β-oxidation which produces reactive oxygen species that 
damage DNA.77 
 
Besides being over-expressed in prostate cancer, AMACR is also over-
expressed in other types of cancer such as breast,78, 79 colon,80 ovarian81 and 
renal cancers.82, 83 It is unknown whether the over-expression of AMACR 
causes the occurrence or progression of these cancers. 
 
It has been shown that inhibiting the activity of AMACR causes a significant 
change in the phenotype of castrate-resistant prostate cancer. A siRNA study 
was used to reduce the protein levels and it targeted AMACR 1A, which is the 
active spliced variant of AMACR (vide infra). The study showed that the 
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androgen receptor and B-cell translocation gene I protein levels were up-
regulated when AMACR expression was suppressed.84 Castrate-resistant 
prostate cancer cells reverted to being androgen-dependent and responsive 
to androgen-deprivation treatments again.84 AMACR inhibition also slows  
down cancer cell growth,85 which may be due to reduced expression of genes 
associated with cancer progression (such as IGF-1 and platelet-derived 
growth factor alpha).84 This makes AMACR a very good drug target as a 
combination of anti-AMACR therapy with androgen-deprivation therapy could 
convert castrate prostate cancer into a more ‘normal’ phenotype and 
potentially cure the cancer or at least make it more treatable.48, 84 In 
comparison to the traditional cytotoxic chemotherapy that kills all fast-growing 
cells, inhibiting AMACR shows a better treatment prospect due to it being a 
specific molecular target.  
 
1.9 Subcellular distribution of AMACR  
AMACR belongs to the family III CoA transferase.86 The class III family can be 
broadly divided into CoA transferases or racemases, and AMACR belongs to 
the latter.87-89 Besides humans,90 AMACR has also been discovered in many 
other mammalian species such as rat91 and mouse.92 AMACR is highly 
conserved; for example, mouse and rat enzymes are 89.7% identical,93 whilst 
the human enzyme is 81% and 77% identical to rat and mouse enzymes, 
respectively.94 
 
The subcellular distributions of AMACR may vary depending on species even 
though the reasons for such variations are still unknown. 2-Arylpropionyl-CoA 
epimerase (which was later shown to be identical to AMACR)95, 96 was 
reported to be localised in the cytosol and mitochondria of rats.97 Later studies 
showed that even though the activity mainly comes from mitochondria, 
peroxisomes also contribute to some of the activity in rats.98, 99 In mice, the 
enzyme is found to be distributed in both peroxisomes and mitochondria.92 In 
humans, it has a preferential distribution in the peroxisome (75-90%) with the 
remainder found in mitochondria.90 The C-terminus of human AMACR 
possesses the amino acid sequence KASL (Appendix 1), which is a 
peroxisomal targeting signal-1 (PTS1).98 The N-terminus may be responsible 
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for targeting the mitochondria, but the exact targeting sequence has not been 
determined.98, 100, 101 Zellweger’s syndrome results from a defect in 
peroxisome biogenesis (i.e., peroxisomes are not formed).102-105 The 
peroxisome-deficient cells retain 10-30% of AMACR activity, which is 
contributed by the mitochondria instead of peroxisomes, consistent with the 
observed distribution.90  
 
Homologous enzymes of human AMACR have been found in bacteria and 
invertebrates. The 2-methylacyl-CoA racemase (MCR) from Mycobacterium 
tuberculosis (vide infra) shares 43% sequence identity with human AMACR 
(Appendix 1)76, 85, 86 and has been used in many studies as a model for human 
AMACR.106-108 A homologous enzyme was also found in the secretions of the 
larvae of a parasitic worm, Anisakis simplex.109 The enzyme appears to play 
an important role in energy production to support the growth and development 
of the larvae.109 
 
1.10 Function of AMACR in the body 
AMACR is found in mitochondria and peroxisomes in humans101 and is 
involved in the metabolism of branched-chain fatty acids.110 Red meats such 
as beef and dairy products in the diet contain an abundance of phytanic acid 
(3R,S,7R,11R,15-tetramethylhexadecanoic acid), a branched-chain fatty 
acid.111, 112 Phytanic acid is turned into phytanoyl-CoA 1 and is shortened by a 
one-carbon unit via α-oxidation to give pristanoyl-CoA (2R,S,6R,10R,14-
tetramethylpentadecanoyl-CoA) (2 and 3) which undergoes further 
metabolism.91, 111-113 Dehydrogenases in both peroxisomes and mitochondria 
that are involved in the subsequent β-oxidation pathway have been shown to 
have an absolute requirement for substrates to have S-stereochemical 
configuration at the centre bearing the 2-methyl group.99, 114-117 The 2-methyl 
fatty acyl-CoA ester (pristanoyl-CoA) produced by α oxidation is a racemic 
mixture of R- and S- configurations at carbon-2 bearing the methyl group.93 
Pristanoyl-CoA with 2S-configuration 3 can be directly β-oxidised whilst those 
with 2R-configuration 2 have to undergo a change in chiral configuration to 2S- 
before metabolism. The 2R- 2 to 2S- 3 conversion of chiral configuration is 






Scheme 1.1: The role of AMACR in the metabolism of branched-chain fatty acids.111, 112  
 
AMACR also plays a part in the synthesis of bile acids. Bile acid intermediates 
such as trihydroxycholestanoic acid (THCA) are produced from cholesterol via 
complex bile acid biosynthetic pathways.118 Mitochondrial oxidation produces 
a product with its α-carbon (position 25 in the conventional numbering of 
cholesterol) that is exclusively in the R- configuration but the subsequent β-
oxidation requires that the substrate possesses S- configuration.93, 119 The 
25R- bile acid intermediate is activated as its acyl-CoA ester and AMACR 










Scheme 1.2: The role of AMACR in bile acid synthesis where it converts (25R)-THC-CoA 
4 to (25S)-THC-CoA 5.118 
 
AMACR ‘racemises’ branched-chain fatty acids and bile acid intermediates to 
give a 1:1 mixture of R- 6 and S- 8 products via a deprotonation/reprotonation 
mechanism (Scheme 1.3).1, 2 The S- product 8 will be taken by the downstream 




Scheme 1.3: Chiral inversion of an R-2-methylacyl-CoA ester 6 to the corresponding S-
2-methylacyl-CoA ester 8 catalysed by AMACR via a deprotonation/reprotonation 
mechanism. 
 
Sensory motor neuropathy has been reported in patients with AMACR 
deficiency due to accumulation of R-pristanic acid and bile-acid 
intermediates.94, 120 The neurological problem could potentially be a serious 
side-effect if AMACR is inhibited. However, an AMACR knock-out study in 
R-2-methylacyl-CoA 6 
ester 








mouse has shown that as long as dietary intake of branched-chain fatty acids 
is restricted, the neurological disorder will not occur.121 The body will adapt to 
the inhibition of AMACR and develop an alternative AMACR-independent 
route to synthesise bile acids, presumably mediated by peroxisomal 
multifunctional enzyme type 1 (pMFE-1), CYP3A11 and CYP46A1.121 
 
1.11 Role of AMACR in the metabolism of 2-arylpropanoic acids (2-APAs) 
Many non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen 9, 
fenoprofen 10 and flurbiprofen 11 have a common 2-arylpropanoic acid (2-
APA) structure (Figure 1.3).122 2-APAs exert their anti-inflammatory activity by 
inhibition of cyclooxygenase-1 and -2 (COX-1 and -2) enzymes and thereby 
the inhibition of the synthesis of prostaglandin.123, 124 
 
 
Figure 1.3: Examples of 2-APA drugs (compound 9, 10, 11, 12 and 14) and the best 
AMACR substrate 13 reported to-date. 
 
2-APAs (except naproxen 12) are usually administered to patients as a 
racemic mixture but only the S-enantiomer is the pharmacologically-active 
form in inhibiting COX enzymes.125, 126 AMACR is responsible for the chiral 
inversion of these drugs into its active S-isomer. First, the 2-APA is coupled to 
coenzyme A by the long-chain acyl-CoA synthetase (LACS) to form a 2-APA-
CoA ester (Scheme 1.4).122, 127-129 The product is a substrate for AMACR, 
which is responsible for catalysing the chiral inversion of the ester from the R- 
to the S- isomer (Scheme 1.4).130, 131 The S-2-APA-CoA ester is subsequently 
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hydrolysed by human acyl-CoA thioesterases (ACOTs),132, 133 possibly ACOT-
1 and ACOT-2131 to give the S-2-APA, which is the active entity (Scheme 1.4). 
The chiral inversion of 2-APAs is uni-directional in vivo129 even though AMACR 
has been shown to ‘racemise’ both R- and S- isomers in vitro.1, 2 This is 
because only the R-2-APA-CoA ester but not the S-2-APA-CoA ester is 
produced by LACS as it has a stereospecific substrate requirement.128, 129, 134 
Even though flurbiprofenoyl-CoA has been shown as a substrate of AMACR 
in vitro,2 flurbiprofen 11 is not a substrate for the chiral inversion pathway in 
humans,135, 136 presumably because the acid is not being converted to acyl-
CoA ester by LCAS.137 
 
 
Scheme 1.4: The in vivo chiral inversion pathway of 2-APAs using ibuprofen as an 
example. 
 
AMACR has been shown to be able to chirally invert 2-APAs but it has different 
affinities for them.2 The best substrate for AMACR reported to-date is 
fenoprofenoyl-CoA 13 (Figure 1.3; vide supra) with a reported Km value to 2.3 
µM.2 Regular use of 2-APAs has been associated with a reduced risk of 
prostate cancer.138, 139 This chemo-preventive effect may be due to the anti-
inflammatory effect of NSAIDs140, 141 but the inhibitory effect of 2-APAs on 
AMACR activity may also play a role in reducing cancer risk.142  R-
Ibuprofenoyl-CoA 16 has been shown to be a moderate AMACR inhibitor, 
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which inhibits the ‘racemisation’ of (25S)-THC-CoA 5, with a Ki value of 5.4 
µM.143  
 
1.12 AMACR inhibitors reported in the literature 
Very few AMACR inhibitors have been synthesised in the past 15 years since 
the enzyme was first identified as a prostate cancer target.47, 75, 76 Even though 
this novel target has attracted researchers’ interest in designing molecules to 
inhibit it, progress has been slow due to the lack of a convenient and high-
throughput assay to measure their potency.76 
 
The very first inhibitors were reported by Carnell et al. in 2007,143 and were 
designed using AMACR’s natural substrate, a 2-methyl-branched fatty acyl-
CoA ester (Figure 1.4). The inhibitors were modified by adding one or more 
fluorine atoms to the structure. Among all the variations, the most potent 
structure is the inhibitor 19 containing a α-trifluoromethyl group, which has a 
reported Ki value of 0.9 µM. The inhibitor 20 containing a α-difluoromethyl 
group has a 22 times larger Ki value of 20 µM. A single fluorine atom that is in 
the β-position relative to the acyl-CoA ester results in inhibitors with low Ki 
values, such as compounds 21, 22 and 23 having Ki values of 1.3, 2.3 and 3.8 
µM, respectively. Adding a fluorine atom next to the α-proton will reduce the 
pKa of α-proton. This may ease the deprotonation step in forming the enolate 
intermediate, and hence make the compound a good competitive inhibitor. 
Carnell et al. also hypothesised that these compounds could undergo fluoride 




Figure 1.4: Inhibitors reported by Carnell et al in 2007.143 
 
These inhibitors may be administered to cells as carboxylic acid pro-drugs as 
they have been shown to be converted into acyl-CoA esters when incubated 
with rat liver homogenate or purified microsomes.143 The activation of these 
pro-drugs is not surprising as R-2-APAs have also be shown to be converted 
stereoselectively in vivo by LACS to their corresponding acyl-CoA esters (vide 
supra).129 LACS could be responsible for esterifying the pro-drugs of these 
inhibitors as well.143 
 
The carboxylic acid precursor of inhibitor 19 has been shown to be cytotoxic 
to several prostate cancer cell lines (PC3, Du145 and CWR22Rv1) when 
tested using the MTT cell proliferation assay. It was least toxic to the 
CWR22Rv1 cell line, which also has the lowest expression levels of AMACR, 
suggesting that the cytotoxic effect may be due to AMACR inhibition.143 
 
In 2011, a series of AMACR competitive inhibitors (compounds 24, 25 and 26) 
with a 2-methylene functional group replacing the 2-methyl group were 
reported (Figure 1.5).144 These reported inhibitors are not more potent than 
the compound 19 reported by Carnell et al.143 in 2007. However, these 
inhibitors have the potential of being developed into a diagnostic tool for 
prostate cancer. One of the inhibitors, (E)-13-iodo-2-methylenetridec-12-
enoyl-CoA 26 with Ki value of 19.0 µM, was further studied. The acid form of 
the inhibitor was labelled with radioactive 131I in order to study its uptake by 
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AMACR-positive prostate cancer cell lines (LNCaP, LNCaP C4-2wt and 
DU145). The acid was hypothesised to be taken up by fatty acid transporters 
and thioesterified by LACS in the cells to form acyl-CoA ester 27. AMACR-
positive prostate cancer cells showed four times higher radioactivity compared 
to benign prostate cells due to the accumulation of compound 27 by binding 
to AMACR. As compound 27 is radioactive and has preferential accumulation 




Figure 1.5: AMACR competitive inhibitors with a 2-methylene group and the 131I-labelled 
compound.144 
 
In 2013, Carnell et al. published a second paper on rationally designed 
AMACR inhibitors (Figure 1.6).145 α–Fluoroibuprofenoyl-CoA 28 and 2-chloro-
2-(4-isobutylphenyl)acetyl-CoA 29 are inhibitors with structures designed 
based on ibuprofenoyl-CoA. Even though inhibitor 28 has its α-proton replaced 
by fluorine and hence is not enolisable, it still shows a very promising Ki value 
(Ki = 0.32 µM). This suggests that enolisability is not essential for a compound 
to be an AMACR inhibitor. Inhibitor 29 can potentially be enolised as it does 
have a α-proton, but its methyl group is replaced by chlorine. Replacing the 
methyl group with an electron withdrawing atom such as chlorine may assist 






Figure 1.6: Examples of inhibitors reported by Carnell et al. in 2013.145 
 
N-Dodecyl-N-methylcarbamoyl-CoA 30 and N-dodecylcarbamoyl-CoA 31 are 
inhibitors designed to mimic the enolate intermediate 7.145 Substrates of 
AMACR are hypothesised to be deprotonated by the enzyme to form enolate 
intermediates 7 (Scheme 1.3; vide supra). The thiocarbamate structure with a 
methylamide group 32 is an isoelectronic and isoelectric mimic 33 of the 
AMACR-bound enolate intermediate 7 (Figure 1.7). The thiocarbamate 
structure makes inhibitor 30 the most potent inhibitor reported to-date with a 
Ki value in the nanomolar range (Ki = 98 nM). However, this inhibitor cannot 
be used in cells as the pro-drug will spontaneously decompose by 
decarboxylation. Inhibitor 31 with a hydrogen atom instead of a methyl group 
attached to the thiocarbamate is nearly 10 times less potent (Ki = 1 µM) than 
inhibitor 30, confirm the importance of the 2-methyl group to fit into the binding 





Figure 1.7: AMACR inhibitor with thiocarbamate structure that isoelectronically mimics 
AMACR-bound enolate intermediate.145 
 
Besides rational drug design, drug screening using a medium-throughput 
assay has been used to look for AMACR inhibitors. Several inhibitors that are 
not substrate-based have been identified, including ebselen 34 (IC50 = 2.79 
µM), ebselen oxide 35 (IC50 = 0.80 µM), 2-(2,5-dihydroxy-4-methylphenyl)-5-
methyl benzene-1,4-diol (DMPMB) 36 (IC50 = 4.34 µM) and rose bengal 37 
(IC50 = 10.0 µM) (Figure 1.8). The inhibition of AMACR by these inhibitors was 
not reversible upon removal of inhibitors by dialysis. Ebselen 34 has been 
postulated to alkylate the His-122 residue of AMACR to cause an irreversible 
inhibition.  Ebselen 34 and DMPBM 36 were tested in prostate cancer cells 
lines and the cancer cell survival was dependent on the level of expression of 
AMACR. For ebselen, the kill (quoted in LD50) was five times greater in 
AMACR-expressing cells (LNCaP) than low-expressing cells (WPMY1). This 
is the first ever screening study reported and it managed to screen nearly 5000 





Figure 1.8: AMACR inhibitors found by drug screening.85 
 
1.13 Current assays to measure AMACR activity and drug potency 
There are several AMACR assays reported, including the wash-out of tritium 
from substrate85 and wash-in or wash-out of deuterium into or from substrate.1  
There are also assays involving the use of high-performance liquid 
chromatography (HPLC),145 gas-liquid chromatography (GLC)90, 91 or circular 
dichroism (CD).106 Some of these assays have been developed just to 
measure AMACR activity whilst others can also be used to screen for AMACR 
inhibitors. 
 
1.13.1 Detection of radioactivity from tritium release 
The method of detecting tritium release was first done as an end-point assay91 
before it was adapted by Wilson et al as a screening assay for drugs.85 
AMACR was incubated with a potential inhibitor in a 96-well plate before the 
[2,3-3H] pristanoyl-CoA substrate was added. As AMACR deprotonates the 
substrate, the radioactive α-proton is released into the reaction buffer. A solid 
phase extraction (SPE) plate is used to separate the unreacted substrate from 
the buffer containing the released tritium. The eluent with 3H2O is transferred 
to a reading plate for its radioactivity to be measured by a 96-well scintillation 
detector. The lower the radioactivity detected, the higher the potency of the 
inhibitor. This is because the deprotonation of the α-proton is inhibited and 
hence the tritium release is reduced.85 
 
Even though the study claimed to be a high-throughput screening, it could only 
be used to screen a small to medium library, so at most, it is a medium 
throughput assay. A considerable level of manipulation is required before the 
radioactivity can be measured. The SPE plate has to be first conditioned using 
methanol or acetonitrile and washed twice with the reaction buffer before it can 
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be used. The AMACR reaction in the 96-well plate has to be quenched with 
acid and then neutralised with base before it can be eluted from the SPE plate 
into a collection plate. Then, it has to be transferred from the collection plate 
into a reading plate in order for radioactivity to be measured by the scintillation 
detector. In addition to the laborious preparation of samples for radioactivity 
measurement, there is also the safety concern of possible exposure to 
radioactivity if spillage occurs.85  
 
1.13.2 1H nuclear magnetic resonance (NMR) spectroscopy 
The enzyme activity of AMACR towards substrates can be explored in the 
presence of 2H2O. Substrates such as S-2-methyldecanoyl-CoA 38 would be 
‘racemised’ by AMACR through deprotonation and reprotonation steps.1 As 
this reaction occurs in 2H2O, the α-proton would be exchanged for deuterium 
(Scheme 1.5).1 The loss of the α-proton could be observed using 1H nuclear 
magnetic resonance (NMR) as the α-methyl peak of the substrate 38 with the 
chemical shift at 1.00 ppm would change from a doublet to a single peak.1 At 
the same time, the peak for the α-proton at δ 2.60 ppm would be reduced and 
would eventually disappear at high substrate conversions.1 The same method 
has been used to test various AMACR substrates such as acyl-CoA esters of 
2-APA2 and straight-chain acyl-CoA esters.147 
 
 
Scheme 1.5: ‘Racemisation’ of S-2-methyldecanoyl-CoA by AMACR in 2H2O. 
 
However, the 1H NMR-based method suffers the problem of low sensitivity. 
The lower the concentration of substrate, the greater the acquisition time is 
required. Even though 1H NMR can measure a substrate concentration in the 
micromolar range, it will have difficulty in accurately detecting concentrations 
below 10-20 µM. In addition, only a single sample can be investigated at a 
time. Hence, if this method were to be translated into an inhibition assay, it will 
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be laborious and low throughput. Moreover, the use of deuterated water is 
likely to result in a solvent kinetic isotope effect.1, 106 
 
1.13.3 High-performance liquid chromatography (HPLC) and gas-liquid 
chromatography (GLC) 
‘Racemisation’ by AMACR can be followed using HPLC148 or GLC.90, 91 After 
the R- or S- substrate is incubated with AMACR, the reaction is quenched with 
acid.90, 91 The acyl-CoA ester product is hydrolysed to form an acid product of 
unknown chirality.90, 91 The resulting acid is coupled with a chiral molecule 
such as R-1-phenylethylamine to form a diastereomeric derivative which can 
be analysed by a HPLC or GLC method.90, 91, 148  
 
This method can be adapted for use in AMACR inhibition studies. The enzyme 
is incubated with the S-ibuprofenoyl-CoA 17 and a potential inhibitor. An 
aliquot is taken from the mixture at an interval of 3 min and quenched with 
acid. Instead of an extra step of coupling the hydrolysed product with a chiral 
molecule to form a diastereomer, the aliquot from the reaction can be directly 
analysed by a HPLC with a chiral column. A chiral column will differentiate the 
S-isomer from the R- isomer as it contains a chiral stationary phase. Multiple 
time points and various inhibitor concentrations will need to be analysed in an 
inhibition assay.145 It will be very time-consuming in analysing multiple 
samples using HPLC as it is low throughput method. 
 
1.13.4 Continuous assay using circular dichroism (CD) 
CD can be used as a continuous assay to detect the rate of ‘racemisation’ of 
substrates possessing a chromophoric side-chain by AMACR. The reported 
study used MCR from M. tuberculosis,106 which is a homologous enzyme of 
human AMACR.86 The MCR enzyme was incubated with the substrate (R- 15 
or S- ibuprofenoyl-CoA 16) and the ‘racemisation’ followed continuously using 
a CD spectrometer at a constant temperature of 37 °C.106 The molar ellipticities 
of R-ibuprofenoyl-CoA 16 and S-ibuprofenoyl-CoA 17 are equal in magnitude 
but opposite in sign106 because the chiral molecules absorb the left- (L) and 
right-handed (R) circular polarised light differently.149 The changes of molar 
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ellipticity correspond with the changes of stereochemical configuration when 
the substrate is ‘racemised’ and this process can be followed with time.106 
 
The main problem in measuring the ‘racemisation’ reaction of AMACR is 
because the end product is very similar to the initial substrate as the only 
change is that the one chiral centre is ‘racemised’. The CD assay offers the 
advantage of recognising the difference in the R- and S- configuration without 
the use of isotopes such as deuterium or tritium. This avoids the complications 
of kinetic isotope effects in the assay.106 Moreover, continuous assays offer 
the advantage of following the reaction in real time and it is unnecessary to 
stop the reaction before measurement, which is required in all end-point 
assays.106 The reported study only measured the ‘racemisation’ of 
ibuprofenoyl-CoA but it has the potential in AMACR inhibitor screening.106 
However, it has a limitation in terms of sample absorbance where high 
concentration of sample will result in high absorbance and hence excessive 
noise.106, 149 In addition, acyl-CoA inhibitors with aromatic side-chain are likely 
to be ‘racemised’ by AMACR, which will lead to very complicated ellipticity 
readings.149 Assays based on CD have been used to study various 
racemases,150-152 but all of them suffer from a common problem, which is low-
throughput. 
 
1.14 The proposed mechanism of human AMACR catalysed reaction 
AMACR is proposed to catalyse the ‘racemisation’ of substrates by a 
deprotonation/reprotonation mechanism.146 The deprotonation was studied 
using a 13C and 2H doubly-labelled substrate 41 (Scheme 1.6).1 The wash-out 
of deuterium label by AMACR was followed using a 13C NMR spectroscopy. 
The triplet (at δ 47.11) of the substrate 41 slowly disappears with the loss of 
the α-2H. A new singlet (at δ 47.55) of the product 43 appears as the 2H is 




Scheme 1.6: The deprotonation and reprotonation of S-2-methyl-2-[13C]-2-[2H]-decanoyl-
CoA 41. 
 
Use of isotopic labelling allows the study of the reprotonation step. An 
unlabelled R- 44 or S- 2-methyl-decanoyl-CoA 38 was ‘racemised’ by AMACR 
in the presence of 2H2O (Scheme 1.5; vide supra). The product was in a nearly 
1:1 racemic mixture regardless of whether the substrate was initially in a R- or 
S-configuration.1 Similar experiments were performed on the acyl-CoA esters 
of 2-APA and consistent results of 1:1 racemic product were obtained.2  
 
The study from Darley et al. also showed that the deprotonation rate was 
almost twice the rate of chiral inversion and the resulting product was a near 
racemic mixture.1 The stereochemical outcomes is suggestive of a planar 
intermediate, with non-steroselective reprotonation (i.e., from both faces of the 
molecule). An enol or enolate 39 is the most plausible intermediate compared 
with other possible intermediates such as a carbanion 45 or a ketene 46 
(Scheme 1.7).107, 108 A carbanion 45 has a tetrahedral structure, so would not 
be so easily converted into a racemic mixture. A ketene 46 is also unlikely as 
quantum chemical modellling on MCR has shown that the intermediate’s C-S 
bond was lengthened (from 1.80 Å to 1.87 Å) but was not broken.107 A ketene 
intermediate would require the C-S bond to be broken. The observation where 
the oxygen atom of the carbonyl became more negatively charged (from -
0.487 to -0.651) with the removal of the α-proton supports the hypothesis of 





Scheme 1.7: The proposed intermediates in the reaction catalysed by AMACR. 
 
To date, the structure of mammalian AMACR has not been determined but the 
X-ray crystal structures of its homologue MCR from M. tuberculosis, have been 
reported (Figure 1.9).146, 153, 154 These homologous structures have always 









Figure 1.9: MCR dimer complexed with a substrate molecule reported by Bhaumik et 
al.146 
 
The X-ray crystal structure and the site-directed mutagenesis study on 
bacterial MCR have identified the catalytic residues of MCR as His-126, Asp-
156 and Glu-241.86, 108, 146 The crystal structure of MCR showed that the 
enzyme is a tight interlocked dimer (Figure 1.9). Each monomer has a large 
domain at the N-terminus followed by a linker, a small domain, a second linker 
and a C-terminus that goes toward its large domain (Figure 1.10).The active 
site is at the interface of the dimer between the large and small domain. The 
active site is contributed by both subunits of the dimer where the His-126 and 
Asp-156 residues are situated at the large domain, within α5 and α7 
respectively, while the Glu-241 residue is situated within the α9 of the small 





Figure 1.10: A simplified diagram of the MCR showing a monomer with a large domain 
(blue), a small domain (purple), two protruding helices (grey), two linkers (orange and red) 
and its C-terminus (green).86 
 
Using the MCR data, it has been proposed that the Asp-152 residue of human 
AMACR 1A deprotonates the R-substrate to form an enolate intermediate 
(Scheme 1.8).76, 86, 146 The enolate intermediate is non-stereoselectively 
reprotonated to give the R and S-product in a ca.1:1 ratio.1 It is unknown if this 
proton is donated by the enzyme catalytic residues (His-122/Glu-237 dyad) or 
by the bulk solvent.1 The His-122 and Glu-237 residues are paired by a 
hydrogen bond and work as a dyad to deprotonate the S-substrate.86, 146 
Again, the reprotonation of the intermediate could be by the Asp-152 residue 




















Scheme 1.8: The proposed catalytic mechanism of AMACR, showing the deprotonation 
of R-2-methylacyl-CoA ester to form an enolate intermediate and reprotonation to give a 
racemic mixture.76, 86, 146 
 
The X-ray crystal structure of MCR has shown that the enolate intermediate is 
stabilised in an oxyanion hole (Figure 1.11). The negatively charged oxygen 
forms hydrogen bonds with His-126, Asp-156 and the backbone of Asp-127. 
His-126 is further stabilised by forming a hydrogen bond with Glu-241 from the 
small domain of the second subunit. The sulfur atom of Met-188 interacts with 
the side-chain of Asp-156 and further stabilises the intermediate.107, 108, 146  
 
 
Figure 1.11: The enolate intermediate stabilised in the oxyanion pocket of MCR.107, 108, 
146 
 
It has been shown that the side-chains of R-substrate and S-substrate bind in 
different pockets within the MCR.146 The pockets are hydrophobic in nature146 
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and allow binding of a broad spectrum of side-chains (Figure 1.12).1, 2, 90 There 
is a methionine-rich hydrophobic site (between residues 195 to 223) that 
allows the substrate sliding from R- to S- pocket and vice versa.146 The methyl 
group has a separate binding pocket between the large and small domain and 
the position of methyl group binding is fixed.146 The methyl binding pocket is 
small and prefers methyl groups and its isosteres,146 which explains the 
preference of the enzyme for 2-methylacyl-CoA substrates.90, 147  
 
 
Figure 1.12: Modelled structure of R-fenoprofenoyl-CoA docked into the active-site of 
MCR. The CoA moiety is in the pocket shown on the left, the carbonyl oxygen, α-proton, 
and α-methyl are situated in the catalytic site in the middle while the acyl side- chain is 
situated at the methionine-rich surface (yellow) shown on the right.2 
 
Understanding the mechanism of enzymes using a X-ray crystal structure is a 
commonly used method, but it has its limitations. The two obvious problems 
are that MCR is not AMACR even though they are quite similar. The second 
problem is that the cystal structure is not necessarily representative of what 






1.15 Different spliced variants of AMACR 
More than one form of AMACR are present in prostate cancer cells. The gene 
encoded for human AMACR is located on the short arm of chromosome 5 at 
position 13 (5p13)157 but alternative splicing has resulted in different spliced 
variants from a single gene locus.158 There have been 10 different spliced 
variants reported (Figure 1.13),158-161 but one recently discovered spliced 
variant (IAs; Genbank accession number: CR618063) was subsequently 
removed from the database.158  
 
The spliced variants can be divided into type I and II variants, where type I 
have an intact exon 5 while type II have an alternative splicing of exon 5.158, 
159 The splice variants can also be sub-divided into classes A and B where A 
has an intact exon 3 whilst B has a deleted an exon 3.158, 160 Even though 
AMACR 1A is the most abundant in prostate cancer, other spliced variants (in 
descending order: IB > IAdel > IIA = IBLi > IIAs) are also up-regulated.158, 161 
 
 
Figure 1.13: The 10 different spliced variants of AMACR.158-161 Spliced variant IAs has 
been recently removed from the Genbank database. 
 
The active site residues of bacterial MCR, His-126 (His-122 for human 
AMACR), Asp-156 (Asp-152 for human AMACR) and Glu-241 (Glu-237 for 
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human AMACR) are encoded on exons 2, 3 and 4, respectively.86, 158 Hence, 
for the enzyme to be catalytically active, it must have intact exons 2, 3 and 4. 
All variants B are proposed to be inactive as they do not have exon 3 and 
hence some catalytic residues are missing.158 Theoretically, all variants A are 
active except variant IAs where part of exon 4 is missing.158 However, an intact 
C-terminus is needed for dimerization to give the active enzyme,86 so variants 
with a truncated C-terminus (IIA and IIAs) are also predicted to be inactive. 
Spliced variant IAdel is likely to be catalytically active but differs from 1A in 
having a C-terminal extension and this removes the PTS1 motif.161 Without the 
PTS1 sequence, the enzyme will not be localised in peroxisomes.98 As 
AMACR 1A is the most abundant and active form of AMACR, all the work done 
in this thesis is on AMACR 1A. 
 
1.16 Single nucleotide polymorphisms of AMACR  
Single nucleotide polymorphisms (SNPs) of AMACR have been shown to 
affect the risk of developing prostate cancer.162-166 The frequencies of 
occurrence of the M9V, D175G, S201L and K277E SNPs have been found to 
be significantly different in patients with hereditary prostate cancer compared 
to the control group.162 Of all of the SNPs, the M9V variant and the haplotype 
of M9V and D175G (the combination of these two SNPs) show the strongest 
association with prostate cancer.162, 163 However, a later study showed that the 
association of M9V and D175G is more significant in sporadic prostate cancer 
instead of hereditary prostate cancer.166 
  
A study by Daugherty et al. showed that the risk of prostate cancer is not 
affected by the occurrence of allele variants but the behaviour of their 
carriers.142 Carriers of M9V, D175G, S201L and K277E variants who regularly 
use ibuprofen have a lower risk of prostate cancer.142 Since ibuprofenoyl-CoA 
has been shown to be an inhibitor of AMACR,91, 143 it may also have an effect 
on these allelic variants of AMACR. The 2-APA-CoA may modulate the activity 
of these variants by competing with their natural substrates and hence confer 
a protective effect against prostate cancer. This protective effect of ibuprofen 
also implies that prostate cancer risk may be linked with higher enzymatic 
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activity and not just protein levels per se, and that the disease-linked SNPs 
give rise to higher enzymatic activity. 
 
1.17 Conclusions 
Inhibiting AMACR in castrate-resistant prostate cancer is a very good 
treatment strategy because it complements the clinically accepted androgen-
deprivation therapy and enhanced the response of the cancer to these 
conventional treatments.48, 84 However, very few inhibitors of AMACR have 
been described in the literature to-date.85, 143-145 So far only one drug 
(trifluoroibuprofen) has been tested in vivo167 and no drug has entered clinical 
trials. One of the reasons for this may be that the enzyme is a racemase. It is 
difficult to assay the activity of a racemase as the substrate and the product 
are difficult to distinguish.1  
 
There is an urgent need to design better and more potent drugs against human 
AMACR but the bottleneck is not having a convenient and high-throughput 
assay. Even though there has been substantial studies on the crystal structure 
and mechanism of MCR (the homologue of human AMACR),86, 108, 146, 154 there 
are significant limitations when translating the data to human AMACR.168, 169 It 
is paramount to understand the active-site of human AMACR in order to 




2 Aims and objectives 
2.1 Aims 
A range of novel compounds will be synthesised using a rational drug design 
approach to explore the SAR of the side-chains of AMACR inhibitors. These 
compounds will be tested using different assays with the aim of developing a 
high-throughput and convenient AMACR assay. The AMACR enzyme will be 
studied using a site-directed mutagenesis in order to identify active-site 
residues and to further understand its catalytic mechanism. 
 
2.2 Objectives 
2.2.1 The development of AMACR inhibitors using the rational drug 
design approach 
In order to explore the SAR of the side-chains of AMACR inhibitors, a range 
of novel compounds will be designed based on the structure of fenoprofenoyl-
CoA 13, the best substrate of AMACR. Both electron-withdrawing groups and 
electron-donating groups at the β-position will be introduced in order to study 
whether a substrate mimic or a transition-state mimic is a better inhibitor. The 
side-chain will be designed to have a meta- or para- substituents to explore 
the optimal structure for side-chain binding. The 2-methyl group will be 
designed to have the R- or S- stereochemical configuration to explore if there 
is a spatial preferential binding. 
 
2.2.2 Inhibitor testing and the development of high-throughput assay 
The inhibitors will be tested with the deuterium wash-in assay and fluorescent-
binding assay to study their binding to AMACR. As AMACR has been recently 
described to catalyse the elimination of 3-fluoro-2-methylacyl-CoA esters, the 
development of this reaction into a high-throughput assay to measure the 
potency of inhibitors will be investigated. In order to validate the fluoride-
elimination assay, novel compounds described above and a number of known 
AMACR ligands will be assessed using 1H NMR and 19F NMR. The novel 





2.2.3 Site-directed mutagenesis on AMACR 
To study the catalytic mechanism of the enzyme to assist drug design, site-
directed mutagenesis will be performed. Potential AMACR active-site residues 
will be identified using the X-ray crystal structure of MCR, a homologous 
bacterial enzyme. Primers to produce the mutant will be designed and each of 
AMACR residues His-122, Asp-152, Met-184, and Glu-237 will be mutated. 
His-tag wild-type and mutant AMACR proteins will be expressed using E. coli 
and purified by metal-chelate chromatography.  
 
2.2.4 The characterisation of mutant enzymes and enzyme assays  
The effects of the above mutations on the protein structure will be investigated 
using dynamic light scattering (DLS), CD and fluorescence study using 8-
anilino-1-naphthalenesulfonic acid (ANS). The wild-type and mutant enzymes 
will be tested using the deuterium wash-in assay and fluoride elimination 
assays to study changes in enzyme activity. The multi-well colorimetric assay 









3 Results and discussion for potential AMACR 
inhibitors 
3.1 Design of potential AMACR inhibitors 
To date, no SAR on the side-chains of AMACR inhibitors have been 
performed. Even though there are some rationally designed inhibitors against 
AMACR, limited numbers of each type of inhibitor have been designed and 
tested.143-145 
 
In order to have better understanding of the SAR, a rational approach was 
used to design potential inhibitors of AMACR based on known substrate 
structures and mechanistic information. All the inhibitors designed have an 
acyl-CoA-ester moiety (Figure 3.1, blue) as the group is absolutely required 
for binding to the enzyme.144 The 2-methyl moiety (Figure 3.1, red) was also 
included as it enhances the binding of substrates to AMACR.145-147 The 
presence of the 2-methyl group will prevent binding to other enzymes 
metabolising straight-chain acyl-CoA esters, thereby enhancing selectivity for 
the target and reducing off-target effects. The side-chains (Figure 3.1, green) 
were varied in order to study their influence on binding affinity and the 
inhibitory effect on the enzyme. 
 
 
Figure 3.1: Design of potential inhibitors with an acyl-CoA ester, a methyl group and a 
varied side-chain.  
 
Fenoprofenoyl-CoA 13 has been shown to be the best substrate of AMACR 
(Figure 3.2), with a Km value to 2.3 µM.2 Hence, to design an inhibitor that 
competitively binds to AMACR, fenoprofenoyl-CoA 13 was chosen as the initial 
structure on which to base inhibitor design. It was thought that the extended 
aromatic rings increase the hydrophobicity of the compound and would 





Figure 3.2: Structure of fenoprofenoyl-CoA, the best substrate of human AMACR 1A.2 
 
To turn a compound into an inhibitor, sulfide (49 and 50) and sulfone (51 and 
52) groups were added adjacent to the 2-methyl group (Figure 3.3). These 
electron-withdrawing groups will increase the acidity of the α-proton, 
promoting the removal of α-proton to form a stable enolate intermediate.143 
The propensity of an inhibitor to forming a stable intermediate allows the 
inhibitor to compete well with the enzyme’s natural substrate.143  
 
A phenoxyphenol side-chain was also designed (Figure 3.3), resulting in 
compounds (53, 54, 55 and 56) with an oxygen at the β-position. Having an 
electron-donating oxygen atom next to the 2-methyl group would suppress the 
formation of an enolate. Hence, the inhibitor would be a poorly enolisable 
substrate. If the inhibition of AMACR is mediated by substrate analogues 
which block the active site instead of transition-state analogues, a poorly 
enolisable compound will be a better inhibitor. 
 
No systematic SAR study on AMACR inhibitor structure has been undertaken 
and the binding of the substrate side-chain (Figure 3.1, green) to AMACR is 
thought to occur at a non-specific hydrophobic surface, which does not have a 
specific side-chain binding pocket. A series of analogues with modified side-
chains at both para- and meta- position (Figure 3.3) were produced in order to 
examine this hypothesis. If the orientation of the side-chain has an effect on 
inhibitor potency, it would provide an insight into the structure of the binding 
pocket. This could be useful in designing further inhibitors to explore optimal 




Figure 3.3: Structures of potential inhibitors of AMACR. 
 
3.2 Synthesis of the proposed inhibitor structures 
3.2.1 Synthesis of 3-sulfide inhibitors 
Synthesis of the proposed 3-sulfide inhibitor 49 was attempted by converting 
the aromatic amine 57 to the corresponding thiophenol 58. The thiophenol 58 
could be reacted with ethyl 2-bromopropanoate followed by deprotection and 





Scheme 3.1: Attempted synthesis of 3-sulfide inhibitor 49 using an aromatic amine. 




, MeCN, -45 °C, 15 min, then ethyl 2-bromopropionate, 




, rt, 18 h. 
 
The synthesis of the thiophenol 58 was attempted with the Sandmeyer 
reaction (Scheme 3.2). The nucleophilic substitution of aromatic amine 57 
occurred via the formation of a diazonium salt intermediate170 61 which was 
reacted with potassium ethyl xanthate.171 The dithioester 62 was hydrolysed 
and subsequently acidified. Instead of giving the predicted thiophenol 58, the 
reaction produced a complex mixture without any of the desired compound. 
As thiophenol 58 is easily oxidised, it is possible that the product had been 
oxidised into acid 63 and/or into a dimer 64 during the reaction. 
 
Scheme 3.2: Attempted synthesis of thiophenol 58 using the Sandmeyer reaction. 
Reagents and conditions: i) DME, conc. H2SO4 aq., NaNO2 aq., 0 °C, 30 min, ii) potassium 




To test if the Sandmeyer reaction had worked, the reaction was repeated with 
the conventional nucleophile, NaI, instead of potassium ethyl xanthate 
(Scheme 3.3). The desired iodo-product 65 (75%) was obtained together with 
a by-product 66 (25%). This showed that potassium ethyl xanthate is not a 
very good nucleophile compared to NaI and could not be utilised in this 
reaction. 
 
Scheme 3.3: Synthesis of iodinated aromatic compound 65 using the Sandmeyer 
reaction. Reagents and conditions: i) DME, conc. H2SO4 aq., NaNO2 aq., 0 °C, 30 min, ii) 
NaI aq., 0 °, 10 min. 
 
As the attempts to synthesize thiophenol 58 using the Sandmeyer reaction 
failed, a new route was investigated. The phenol 67 was first coupled to N,N-
dimethylthiocarbamoyl chloride to form thiocarbamate 68 which was then 




Scheme 3.4: Synthesis of thiophenol 58 using the Newman-Kwart reaction. Reagents 
and conditions: i) NaH, DMF, 10 °C, then N,N-dimethylthiocarbamoyl chloride, 70 °C, 21 
h; ii) argon atmosphere, 280 °C, 1.7 h; iii) 2.5 M NaOH aq., MeOH, reflux, 4 h. 
 
The rearrangement from thiocarbamate 68 to carbamothioate 69 is named the 
Newman-Kwart reaction, in which the compound is heated to a very high 
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temperature to allow intra-molecular rearrangement of oxygen and sulfur 
atoms (Scheme 3.5).172, 173 The conversion was initially trialled at 260 °C 
following the protocol described by Brown et al.174 However, no conversion 
was observed at this temperature. The temperature was increased to 300 °C 
which resulted in some product formation but in very low yield (3%). The 
temperature was optimised and it was found that 280 °C gave the best 
conversion (36%) whilst minimising decomposition.  
 
Scheme 3.5: The proposed mechanism of the Newman-Kwart reaction.172, 173 
 
The carbamothioate 69 from the Newman-Kwart reaction was hydrolysed at 
reflux in methanol to obtain the thiophenol 58, which was purified by column 
chromatography to ca. 90% purity. Unfortunately, the thiophenol 58 was 
rapidly oxidised and it proved impossible to obtain the product in 100% purity 
and it was used without further purification. Later experiments showed that 
purification was unnecessary as long as the crude thiophenol 58 was used 
immediately to form the ester 59. The ester 59 was deprotected by reacting 
with a strong base to form the acid 60. The deprotected acid 60 was activated 
with CDI to form a carbonylimidazole intermediate 72 before being coupled to 
CoA-Li3 to form the corresponding acyl-CoA ester 49 (Scheme 3.6). The acyl-
CoA ester 49 was purified using solid phase extraction. The meta- acyl-CoA-
ester 50 was synthesised by an analogous route starting from meta-





Scheme 3.6: Synthesis of acyl-CoA ester 49 from its deprotected acid 60. Reagents and 
conditions: i) DCM, rt, 1 h; ii) THF, 0.1 M NaHCO
3 aq.
, rt, 18 h. 
 
 
Scheme 3.7: Synthesis of meta- acyl-CoA-ester 50 from meta- phenoxyphenol 73. 
Reagents and conditions: i) NaH, DMF, 10 °C, then N,N-dimethylthiocarbamoyl chloride, 





, MeCN, -45 °C, 15 min, then ethyl 2-bromopropionate, rt, 20 h; v) 2.5 M NaOH 






3.2.2 Synthesis of 3-sulfone inhibitors 
To synthesise para- sulfone 51, H2O2 was first used as an oxidising agent to 
convert the sulfide 59 to sulfone 79 (Scheme 3.8).41 The desired product was 
obtained but was mixed with ca. 40% of an unknown impurity which could not 
be separated. It was postulated that H2O2 is not a sufficiently strong enough 
oxidising agent to fully oxidise the sulfide.  
 
 
Scheme 3.8: Attempted synthesis of para- sulfone 79. Reagents and conditions: i) 
cyanuric chloride, MeCN, 30% (w/w) H2O2 aq., rt, 22 h. 
 
Another oxidising agent, OXONE® was tried and gave a yield of 82% of sulfone 
79 (Scheme 3.9).175 The synthetic routes for both para- and meta- sulfone 
were similar, with the reaction time being the only variation. The formation of 
para- sulfone 79 took only 4 hours (Scheme 3.9), whilst the reaction to produce 
the meta- sulfone 80 took 21 hours (Scheme 3.10) to go to completion. The 
resulting para- and meta- sulfones (79 and 80 respectively) were deprotected 
to form their corresponding acids (81 and 82, respectively). 
 
Scheme 3.9: Synthesis of para- sulfone 79 and its deprotection. Reagents and conditions: 
i) OXONE®, MeOH/THF (1:1), rt, 4 h; ii) 2.5 M NaOH aq., MeOH, rt, 2 h. 
 
 
Scheme 3.10: Synthesis of meta- sulfone 80 and its deprotection. Reagents and 




The para- deprotected acid 81 was coupled with CoA-Li3 to form acyl-CoA 
ester 51 (Scheme 3.11). A significant amount of uncoupled free CoA was 
found at the end of the reaction and the yield of para- acyl-CoA ester 51 was 
relatively low. The same procedure of CoA coupling was repeated on the 
meta- deprotected acid 82 and none of the meta- acyl-CoA ester 52 was found. 
A 1H NMR experiment (reaction followed with 1H NMR over time) showed that 
the imidazole derivative did not form. The coupling reaction was repeated 
using a standard acid (naproxen 12)2 and the imidazole derivative 84 formed 
with reasonable (71%) yield (Scheme 3.12). This suggested that the procedure 
of activating acids using carbonyldiimidazole worked but in this case the 
sulfone electron-withdrawing group might render the starting material less 
reactive to behave as a nucleophile. It seems that the electron-withdrawing 
effect was more significant with a sulfone possessing a meta- substituted 
aromatic side-chain compared to a sulfone possessing a para- substituted 
aromatic side-chain. Hence a low yield of the para- acyl-CoA ester 51 and zero 
yield of meta- acyl-CoA ester 52 were observed. 
 
 
Scheme 3.11: Synthesis of para- acyl-CoA ester 51 from its deprotected acid. Reagents 
and conditions: i) DCM, rt, 1 h; ii) THF, 0.1 M NaHCO
3 aq.







Scheme 3.12: Coupling of naproxen with CDI. Reagents and conditions: i) DCM, rt, 1h. 
 
Instead of activating the acid with carbonyldiimidazole 71, the activation of acid 
81 was attempted with ethyl chloroformate 85 (Scheme 3.13), which is another 
standard method of producing acyl-CoA esters.1, 176, 177 However, this method 
did not result in the formation of desired acyl-CoA ester 51.  
 
Scheme 3.13: Attempted synthesis of acyl-CoA ester 51. Reagents and conditions: i) 
THF, triethylamine, ethyl chloroformate, rt. 0.5 h; ii) THF, 0.1 M NaHCO3 aq., rt, 66 h.1 
 
3.2.3 Synthesis of phenoxyphenol side-chain inhibitors 
Instead of a 3-sulfide or 3-sulfone group, the 3-position was replaced with an 
oxygen atom (Figure 3.4) to investigate the effect of an electron-donating 
group on inhibitor potency. It has been shown that the side-chains of the R- 
and S- substrate binds to slightly different hydrophobic surface within the 
enzyme active site of MCR.146 Carnell et al. has also suggested that the R-
ibuprofenoyl-CoA 16 may be a more potent inhibitor of human AMACR (Ki = 
5.4 µM) than the S-ibuprofenoyl-CoA 17 (Ki = 19.2 µM).143 Hence, the 2-methyl 
group was arranged in both the R- and S- stereochemical configurations 
(Figure 3.4) to investigate any differences in competing with the natural 
substrate. The phenoxyphenol side-chain was arranged in a meta- or para- 
position (Figure 3.4) to investigate if it could bind differently to the enzyme and 





Figure 3.4: Potential AMACR inhibitors with a phenoxyphenol side-chain. 
The synthesis of the proposed inhibitors (Figure 3.4) was started by reacting 
the appropriate methyl lactate with a phenoxyphenol to produce the 
corresponding methyl ester. The methyl ester was hydrolysed to form the 
corresponding acid. The acid was coupled with CoA-Li3 using the standard 
carbonyldiimidazole method (vide supra). The whole reaction scheme starting 
from phenoxyphenol to the final acyl-CoA ester was shown in Scheme 3.14. 
Only one example of the acyl-CoA ester 53 is shown as all of them followed 
the same route. 
 
Scheme 3.14: Synthesis of acyl-CoA ester 53 from its corresponding phenoxyphenol. 
Reagents and conditions: i) Triphenylphosphine, methyl S-lactate, THF, DEAD, rt, 24 h; 
ii) 2.5 M NaOH aq., MeOH, rt, 2.5 h; iii) DCM, CDI, rt, 1 h, then THF, 0.1 M NaHCO3 aq., 
CoA-Li
3




A 4-phenoxyphenol 67 and 3-phenoxyphenol 73 were used to produce a 
methyl ester with a para- (87 and 91) and meta- (93 and 95) side-chains, 
respectively. The phenoxyphenol could either react with a methyl S-lactate 89 
to form the R-methyl esters (87 and 93) or a methyl R-lactate 90 to form the 
S-methyl esters (91 and 95). Methyl esters (87, 91, 93 and 95) were 
hydrolysed to form the corresponding acids (88, 92, 94 and 96, respectively) 
(Scheme 3.15). 
 
Scheme 3.15: Various combinations of phenoxyphenol and methyl lactate to produce 
methyl esters with a para- or meta- side-chain and R- or S- stereochemical configuration. 
These were hydrolysed to form the corresponding acids. Reagents and conditions: i) 
Triphenylphosphine, THF, diethyl azodicarboxylate (DEAD), rt, 24 h; ii) 2.5 M NaOH aq., 
MeOH, rt, 2.5 h. 
The reaction of phenoxyphenol and methyl lactate was performed using the 
Mitsunobu reaction (Scheme 3.16).178-180 Triphenylphosphine 97 first reacted 
with the diethyl azodicarboxylate (DEAD) 98 to produce an intermediate 99 
that would deprotonate the phenol 67. The OH group from the methyl lactate 
89 attacks the positively charged phosphorus atom to produce an oxonium 
105. The phenoxide 100 reacted with the resulting oxonium cation 105. This 
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is substituted using an SN2 reaction which led to the formation of a methyl 
ester 87 with inversion of stereochemical configuration.  
Scheme 3.16: The mechanism of the Mitsunobu reaction.178-180 
 
3.2.4 Synthesis of long-chain inhibitors 
In addition to substrates with a sulfide and sulfone group at β-position, these 
groups were also placed at the γ-position. It would be interesting to see if 
having these group at γ-position has any electron-withdrawing effect to the α-
proton, and whether they could affect the enolisability of the compound. If they 
could improve the enolisability, the compound would mimic the transition-state 
analogues better and could potentially increase the inhibitor potency. As Dr 
Daniel Darley from the MDL group has already prepared long-chain acids with 
sulfide 107 and sulfone 108 at the γ-position, no further acids were 
synthesised. These acids were analysed to confirm their identity and purity, 
and subsequently coupled with CoA-Li3 to produce the corresponding acyl-





Scheme 3.17: Synthesis of long-chain inhibitors from their corresponding acids. 







3.3 Limitations of the currently reported assays 
Attempts to measure the activity of AMACR and to test the potency of AMACR 
inhibitors are hampered by the limited number of convenient assays 
available.1, 85, 106, 145 This is mainly due to the enzyme being a racemase. 
AMACR ‘racemises’ the 2-methyl group from one stereochemical 
configuration to another while the remaining structure of substrate remains 
unchanged.1 This makes the substrate and product almost indistinguishable 
from one another by most analytical methods except by measurements of 
chirality which are insensitive and time-consuming. Another draw-back is that 
acyl-CoA inhibitors can potentially undergo ‘racemisation’ as they are 
structurally similar to substrate.Therefore, it might be difficult to determine if it 
is substrate or inhibitor ‘racemisation’ that is been measured. Hence, it is very 
tricky to develop an assay to measure the change from the substrate to the 
product (i.e., enzyme activity) or to measure the suppression of such a change 
(i.e., drug potency). Assays for other racemases also suffer from the same 
problems, and a very limited number of assays, especially high-throughput 
assays, have been developed.181-183 
 
Currently, there are AMACR assays that are based on the use of hydrogen 
isotopes such as the exchange of hydrogen with deuterium which can be 
measured with 1H NMR1, 2, 147, 184 or the measurement of radioactivity due to 
the release of tritium from a 3H-labelled substrate.85, 91 These methods 
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measure α-proton exchange and not ‘racemisation’ and a kinetic isotope effect 
is probably also present, which complicates analyses. There are also HPLC or 
GLC methods for measuring AMACR activity91, 145 as well as a CD assay106 to 
study the changes in chirality between the substrate and the product. 
However, each assay has its own flaws and as they are not high-throughput, 
the measurements are very time consuming. 
 
3.4 Assay to determine binding of potential AMACR inhibitors to the 
enzyme 
A limited number of compounds were designed as potential AMACR inhibitors 
in this current study. The number of compounds synthesised might not be 
sufficient to fully explore the SAR of AMACR inhibitors, but they serve as a 
good starting point to allow parallel study of inhibitor design as well as the 
development of a more convenient AMACR assay. 
 
To characterise the potential inhibitors which were synthesised, they were first 
tested using the deuterium wash-in assay.1, 2 If AMACR catalyses α-proton 
exchange, it shows that the compound binds to the enzyme and is a substrate, 
and therefore potentially of use as a competitive inhibitor. If the compound is 
a substrate of AMACR, it will probably also be ‘racemised’ by the enzyme (for 
a definite confirmation of ‘racemisation’, a derivatisation of products has to be 
performed).1 
 
Inhibitor acyl-CoA esters were dissolved in 2H2O and the concentrations of the 
stock solutions were determined by 1H NMR.2 These acyl-CoA esters were 
incubated with AMACR in the presence of 2H2O. Heat-inactivated AMACR was 
used as a negative control. After 1 h of incubation at 30 °C, the enzyme was 
heat inactivated and 1H NMR was used to measure the levels of α-proton 
exchange. 
 
When acyl-CoA ester 49 was incubated with active AMACR, its α-proton was 
exchanged for deuterium. As a result, the 2-methyl peak turned from a doublet 
(at 1.34 ppm) to an unresolved triplet (appeared as a single peak at 1.33 ppm) 
as it was next to a deuterium instead of a proton and is no longer split by a 
54 
 
proton (Figure 3.5 C). The doublet of the compound when incubated with heat-
inactivated enzyme (Figure 3.5 B) and the single peak resulted from the action 
of live enzyme on the compound (Figure 3.5 C) were integrated. These 
integrals were used to calculate the percentage of exchange. A limited amount 
of non-enzymatic exchange occurrs, as shown by the spectrum from the 
incubation of the compound with the heat-inactivated enzyme (Figure 3.5 B). 
This may be due to the electron-withdrawing properties of the sulfide which 
reduces the pKa of the α-proton and makes the deprotonation event occur 
more readily. After taking into account the non-enzymatic exchange, acyl-CoA 




























Figure 3.5: Different splitting patterns of 2-methyl peak at ca. 1.35 ppm of potential 
inhibitor 49 on 1H NMR spectra. A) The compound was dissolved in 2H2O prior to the 
enzyme assay; B) The compound (final assay concentration 100 µM) incubated with heat-
inactivated AMACR (final assay concentration 0.18 mg mL-1; 3.82 µM); C) The compound 
(final assay concentration 100 µM) incubated with active AMACR (final assay 
concentration 0.18 mg mL-1; 3.82 µM). 
 
With acyl-CoA ester 50, an extensive non-enzymatic exchange has occurred, 
resulted in very similar spectra for both the samples containing heat-
inactivated enzyme (Figure 3.6 B) and active enzyme (Figure 3.6 C). More 
than 70% deuterium exchange has occurred in the sample containing heat-
inactivated enzyme, showing that exchange of the α-proton in this compound 












Figure 3.6: Different splitting patterns of 2-methyl peak at ca. 1.30 ppm of potential 
inhibitor 50 on 1H NMR spectra. A) The compound was dissolved in 2H2O prior to the 
enzyme assay; B) The compound (final assay concentration 100 µM) incubated with heat-
inactivated AMACR (final assay concentration 0.18 mg mL-1; 3.82 µM); C) The compound 
(final assay concentration 100 µM) incubated with active AMACR (final assay 
concentration 0.18 mg mL-1; 3.82 µM). 
 
The deuterium wash-in assay was only used to investigate a couple of the 
potential inhibitors which were synthesised. It aimed to prove that the 
manipulation of the side-chain of acyl-CoA ester would still allow the binding 
of the compound to AMACR and it predicts that these compounds would 








compounds tested have been shown to be substrates of AMACR and 
underwent α-proton exchange. This was not surprising as AMACR has been 
shown to accept a spectrum of substrates with a number of different types of 
side-chains structures.2, 76, 146 
 
This assay could be used to test whether a compound is a substrate for 
AMACR but would not be useful as an inhibitor assay for several reasons. Both 
the substrate and the potential inhibitor of AMACR have a 2-methyl group 
which has a chemical shift of ca. 1.00 ppm.1 To observe deuterium exchange 
by integrating the change from doublet to single with overlapping peaks would 
be very difficult if not impossible. In addition, the involvement of deuterium in 
both substrate and inhibitor might complicate the results due to the operation 
of a solvent kinetic isotope effect. 
 
3.5 Fluoride elimination assay  
As the deuterium wash-in assay was unsuitable for measuring the potency of 
the compounds as AMACR inhibitors, an alternative assay method was 
sought. Yevglevskis et al. reported that syn- 113 and anti- 3-fluoro-2-
methyldecanoyl-CoA 114 could undergo an elimination reaction catalysed by 
AMACR (Figure 3.7).3 This was the first report that AMACR could perform a 
reaction other than ‘racemisation’ on one of its substrates.3  
 
 
Figure 3.7: Syn- and anti- 3-fluoro-2-methyldecanoyl-CoA substrates reported by 
Yevglevskis et al.3 
 
As discussed previously, the analysis of 1H NMR can be complicated by 
multiple peaks from the substrate and the product. In addition, to probe the 
substrates stereochemical configuration entailed a derivatisation step, which 
can be tricky on the small amount of material involved. The 3-fluoro-2-
methyldecanoyl-CoA esters were originally synthesised with the aim of 
overcoming these problems. If the ester was ‘racemised’ by AMACR, it would 
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produce diastereomers (Scheme 3.18) which have different chemical shifts in 
the 1H and 19F NMR spectra. Since the only peaks in the 19F spectra would be 
from the substrate (i.e., no background peaks as fluorine is relatively rare, 
unlike in the 1H spectrum), it would be easier to analyse the reaction mixture 
as only two peaks of diastereotopic fluorine would be expected.3 
 
Scheme 3.18: The expected ‘racemisation’ reaction catalysed by AMACR.3 
 
However, the results showed that instead of being ‘racemised’ by AMACR, the 
3-fluoro-2-methyldecanoyl-CoA esters 114 underwent elimination. In the 1H 
NMR spectrum, the 2-methyl peak did not convert from a doublet into an 
unresolved triplet. Instead the 2-methyl doublet at ca. 1.10 ppm diminished 
with time (Figure 3.8). A new peak at ca. 1.75 ppm also appeared and 
increased in intensity over time (Figure 3.8). This new peak corresponded to 
a methyl peak next to a double bond, suggesting that the saturated substrate 
was converted into an unsaturated product. When the reaction was analysed 
by 19F NMR spectrum, the organic fluorine peak at ca. -181 ppm disappeared 
and a peak that corresponded to the inorganic fluoride anion at ca. -122 ppm 
appeared. This showed that anti-3-fluoro-2-methyldecanoyl-CoA 114 
underwent an elimination reaction catalysed by AMACR to form an 
unsaturated product 117 and inorganic fluoride 118 (Figure 3.8). The identity 
of the unsaturated product 117 was confirmed by the synthesis of an authentic 
product.3 The same elimination reaction was observed with syn-3-fluoro-2-
methyldecanoyl-CoA 113 but as this was less stable, it underwent a significant 
non-enzymatic elimination reaction.3 The AMACR-catalysed elimination 
reaction was irreversible as the incubation of the unsaturated compound 117 





Figure 3.8: 1H NMR time course of (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 (final 
assay concentration 100 µM) when incubated with AMACR (final assay concentration 
0.12 mg mL-1; 2.55 µM) over 60 min. The saturated substrate decreased over time (shown 
by diminished peak at ca. 1.10 ppm) and the unsaturated product increased over time 
(shown by the formation of peak at ca. 1.75 ppm). 
 
3.5.1 Evaluation of potential AMACR inhibitors using fluoride elimination 
assay 
The fluoride elimination assay could be used to test for potential AMACR 
inhibitors as the methyl peaks of the substrate and the product have 
significantly different chemical shifts (at ca. 1.10 and 1.75 ppm respectively). 
Non-overlapping peaks make it much easier to quantify the extent of substrate 
conversion. As the anti-acyl-CoA ester 114 has been shown to be more stable 
than the syn- ester 113,3 (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 (anti-) 
was chosen for use in the fluoride elimination assay. If a compound was an 
inhibitor of AMACR, it would inhibit the elimination reaction of the (2R,3R)-3-
fluoro-2-methyldecanoyl-CoA 114, and this would be reflected by a reduction 
in conversion as measured by integration of the peaks at ca. 1.10 and 1.75 
ppm (Figure 3.9). 
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In the absence of an inhibitor, around 50% of (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA 114 substrate was converted to product after 1 h in the 
presence of active enzyme. The spectrum shows almost equal integration for 
the doublet at ca. 1.10 ppm and singlet at ca. 1.75 ppm (Figure 3.9 B). In the 
presence of an inhibitor, the level of elimination will be reduced to an extent 
depending on the potency of the inhibitor. Hence, there is less conversion from 
the doublet to the singlet (Figure 3.9 C). In the negative control (heat-
inactivated enzyme), there was only non-enzymatic background elimination so 
the spectrum shows mostly a doublet with a minimal amount of singlet (<10% 
conversion) (Figure 3.9 D). The inhibitor N-dodecyl-N-methylcarbamoyl-CoA 
30 at 100 µM almost completely abolished the enzyme activity as shown by 
peaks in the sample with active enzyme (Figure 3.9 B), inhibitor (Figure 3.9 C) 

























Figure 3.9: 1H NMR spectra of the fluoride elimination assay using (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA 114 (final assay concentration 100 µM) as the substrate, incubated 
with AMACR (final assay concentration 0.12 mg mL-1; 2.55 µM). The red circles show the 
doublet at ca. 1.10 ppm of the 2-methyl group from the saturated substrate 114 and the 
green circles show the singlet at ca. 1.75 ppm of the 2-methyl group from the unsaturated 
product 117. A) Substrate 114 in 2H2O prior to the enzyme assay; B) Positive control 
without any inhibitor; C) Reaction in the presence of an inhibitor (N-dodecyl-N-















Standard (prior to enzyme assay) 
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To quantify the level of elimination, the doublet at ca. 1.10 ppm and the singlet 
at ca. 1.75 ppm were integrated. Enzymatic conversion was calculated by 
correcting for background elimination in the negative control. The elimination 
of the substrate in the absence of an inhibitor was used as a comparison 
standard to allow a ‘rank order’ of compounds to be produced between 
different experiments. The percentage of elimination in the presence of an 
inhibitor was calculated by subtracting the integration from the negative control 
and was normalised to positive control. The measurements were done in 
duplicates and average values and standard deviations were calculated. 
 
19F NMR was also run to detect the presence of inorganic fluoride anion. In 
the positive control, both the organic fluorine peak at ca. -181 ppm and 
inorganic fluoride peak at ca. -122 ppm were observed as ~50% of the 
substrate had undergone elimination after 1 h (Figure 3.10 B). In the presence 
of an inhibitor, this elimination was much reduced and less fluoride anion was 
produced as was shown by a smaller integration at peak of ca. -122 ppm 
(Figure 3.10 C). No significant elimination occurred in the negative control 
containing heat-inactivated enzyme, so no peak at ca. -122 ppm was observed 
(Figure 3.10 D). These results are consistent with those obtained by 1H NMR. 
 
















Figure 3.10: 19F NMR spectra of fluoride elimination assay using (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA 114 (final assay concentration 100 µM) as the substrate, incubated 
with AMACR (final assay concentration 0.12 mg mL-1; 2.55 µM). A) Substrate 114 in 2H2O 
prior to the enzyme assay; B) Positive control in the absence of an inhibitor; C) Reaction 
in the presence of an inhibitor (final assay concentration 100 µM); D) Negative control 
containing heat-inactivated AMACR. The red circles show the organic fluorine peak from 
the substrate while the green circles show the inorganic fluoride anion peak formed from 
the elimination reaction. Please note that the regions at -181 and -122 ppm were 
expanded and the spectra were not continuous (as indicated by the double lines).  
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The initial protocol involved adding the substrate and the potential AMACR 
inhibitor at the same time to the enzyme. The percentage conversion was 
calculated using 1H NMR based on the integration of the 2-methyl peaks from 
the substrate and the product. The inhibitor was first tested at a final 
concentration of 50 µM. It was found that the inhibition was minimal especially 
for a weak inhibitor and this could result in large errors due to the difficulty in 
quantifying small changes. The final concentration of inhibitor was therefore 
set at 100 µM for subsequent tests. 
 
All the potential AMACR inhibitors that had been synthesised were tested 
using the fluoride elimination assay and the results are shown in Table 3.1. 
Except for compound 55 which showed almost no inhibition of AMACR (<5%), 
all of the novel compounds (49, 50, 51, 53, 54, 56, 109 and 110) were 
moderate inhibitors of the enzyme (15-38% inhibition). In addition to the novel 
compounds, some known compounds were also tested. Ibuprofenoyl-CoA 119 
has previously been shown to be an inhibitor of AMACR with Ki value of 56 
µM.91 It was tested in this assay and gave a positive result, inhibiting the 
elimination of the substrate by 24%, consistent with previous findings91, 143 that 
it was a moderate AMACR inhibitor. Darley et al. reported that R- 44 and S-2-
methyldecanoyl-CoA 38 were substrates of AMACR with Km values of 1.2 mM 
for both of them.1 These substrates are expected to behave as competitive 
inhibitors of AMACR. They were tested in the fluoride elimination assay and 
showed moderate to weak inhibition on AMACR (19% for R-acyl-CoA ester 44 




















Compound Relative conversion 
compared to no inhibitor 
Reduction in conversion 
compared to no inhibitor 
No inhibitor 100% 0% 
38 88.9 ± 6.4% 11.1% 
44 80.9 ± 5.3% 19.1% 
49 78.1 ± 10.4% 21.9% 
50 76.1 ± 0.5% 23.9% 
51 75.0 ± 1.7% 25.0% 
53 61.8 ± 7.1% 38.2% 
54* 84.6 ± 15.0% 15.4% 
55 >95% <5% 
56* 61.8 ± 3.4% 38.2% 
109 72.0 ± 5.5% 28.0 % 
110 80.5 ± 5.8% 19.5% 
119 76.1 ± 0.2% 23.9% 
Table 3.1: Fluoride elimination assay. (2R,3R)-3-Fluoro-2-methyldecanoyl-CoA 114 
substrate (final assay concentration 100 µM) and potential inhibitor were added to 
AMACR (final assay concentration 0.12 mg mL-1; 2.55 µM) at the same time and 
incubated with the enzyme for 1 h. The results show the percentage of elimination after 
correction for non-enzymatic conversion and are normalised to the positive control 
(100%). The results are quoted as average values (2 replicates) ± standard deviation. All 
inhibitors tested were in final concentration of 100 µM except those with an asterisk which 
were tested at 50 µM. 
 
The problem with adding the inhibitor and substrate to the enzyme at the same 
time is that the inhibitor may not have a chance to bind to the enzyme before 
it competes for binding with the substrate. The relative kinetics and binding 
affinities of substrate compared to inhibitor could affect the results. This is 
usually not a problem for a classical reversible inhibitor that associates and 
dissociates from the enzyme at a rate much faster than the formation of the 
product.185 If a compound is a slow-binding inhibitor, not pre-incubating it with 
the enzyme would underestimate the potency of the inhibitor and potentially 
could give a false negative result. A slow-binding inhibitor will bind in a time-
dependent fashion, so sufficient pre-incubation time allows it to bind to the 
binding site of the enzyme to compete with the substrate.186 Hence, the 
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protocol was modified to incorporate a 10-min pre-incubation time of inhibitor 
and enzyme in order to identify time-dependent inhibitors. The final 
concentration of inhibitor was the same as the previous protocol (100 µM) to 
allow comparisons between protocols. 
 
The results using the protocol involving pre-incubation (Table 3.2) were 
generally improved compared to the previous protocol. The best inhibitors from 
the previous protocol was 53 and 56 with 38% inhibition. The percentage 
inhibition was markedly increased to 51% for inhibitor 53 but there was no 
change for 56 (38%). This suggests that inhibitor 53 could be a slowly binding 
but a potent inhibitor and pre-incubation allowed it to bind to the enzyme to 
compete with the substrate. On the other hand, compound 56 was a fast 
binding inhibitor. Binding reached equilibrium rapidly so pre-incubation made 
no significant difference to its ability in inhibiting the enzyme. The previous 
protocol also gave a false negative result with compound 55 which showed 
<5% inhibition (vide supra). Using the pre-incubation protocol, compound 55 
was shown to be a moderate inhibitor where it inhibited the elimination of the 
substrate by 27%. The differences in results could be due to the relative 
kinetics of inhibitor binding compared to the substrate. 
 
Known compounds were also tested as inhibitors using the pre-incubation 
protocol. The most potent inhibitor reported to-date is N-dodecyl-N-
methylcarbamoyl-CoA 30 with Ki value of 98 nM.145 Using the fluoride 
elimination assay, N-dodecyl-N-methylcarbamoyl-CoA 30 was shown to inhibit 
the enzyme by 83%, consistent with the finding that it was a potent inhibitor. 
The acyl-CoA esters of 2-APA drugs were also tested as they are known 
substrates of AMACR.2 Presumably, they would behave as competitive 
inhibitors of the elimination reaction. Fenoprofenoyl-CoA 13 and ibuprofenoyl-
CoA 119 showed moderate inhibition to AMACR, at 25% and 26%, 
respectively.  Ketoprofenoyl-CoA 120, naproxenoyl-CoA 121 and 
flurbiprofenoyl-CoA 122 each showed ca. 10% reduction in conversion, 




Ebselen 34, ebselen oxide 35 and rose bengal 37 have been identified as 
inhibitors of AMACR by Wilson et al.85 Ebselen oxide 35 was the most potent 
inhibitor reported in their assays, with an IC50 value of 0.80 µM, while ebselen 
34 had an IC50 of 2.79 µM and rose bengal 37 had an IC50 of 10.0 µM.85 
Surprisingly, the fluoride elimination assay shows that of these 3 inhibitors, 
ebselen oxide 35 was the least potent, only inhibiting the elimination by 12%. 
In contrast, ebselen 34 and rose bengal 37 inhibited the elimination by more 
than 95%. As ebselen 34 covalently binds to the histidine residue to inactivate 
the enzyme,85 measuring IC50 values is an inappropriate method of 
determining the potency of irreversible inhibitors. Rose bengal 37 is not a 
conventional reversible inhibitor. Its ability to inactive the enzyme appears to 
be mediated by the production of singlet oxygen followed by oxidative damage 
of the enzyme187-189 and hence its effects are not pharmacologically 
tractable.190 Hence, the results of fluoride elimination assay are not directly 






















Compound Relative conversion 
compared to no inhibitor 
Reduction in conversion 
compared to no inhibitor 
No inhibitor 100% 0% 
13 75.0 ± 0.4% 25.0% 
30 16.8 ± 1.9% 83.2% 
34 <5% >95% 
35 88.2 ± 5.4% 11.8% 
37 <5% >95% 
53 49.2 ± 0.9% 50.8% 
54 68.2 ± 1.9% 31.8% 
55 72.8 ± 0.9% 27.2% 
56 62.1 ± 5.5% 37.9% 
119 74.1 ± 7.2%  25.9% 
120 92.0 ± 8.6% 8.0% 
121 88.8 ± 4.0% 11.2% 
122 91.6 ± 2.0% 8.4% 
Table 3.2: Fluoride elimination assay. Potential AMACR inhibitors (final assay 
concentration 100 µM) were pre-incubated with human AMACR (final assay concentration 
0.12 mg mL-1; 2.55 µM) for 10 min before (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 
substrate (final assay concentration 100 µM) was added to the enzyme/inhibitor mixture. 
The results show the percentage of elimination after correction for non-enzymatic 
conversion and are normalised to the positive control (100%). Data are quoted as average 
values (2 replicates) ± standard deviation.  
 
A range of small molecules were sent to our lab by Professor Paul 
Groundwater from the University of Sydney, Australia for testing using the 
fluoride elimination assay (Table 3.3). These molecules had been identified as 
potential inhibitors by structure-based design using the MCR crystal 
structures. These drug-like molecules have small molecular weights (ranging 
between 200-350 Da.) and do not have the CoA moiety which is bulky and 
highly charged. They were first tested using a final concentration of 100 µM 
for both substrate and inhibitor. None of the compounds showed any inhibition 
to the enzyme under these assay conditions.  
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The Km of the (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 substrate has been 
shown to be 21 µM.3 As the concentration of substrate used in the assay is 
nearly 5 times the Km value, competitive inhibition could be overcome by high 
concentration of substrate. Hence, the small reduction in activity by a weak 
competitive inhibitor would be difficult to observe. To investigate if the inhibition 
was masked by the high concentration of substrate, the concentration of 
(2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 was lowered to 20 µM. 
 
The experiment was re-run with 100 µM of potential inhibitor and 20 µM of 
substrate (Table 3.3). Except for compound 123 which still did not show any 
inhibition, the other four compounds showed some inhibition of the enzyme at 
20 µM substrate. The most promising compound was 124, which inhibited the 
enzyme by 44%. The other compounds 125, 126 and 127 inhibited the enzyme 
by 16%, 23% and 6% respectively. The level of inhibition was still significantly 
lower than that of the novel fenoprofenoyl-CoA analogue 56 which inhibited 
the enzyme by 38% in assays containing 100 µM substrate and 69% in assays 








Compound Relative conversion 
compared to no inhibitor 
Reduction in conversion 
compared to no inhibitor 
No inhibitor 100% 0% 
56  31.3 ± 8.5% 68.7% 
123 ˃95% <5% 
124 56.1 ± 2.4% 43.9% 
125 83.6 ± 3.6% 16.4% 
126 76.6 ± 8.2% 23.4% 
127 94.1 ± 14.7% 5.9% 
Table 3.3: Fluoride elimination assay on small molecules designed by Professor Paul 
Groundwater. The compounds (final assay concentration 100 µM) were pre-incubated 
with human AMACR (final assay concentration 0.01 mg mL-1; 0.21 µM) for 10 min before 
(2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 substrate (final assay concentration 20 µM) 
was added to the enzyme/inhibitor mixture. The results show the percentage of 
elimination after correction for non-enzymatic conversion and are normalised to the 






3.5.2 Attempts to develop a high-throughput assay based on fluoride 
elimination 
The fluoride elimination assay offers advantages compared to the deuterium 
wash-in assay, as product formation is irreversible and the peaks of substrate 
and product are non-overlapping. However, using 1H NMR to quantify the 
conversion is still a laborious method which is time-consuming and low-
throughput. The aim was to turn this assay into a high-throughput multi-well 
assay to allow efficient screening of potential AMACR inhibitors. This can be 
done by the use of sensors to quantify the levels of the fluoride product. The 
fluoride anion 118 released from the fluoro-substrate 114 (Scheme 3.19) could 
be detected by a fluoride sensor and could potentially be developed into a 
multi-well high-throughput assay. 
 
 
Scheme 3.19: Irreversible elimination of fluoride from (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA 114 substrate by AMACR. 
 
3.5.2.1 tert-Butyldimethylsilyl-protected fluorescein as a fluoride sensor 
Rydzik et al. reported a fluorescent assay based on fluoride release to 
measure the activity of γ-butyrobetaine hydroxylase and to screen for potential 
inhibitors.191 The fluoride anions removed the silyl-protecting group from tert-
butyldimethylsilyl-protected fluorescein 128 (Scheme 3.20) and the 
fluorescence intensity of the fluorescein 129 is proportional to the enzyme 
activity.191 The protected fluorescein 128 could be used in organic/aqueous 
environment and should be ideal for AMACR which needs a buffer system but 
can tolerate DMSO (vide infra). This fluoride sensor 128 was investigated to 




Scheme 3.20: The released fluoride anions react with the protected fluorescein to yield 
fluorescence at 520 nm. 
 
The tert-butyldimethylsilyl-protected fluorescein 128 was synthesised using 
the same method described by Rydzik et al.191 To quantify the enzyme activity, 
the fluorescence intensity requires a linear relationship with the concentration 
of fluoride anion. Fluorescence intensity as a function of fluoride anion 
concentration was therefore determined. 
 
Different concentrations of fluoride (up to 20 µM) were incubated with 
protected fluorescein in a mixture of DMSO and NaH2PO4-NaOH buffer. The 
buffer was prepared using highly purified water in order to prevent fluoride 
contamination from the water source. The fluorescence intensity was 
measured and plotted against fluoride concentration. No linear relationship 
was observed, and in fact, the results seemed quite erratic despite several 
attempts to repeat the experiment.  
 
The buffer system was changed to Tris-HCl as this buffer was reported to give 
less background noise.191 The concentration of fluoride was increased to a 
much higher range than what was reported previously.191 The result shows an 
almost linear relationship (hyperbolic curve) between fluorescence intensity 
and high concentrations of fluoride (Figure 3.11). However, very high levels of 
scatter in the data was observed at low concentrations of fluoride, which are 
similar to the concentrations anticipated to be found in the enzyme assay 
(Figure 3.12). As the assay was intended to be used to screen for potential 
AMACR inhibitor, it is important to have a linear relationship at low 
concentrations of fluoride. High levels of scatter make it difficult to determine 
the residual enzyme activity, which is required to measure potency. There 
could be a number of reasons for high levels of scatter; could be due to fluoride 
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contamination from external sources, spontaneous decomposition of the 
sensor or aggregation of the sensor, etc. High scatter in this range of 
concentrations made it very unreliable when correlating fluorescence with 
enzyme activity, and hence this method was not developed further. 
Fluoride concentration (micromolar)

























Figure 3.11: The calibration curve of corrected fluorescence intensity against fluoride 
concentration. The hyperbolic curve shows an almost linear relationship between 40 µM 
to 320 µM of fluoride and reaches saturation at higher concentrations. Large scatter in 
the data is observed at low concentrations of fluoride. 














Figure 3.12: The expansion of the calibration curve from Figure 3.11. Corrected 
fluorescence intensity was plotted against 0 µM to 40 µM of fluoride. Large scatter in the 
data is observed in this concentration range. The results are quoted as average values 
(n = 12) ± standard deviation. 






























































3.5.2.2 Boronate-based fluorescent probe as a fluoride sensor 
A large scatter in data was observed at low concentrations of fluoride when 
using a fluoride sensor that was turned on by fluoride anions (silyl-protected 
fluorescein). In order to reduce the error margin, a “turn-off” sensor was tried. 
Sun et al. reported a boronate-based fluorescent sensor 131 that could be 
switched off by a strong nucleophile and was used for the detection of 
peroxynitrite, a strong oxidant in cells.192 Fluoride, just like peroxynitrite, is a 
strong nucleophile, and was expected to interact with the sensor in the same 
way. 
 
The boronate-based fluorescent sensor 131 has extended planar aromatic 
rings and is strongly fluorescent (Scheme 3.21 A). As boron is an electron-
deficient atom, it forms a strong interaction with the nitrogen atom. Hence, the 
lone pair of the nitrogen is not available to the fluorophore (extended planar 
aromatic rings) to cause photoinduced electron transfer (PET). Fluoride anion 
is a strong nucleophile and can bind to the electron-deficient boron to release 
the nitrogen lone pair of electrons (Scheme 3.21 B). The lone pair of the 
nitrogen can now act as an electron donor to the fluorophore which has its 
electron in the excited state.193 This process is called PET where it quenches 
the fluorescence and “turns off” the probe. The higher the concentration of 
fluoride anions, the greater the quenching effect due to PET. The fluorescence 




Scheme 3.21: Boronate-based fluorescent probe as a fluoride sensor: A) Strongly-
fluorescent sensor in the absence of fluoride anions; B) The proposed mechanism of 
fluorescence quenching by photoinduced electron transfer (PET) where fluoride anions 
release the lone pair of the nitrogen and make them available to cause fluorescence 
quenching. 
 
A sample of the boronate-based fluorescence sensor 131 was obtained from 
Dr Xiaolong Sun192 to be tested with fluoride anions. A standard calibration 
curve of fluorescence intensity against fluoride concentration was plotted. As 
the probe has been shown to work well between pH 3.0 and pH 8.0,192 the 
usual buffer for AMACR, NaH2PO4-NaOH, pH 7.4, was used. The experiments 
were initially performed in 80% (v/v) acetonitrile and 20% (v/v) buffer. An 
overall trend of decreasing fluorescence intensity with increasing fluoride 
concentration was observed (Figure 3.13). However, the fluorescence 
readings fluctuated with very large scatter of the data at low concentrations of 

















Figure 3.13: The calibration curve of fluorescence intensity against fluoride concentration 
in a reaction mixture in 80% (v/v) acetonitrile. 
 
The assay was repeated using 100% (v/v) acetonitrile where 
tetrabutylammonium fluoride (TBAF) was used as the fluoride source. The 
result showed an inverse standard linear curve reaching saturation at 75 μM 
fluoride (Figure 3.14). The promising result obtained using a pure organic 
solvent system suggested that the large scatter of the data in the previous 
experiment might be due to high amount of aqueous buffer in the final assay. 
Further experiments were attempted by increasing the concentration of 
organic solvent to 95% (v/v). The first experiment using 95% (v/v) acetonitrile 
showed a promising inversely linear relationship at low concentrations of 
fluoride (0-50 µM) (Figure 3.15). Unfortunately, the result was not re-
producible. Variable readings were recorded in subsequent experiments under 
the same conditions. 
 
 





































Figure 3.14: The calibration curve of fluorescence intensity against fluoride concentration 
in a reaction mixture in 100% (v/v) acetonitrile. 










Figure 3.15: The calibration curve of fluorescence intensity against fluoride concentration 
in a reaction mixture in 95% (v/v) acetonitrile. 
 
The results showed that reaction has to be performed in organic solvent to 
obtain an inversely linear curve. The presence of small amounts of buffer 
solution distorts the result, possibly caused by variable levels of hydration of 
the fluoride anion in water, resulting in a variable amount of nucleophile 
available for the reaction. Hence, the probe is not suitable for testing the 
















































elimination of fluoride from the substrate by AMACR. The system would need 
to be able to tolerate an aqueous solution as the fluoride would be released 
by the AMACR in a buffer solution. In addition, it would need to have a 
linear/inverse linear relationship at low concentrations of fluoride in order to 
measure enzyme activity at low concentrations of substrate. 
 
3.6 Fluorescence-based competitive binding assay 
Even though fluoride detection using a fluoride sensor has the potential to be 
developed into a multi-well assay, it has been difficult to create a working 
system that gives accurate and reproducible data. An alternative was to 
measure the inhibitor potency using a fluorescence-based competitive binding 
assay. A fluorescent ligand 134 of AMACR was synthesised by Dr Maksims 
Yevglevskis.194 The ligand has two domains; the acyl-CoA ester binds to the 
enzyme acting as an enolate-intermediate analogue, and the extended 
aromatic rings are the fluorophore (Figure 3.16).194 The fluorescence intensity 
is different depending on whether ligand 134 is bound to the enzyme or exists 
freely in a solution.194 The binding constant of the fluorescent ligand 134 was 
measured as 3 µM.194 
 
 
Figure 3.16: Fluorescent ligand synthesised by Dr Maksims Yevglevskis.194 
 
A sample of the fluorescent ligand was obtained from Dr Maksims Yevglevskis 
to measure the potency of AMACR inhibitors. The fluorescent ligand was 
allowed to bind to the enzyme and the inhibitor was added after 10 min. The 
fluorescence intensity decreased with increasing concentrations of inhibitor as 
the fluorescent ligand was displaced by the inhibitor. IC50 and Ki values of the 
inhibitors were calculated (Table 3.4). A number of compounds produced 
random data that did not fit to a standard IC50 curve. They were assumed to 
have IC50 values of more than 1000 µM (Table 3.4). The experiment was 
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repeated but unfortunately, all of the data were not re-producible. Further 
investigations showed that fluorescent quenching had occurred even though 
the sample was incubated in the dark, suggesting that the ligand might be 
prone to rapid degradation.  
 
 
Compound IC50 value (µM) Ki value (µM) 
38 6.6 2.3 
49 >1000 - 
50 169.6 63.0 
53 3.1  1.0 
54 15.6 5.6 
55 451.9 168.2 
56 >1000 - 
109 5.1 1.7 
110 >1000 - 
Table 3.4: IC50 and Ki values of compounds tested with the fluorescence-based 
competitive binding assay. Ki values were calculated using the Ki calculator (website: 
http://sw16.im.med.umich.edu/software/calc_ki/).195, 196 
 
In considering potential differences in relative kinetics and binding affinities of 
substrate compared to inhibitors (vide supra), an alternative protocol where 
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the potential inhibitor was pre-incubated with AMACR before addition of the 
fluorescent ligand was also attempted. However, there was large scatter in the 
data and no correlation between fluorescence intensity and the concentrations 
of several inhibitors was found. Sensible IC50 values could not be obtained. 
Multiple attempts on the fluorescent-binding assay were unsuccessful. 
 
3.7 Multi-well colorimetric assay 
Instead of having an external probe that detects the product from an enzyme’s 
reaction (for example, a sensor that detects fluoride anion from the elimination 
of the fluoro substrate 114), Dr Maksims Yevglevskis has developed an 
alternative substrate of AMACR, 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-
CoA 135 (Figure 3.17).197 A colour is produced directly by the action of 




Figure 3.17: Substrate of AMACR that allows in situ detection of AMACR reaction.197 
 
The α-proton of the substrate 135 is deprotonated by catalytic bases of the 
enzyme to form an enolate intermediate (Scheme 3.22). The enolate 
intermediate 136 produces 2,4-dinitrophenolate 137 by elimination of the 
substrate side-chain (Scheme 3.22), in a similar way to the fluoride anion been 
eliminated from (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114. The enolate 
intermediate of substrate undergoes elimination as it has a moderate leaving 
group, 2,4-dinitrophenolate 137 (pKa value of the acid is 4.1).198 Unlike the 
fluoride anion which needs to be detected with a fluoride sensor, the product, 
2,4-dinitrophenolate 137 absorbs in the UV range so it can be directly 
measured. The substrate 135 is developed into a multi-well assay where its 





Scheme 3.22: The proposed mechanism of the elimination of 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 135 to form 2,4-dinitrophenolate 137, which absorbs at 354 nm (ε 
= 15.3 mM-1 cm-1).199 
 
A sample of 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135  was obtained 
from Dr Maksim Yevglevskis and used to measure the potency of potential 
AMACR inhibitors in a 96-well plate assay. An AMACR inhibitor was expected 
to reduce the production of 2,4-dinitrophenolate 137 and hence decrease the 
UV absorbance. The product 137 has a peak absorbance at 354 nm so the 
UV absorbance was measured at this wavelength. However, some aromatic 
inhibitors might have an UV absorbance with a maximum absorbance near to 
this wavelength, so a secondary absorbance at 390 nm was recorded as an 
alternative. The Km value of the substrate (58 µM) was used to decide the final 
concentration of the substrate in the assay. The average absorbance reading 
against the concentration of inhibitor was plotted to obtain the IC50 value of the 
inhibitor (Figure 3.18). For competitive inhibitors, Ki values (binding affinity of 
inhibitor) were calculated from IC50 values using the Cheng-Prusoff 
equation:200 
 
        ____________ 
 
where IC50 is the concentration of the inhibitor at which the inhibition is 50%, 
[S] is the substrate concentration used in the experiment and Km is substrate 
concentration to produce half of the maximal enzyme activity (58 µM). 
IC50 
1 + ([S]/Km) 
Ki =   
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Figure 3.18: A typical IC50 curve of an AMACR inhibitor. 
 
Even though Carnell et al. reported that R-ibuprofenoyl-CoA 16 was about four 
times more potent than S-ibuprofenoyl-CoA 17 (Ki = 5.4 µM vs. 19.2 µM),143 
such a trend was not observed in the novel fenoprofenoyl-CoA analogues 
(Table 3.5). R-inhibitors (53and 54) and S- inhibitors (55 and 56) did not show 
significantly different IC50 and Ki values (Table 3.5). No significant difference 
in the potency of inhibitors with a para- or meta- aromatic side-chains (49, 53 
and 55 compared with 50, 54 and 56, respectively) was observed. It is 
unknown why the acyl-CoA ester with a 3-sulfone group 51 has a six-times 
higher Ki value than the one with a 3-sulfide group 49 (479 nM vs. 80 nM). A 
sulfone group was expected to be more electron withdrawing and thus allow 
easier enolization and make the compound a better competitive inhibitor. The 
relatively high Ki value might be due to the steric hindrance by a bulky sulfone 
group compared to sulfide. The active site of AMACR seemed to be quite 
restricted around the area binding the 2-methyl group according to the 
modelling of the AMACR active site based on the MCR crystal structure.2, 108, 
146 Hence a large bulky group next to the 2-methyl group might affect the 
binding of the inhibitor in the active site of the enzyme. 
 



















All novel aromatic compounds showed quite similar Ki values and their 
differences were not greater than 10-fold. No specific structural features that 
improved the Ki value significantly were observed. The obtained data did not 
allow defining of the features resulting in higher potency in order to determine 
structural-activity relationships. This lack of selectivity in inhibitors binding to 
the enzyme is probably due to the side-chains binding to the methionine-rich 
hydrophobic surface which accepts a wide variety of structures. Aromatic rings 
seem to bind well to this region to give Ki values in nanomolar range (50- 480 
nM) (Table 3.5). Long alkyl-chain inhibitors 109 and 110 bind less well, as 
shown by their Ki values, which are in the low micromolar range (2 and 11 µM 
respectively) instead of nanomolar range (Table 3.5). The results suggest that 
π-interactions from aromatic rings could be important for binding. 
 
The novel fenoprofenoyl-CoA analogues were shown to be moderate AMACR 
inhibitor using the multi-well colorimetric assay and the results were consistent 
with the fluoride elimination assay (vide supra). Even though these novel 
compounds were not significantly more potent than the acyl-CoA ester of the 
2-APA (Table 3.6), the assay has shown that these inhibitors bind to AMACR. 
It is a promising start for the rational design of AMACR inhibitors as further 
exploration of the SAR of side-chains and other regions is now possible with 












Compound IC50 value (nM) Ki value (nM) 
49 135.0 79.9 
50 89.8 53.2 
51 809.8 479.2 
53 189.8 112.3 
54 515.1 304.8 
55 543.9 321.8 
56 283.3 167.6 
109 3331 1971 
110 18670 11050 
Table 3.5: IC50 and Ki values of novel compounds tested with the multi-well colorimetric 
assay. 
 
The results showed that having an electron-donating group (oxygen) or 
electron-withdrawing groups (sulfide and sulfone) next to the α-proton did not 
make a siginificant difference in the potency of fenoprofenoyl-CoA analogues 
(Table 3.5). The most potent fenoprofenoyl-CoA analogue with an electron 
withdrawing group was 50 with Ki value of 53 nM while the one with an electron 
donating group was 53 with a Ki value of 112 nM. Their Ki values were different 
by just 2-fold and such difference is probably not statistically significant. 
The small molecules designed by Professor Paul Groundwater (Figure 3.19) 
were also tested using the multi-well colorimetric assay. They did not inhibit 
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the elimination of 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 
sufficiently to give any sensible IC50 value. These results were consistent with 
the fluoride elimination assay (vide supra) where they did not show any 
inhibition at 100 µM substrate and very limited inhibition at 20 µM substrate.  
 
 
Figure 3.19: Small molecules designed by Professor Paul Groundwater. 
 
A range of known compounds were also tested as AMACR inhibitors using the 
multi-well colorimetric assay (Table 3.6). The Ki values of acyl-CoA esters of 
several 2-APAs were similar and the most potent of them was fenoprofenoyl-
CoA 13 with Ki value of 168 nM. It was followed by ketoprofenoyl-CoA 120, 
flurbiprofenoyl-CoA 122, ibuprofenoyl-CoA 119 and naproxenoyl-CoA 121 (Ki 
values = 177, 216, 235 and 291 nM respectively) (Table 3.6). The results were 
largely similar to the fluoride elimination assay except for ibuprofenoyl-CoA 
119 which showed greater inhibition in the fluoride elimination assay 
compared to ketoprofenoyl-CoA 120 (Table 3.2; vide supra). However, the 
relative inhibition from the fluoride elimination assay was a single-point assay 
and so the results using the two assays are not directly comparable. Both 
assays gave consistent results showing that the acyl-CoA esters of 2-APA 
were moderate AMACR inhibitors. 
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Ibuprofenoyl-CoA 119 has been reported as an inhibitor of AMACR with Ki 
value of 56 µM,91 which was much higher compared to the current data (Ki = 
235 nM). However, the previous assay used AMACR from rat liver and the 
multi-well colorimetric assay in this study used human recombinant AMACR. 
These two enzymes only shared 81% amino acid homology.94 As they are not 
identical enzymes, ibuprofenoyl-CoA 119 may exhibit different degree of 
inhibition to both enzymes. It is noteworthy that the rat liver enzyme is a native 
enzyme whilst the human AMACR is a recombinant enzyme expressed using 
a bacterial system and different levels of activity between native enzyme and 
recombinant enzyme is not uncommon.  
 
The data from the multi-well colorimetric assay has shown consistent lower Ki 
values compared to previous studies. N-Dodecyl-N-methylcarbamoyl-CoA 30, 
the most potent AMACR inhibitor reported to-date has a Ki value of 98 nM 
according to Carnell et al.145 The results from this study showed that N-
dodecyl-N-methylcarbamoyl-CoA 30 is still the most potent inhibitor, but the Ki 
value obtained was much lower, 0.4 nM (Table 3.6). Carnell et al. used human 
AMACR expressed using a mammalian cells (HEK293 kidney cell culture)145 
while the enzyme used in this study was expressed using a bacterial cells (E. 
coli). Enzymes expressed by different systems would have considerably 
different level of activity and it is difficult to compare data across studies. In 
addition, an end-point assay was used by Carnell et al. to study N-dodecyl-N-
methylcarbamoyl-CoA 30145 whilst a continuous assay was used in this study 
to examine its potency. The latter is usually more accurate than the former. 
 
Alkyl acyl-CoA esters with various chain-lengths were also tested as AMACR 
inhibitors (Table 3.6). Acetyl-CoA 139 has a Ki value of 18 µM. Butyryl-CoA 
140 was a poor AMACR inhibitor and its data could not be fitted in a standard 
curve to obtain a sensible IC50 value. Hexanoyl-CoA 141, octaboyl-CoA 142 
and decanoyl-CoA 143 have Ki values of 5, 4 and 1 µM, respectively (Table 
3.6). The results showed that the longer the chain-length, the lower the IC50 
and Ki values. This observation was consistent with the data reported by Sattar 
et al. who showed that the longer the chain-length, the higher the conversion 
rate experienced by the alkyl acyl-CoA esters (i.e., they were better 
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substrates).147 With longer side-chain, these alkyl acyl-CoA esters have a 
higher level of hydrophobicity, and hence also behave as better competitive 
inhibitors.147 Long-chain alkyl compounds still have higher Ki values than 
aromatic compounds, such as acyl-CoA esters of 2-APA. The tight binding 
exhibited by aromatic compounds could be due to greater hydrophobicity or 
stronger π-interactions from the aromatic rings. 
 
In contrary to the data from Sattar et al.,147 iso-butyryl-CoA 144 was a better 
AMACR inhibitor than butyryl-CoA 140 even though it has the same number 
of carbon units. This probably is because iso-butyryl-CoA 144 has a 2-methyl 
group which fits into the specific methyl-pocket in the enzyme and binds more 
tightly.146 The same trend was observed with 2-methyldecanoyl-CoA and 
decanoyl-CoA 143. Decanoyl-CoA 143 has a Ki of 1164 nM while R-2-
methyldecanoyl-CoA 44 has a Ki of 263 nM and S-2-methyldecanoyl-CoA 38 
has a Ki value of 379 nM, both significantly lower than decanoyl-CoA 143. 
Having a 2-methyl group improved the Ki value by 3-fold for the S-acyl-CoA 
ester 38 and more than 4-fold for R-acyl-CoA ester 44. This observation was 
consistent with the data reported by Sattar et al. who observed the exchange 
efficiency of S-2methyldecanoyl-CoA 38 to be three times greater than 
decanoyl-CoA 143.147 Having a 2-methyl group improved the specificity and 
made it a better substrate and a more potent competitive inhibitor. 
 
The acyl-CoA ester of S-mandelic acid (S-2-hydroxy-2-phenylacetyl-CoA 145) 
has been previously proposed to be substrate of AMACR just like the acyl-
CoA esters of 2-APA.201 It was later proven not to be the case by Yevglevskis 
et al. who showed that both S- 145 and R- 2-hydroxy-2-phenylacetyl-CoA 146 
were not substrates of AMACR.184 The 2-hydroxyl group was thought to 
prevent binding to AMACR.184 These acyl-CoA esters of S- 145 and R-
mandelic acid 146 were tested to see if they could be inhibitors of AMACR. 
The results showed that these two compounds were poorer inhibitors 
compared to acyl-CoA esters of 2-APA (Table 3.6). The Ki values were 0.84 
µM for R-inhibitor 146 and 0.45 µM for S-inhibitor 145. This was not 
unexpected, as the presence of a hydrophilic 2-hydroxyl group might fit poorly 
in the hydrophobic 2-methyl pocket in the enzyme,184 and hence made it a 
90 
 
poor competitive inhibitor. However, limited binding might still occur as the 
compound has an aromatic side-chain and acyl-CoA moiety which could 
occupy the appropriate binding sites in AMACR, allowing it to inhibit the 
enzyme to some extent.  
 
3-Fluoro-2-methyldecanoyl-CoA, the substrate used in fluoride elimination 
assay was also tested as an inhibitor using the multi-well colorimetric assay. 
Both the R- 114 and S- compounds 147 were very good AMACR inhibitors 
with Ki values in the low nanomolar range (Table 3.6). However, the results 
were complicated by the fact that these compounds undergo fluoride 
elimination reaction catalysed by AMACR and the product might also be an 
inhibitor of different potency, giving variable inhibition with time. As they were 
not simple reversible inhibitors, it was not appropriate to quote IC50 values in 
discussing their potency.  
 
The IC50 of ebselen 34, ebselen oxide 35 and rose bengal 37 were also 
measured using the multi-well colorimetric assay. The IC50 value of ebselen 
34 was about 20-fold smaller than ebselen oxide 35 (Table 3.6) and these 
results were consistent with the fluoride elimination assay (Table 3.2; vide 
supra). However, these inhibitors have been proposed to inhibit the enzyme 
by covalent modification or other mechanisms and are not simple reversible 
inhibitors.85, 187-189 Their mode of binding to AMACR should be studied and 
confirmed (vide infra) as IC50 would not be an accurate representation of 











Compound IC50 value (nM) Ki value (nM) 
13 283.1 167.5 
30 0.7 0.4 
34 41.3 24.4 
35  872.4 - 
37  1612 953.8 
38  640.0 378.7 
44 445.0 263.3 
114  65.1 38.5 
119 397.6 235.3 
120 298.4 176.6 
121 492.0 291.1 
122 364.6 215.7 
139 29960 17730 
140 >1000000 - 
141  8294 4908 
142  7241 4285 
143 1967 1164 
144 42230 24990 
145 1457 862 
146 2702 1599 
147 205.3 121.5 
Table 3.6: IC50 and Ki values of known compounds tested with the multi-well colorimetric 
assay. The Ki value of ebselen oxide 35 was not calculated using the Cheng-Prusoff 
equation as it is not a competitive inhibitor (vide infra). 
 
3.7.1 Mode of binding of inhibitors 
The multi-well colorimetric assay can also be used to study the mode of 
binding of inhibitors, and to examine the compound to see if it is a reversible 
or irreversible inhibitor. Three separate experiments should be performed to 
study the mode of binding. They will be simplified here as experiment 1, 
experiment 2 and experiment 3. Experiment 1 and experiment 3 were intended 
to study association of the inhibitor with the enzyme. Experiment 1 involved a 
pre-incubation of the inhibitor with AMACR while experiment 3 did not. A 
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simple reversible inhibitor would show no difference in the absorbance reading 
in both experiment 1 and 3 because the binding is fast (equilibrim achieved in 
~1 seconds) so pre-incubation should not make a difference to the observed 
potency (Figure 3.20). However, a slow-binding, tight-binding or irreversible 
inhibitor would show greater inhibition in experiment 1 compared to experiment 
3 as pre-incubation allowed the inhibitor either to bind to the enzyme (slow and 
tight-binding inhibitors) or inactivate the enzyme (irreversible inhibitors) 
(Figure 3.22). Experiment 2 used a small volume but high concentration of 
enzyme (100× final concentration) and inhibitor (20× IC50) during pre-
incubation phase. On dilution, the enzyme concentration was the same as 
experiment 1 but the inhibitor concentration was 0.4× IC50. Experiment 2 was 
used to study whether the enzyme activity could be restored upon dilution of 
the inhibitor. A fast reversible inhibitor or a slow-binding but fast-release 
inhibitor would dissociate rapidly from the enzyme and the enzyme activity 
would be restored (Figure 3.20 and 3.21); whilst a tight-binding inhibitor could 
have a time-dependent dissociation. Covalent inhibitors which irreversibly 
modify the enzyme are predicted to show no recovery of activity under these 
conditions (Figure 3.22). 















Figure 3.20: Mode of binding experiment for a fast reversible inhibitor (ibuprofenoyl-CoA 
119). Experiment 1 and 3 show rapid binding as the observed absorbance readings are 
the same with or without pre-incubation; experiment 1 and 2 show that the reaction is 
reversible as the activity is restored upon dilution of the inhibitor. The positive control 
























Figure 3.21: Mode of binding experiment for a slow-binding/fast release inhibitor (ebselen 
34). Experiment 1 and 3 show that the binding is slow as the absorbance is lower (lower 
enzyme activity) with pre-incubation; experiment 1 and 2 show that the reaction is 
reversible and the release of inhibitor is fast as the activity is restored upon dilution of the 
inhibitor. The positive control lacked an inhibitor while the negative control lacked an 
active AMACR. Wavelength at 390 nm instead of 354 nm was measured as ebselen 34 
has a maximal UV absorbance near 354 nm. 















Figure 3.22: Mode of binding experiment for an irreversible inhibitor (ebselen oxide 35). 
Experiment 1 and 2 show the reaction is probably irreversible as there is very limited 
recovery of activity upon dilution of the inhibitor. The positive control lacked an inhibitor 















A selection of novel synthesised compounds and known compounds were 
tested to examine their mode of binding to AMACR and the results were shown 
in Table 3.7. The results showed that ibuprofenoyl-CoA 119 was a fast 
reversible inhibitor, and hence all acyl-CoA esters of 2-APA are also likely to 
be fast reversible inhibitors. This is consistent with them been known as 
alternative substrates.2 All novel fenoprofenoyl-CoA analogues are probably 
fast reversible inhibitors, as represented by 49 and 53. Long alkyl acyl-CoA 
esters such as 3-(hexylsulfanyl)-2-methylpropanoyl-CoA 109 and R-2-
methyldecanoyl-CoA 44 were also shown to be fast reversible inhibitors. It was 
not surprising as they were meant to mimic the natural substrate of AMACR 
and act as competitive inhibitors. 
 
Even though ebselen 34 and rose bengal 37 were predicted to be irreversible 
inhibitors of AMACR, they were shown to be slow-binding inhibitors in this 
study. Ebselen oxide 35 was shown to be an irreversible inhibitor which bound 
to the enzyme and did not dissociate upon dilution (Figure 3.22). To confirm 
that it reacted the enzyme irreversibly, the Kitz-Wilson analysis was performed 
to determine whether the inactivation was time-dependent (which is 





Compound Mode of binding 
30 Fast reversible 
34 Slow binding but fast release 
35 Irreversible 
37 Slow binding but fast release 
44 Fast reversible 
49 Fast reversible 
53 Fast reversible 
109 Fast reversible 
114 Fast reversible 
119 Fast reversible 





3.7.2 Kitz-Wilson analysis  
In order to confirm ebselen oxide 35 was an irreversible inhibitor, Kitz-Wilson 
analysis85, 202 was carried out. AMACR was pre-incubated with ebselen oxide 
35 at concentrations 10 times higher than the final concentrations in the assay. 
High inhibitor concentrations during the pre-incubation phase allowed the 
irreversible inhibitor to inactivate the enzyme before the substrate was added. 
Ebselen oxide 35 inactivated the enzyme during pre-incubation in a time-
dependent manner (Figure 3.23). It was shown to be an irreversible inhibitor 
using the Kitz-Wilson analysis.  






                
 
Figure 3.23: Kitz-Wilson analysis on ebselen oxide 35. Inhibitor concentration and pre-
incubation time are inversely correlated with the activity of AMACR. 
 
The data was analysed using the Michalis-Menten model and the kinetic 
parameters were calculated using the Direct Linear Plot, which gives median 
values and discards outliers (Figure 3.24).203, 204 The KI value was estimated 
to be 0.975 µM and Kinact value was 0.00085 s-1, represented by the 
intersection of lines. The data given by the Direct Linear Plot was rather 
inaccurate as the plot showed poor convergence. 
 
An irreversible enzyme inhibitor should show saturation kinetics if it binds to 
























single molecule binds to the enzyme and the reaction occurs at first order and 
then becomes zero order when saturation occurs. When the data were plotted 
using the Michaelis-Menten model (Figure 3.25), it did not show the classical 
hyperbola curve (i.e., saturation at high concentration), suggesting that 
ebselen oxide 35 is a non-specific inactivator that does not saturate. Ther 
residual plot also showed that the Michaelis-Menten model is inappropriate as 
the errors are not random scatter (Figure 3.26).205 








Figure 3.24: Direct Linear Plot of ebselen oxide 35. 
 










Figure 3.25: Michaelis-Menten Plot of ebselen oxide 35. 


















































Figure 3.26: Residual plot of ebselen oxide 35. 
 
However, when the rate constant of ebselen oxide 35 was plotted against the 
concentration of inhibitor, a straight line was obtained (Figure 3.27). This 
showed a standard second order reaction, which was dependent on time and 
the concentration of ebselen oxide 35. The second order rate constant of 
ebselen oxide 35 was 1142.6 M-1 s-1. The results suggest that ebselen oxide 
35 is not a typical irreversible inhibitor that binds to the active-site of AMACR 
and can reach saturation, instead, its inactivation occurs by non-specific 
single-step mechanism that is characteristic of non-specific inactivating 
agents.190 It is possible that ebselen oxide 35 modifies enzyme residues, 
possibly histidines, on the outside of the protein.  
 
























Figure 3.27:  The graph showed a linear relationship between the concentration of 
ebselen oxide 35 and its rate constant.  
  
















4 Results and discussion for site-directed 
mutagenesis study 
4.1 Investigation into role of catalytic residues to assist rational drug 
design 
A very powerful approach in drug discovery is to rationally design drugs, which 
is a strategy used in the design of novel fenoprofenoyl-CoA analogues as 
AMACR inhibitors (vide supra). In order to rationally design drugs to target 
AMACR, a good understanding of the enzyme structure and its active-site 
residues is paramount. Rational design is a good strategy for AMACR as all 
inhibitors produced will be specific in inhibiting the enzyme activity and a 
targeted therapy can be produced.  
 
There is no X-ray crystal structure of human or a mammalian AMACR reported 
to date. The identity of the active-site residues have not been conclusively 
proven and its catalytic mechanism is still incompletely understood. The 
homologous enzyme of human AMACR that has been widely studied is MCR, 
from M. tuberculosis.86, 108, 146 This enzyme shares 43% sequence identity with 
human AMACR (Figure 4.1).76, 86 There have been a number of studies (X-ray 
crystallography, quantum chemical modelling and site-directed mutagenesis) 
that predict the active-site residues and catalytic mechanism of human 
AMACR based on studies on MCR.86, 107, 108, 146, 153 These findings have shed 
some light on the mechanism of human AMACR. However, as these studies 
were not performed on human AMACR, the predictions are not be absolutely 
definitive. Studies have shown that homologous enzymes can have different 






Figure 4.1: Protein sequences of MCR (accession number O06543) and human AMACR 
1A (accession number Q9UHK6). The asterisk shows a fully conserved residue, the colon 
shows amino acids of MCR and AMACR with strongly similar properties, the period shows 
amino acids of MCR and AMACR with weakly similar properties. The highlighted red 
residues show those chosen for site-directed mutagenesis in this study (vide infra). 
 
The catalytic residues and mechanism of human AMACR was proposed based 
on the previous data from the site-directed mutagenesis study86 and X-ray 
crystal structures of MCR.107, 146, 153 His-122 and Glu-237 residues in human 
AMACR correspond to His-126 and Glu-241 residues in MCR (Figure 4.1; vide 
supra), which have been proposed to be working together as a basic dyad for 
the S-substrate.146 Asp-152 in the human enzyme, which corresponds to Asp-
156 in the active site of the MCR, is proposed to work as the catalytic base for 
the R-substrate.146 This proposed mechanism with two distinct catalytic bases 
involved in the ‘racemisation’ of the R- and S-substrate is known as the two-
base mechanism (Scheme 4.1).  The two-base mechanism is based on the 
MCR model86, 91 and has been observed in other racemases such as the 
mandelate racemase208 and proline racemase209. The defining feature of a 
two-base mechanism is that the product of the enzymatic reaction has a 
configuration which is inverted compared that of the substrate. Moreover, 
 
MCR             MAGPLSGLRVVELAGIGPGPHAAMILGDLGADVVRIDRPSSVDGISRDAMLRNRRIVTAD 
AMACR           --MALQGISVVELSGLAPGPFCAMVLADFGARVVRVDRPGSRYDVSR--LGRGKRSLVLD 
                   .*.*: ****:*:.***..**:*.*:** ***:***.*  .:**  : *.:* :. * 
 
MCR             LKSDQGLELALKLIAKADVLIEGYRPGVTERLGLGPEECAKVNDRLIYARMTGWGQTGPR 
AMACR           LKQPRGAAVLRRLCKRSDVLLEPFRRGVMEKLQLGPEILQRENPRLIYARLSGFGQSGSF 
                **. :*  :  :*  ::***:* :* ** *:* ****   : * ******::*:**:*.  
 
MCR             SQQAGHDINYISLNGILHAIGRGDERPVPPLNLVGDFGGGSMFLLVGILAALWERQSSGK 
AMACR           CRLAGHDINYLALSGVLSKIGRSGENPYAPLNLLADFAGGGLMCALGIIMALFDRTRTGK 
                .: *******::*.*:*  ***..*.* .****:.**.**.::  :**: **::*  :** 
 
MCR             GQVVDAAMVDGSSVLIQMMWAMRATGMWTDTRGANMLDGGAPYYDTYECADGRYVAVGAI 
AMACR           GQVIDANMVEGTAYLSSFLWKTQKSSLWEAPRGQNMLDGGAPFYTTYRTADGEFMAVGAI 
                ***:** **:*:: * .::*  : :.:*  .** ********:* **. ***.::***** 
 
MCR             EPQFYAAMLAGLGLDAAELPPQNDRARWPELRALLTEAFASHDRDHWGAVFANSDACVTP 
AMACR           EPQFYELLIKGLGLKSDELPNQMSMDDWPEMKKKFADVFAKKTKAEWCQIFDGTDACVTP 
                *****  :: ****.: *** * .   ***::  :::.**.: : .*  :* .:****** 
 
MCR             VLAFGEVHNEPHIIERNTFYEANG---GWQPMPAPRFSRTASSQPRPPAATIDIEAVLTD 
AMACR           VLTFEEVVHHDHNKERGSFITSEEQDVSPRPAPLLLNTPAIPSFKRDPFIGEHTEEILEE 
                **:* ** :. *  **.:*  ::    . :* *    : : .*  * *    . * :* : 
 
MCR             WDG----------------------- 
AMACR           FGFSREEIYQLNSDKIIESNKVKASL 
                :.                         
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performing the reaction in 2H2O results in incorporation of 2H into the product, 
with very little into the substrate. However, the study of Darley et al. suggested 
that human AMACR does not fit in the classical two-base mechanism and may 
operate with an one-base mechanism.1 This conclusion was reached because 
the product is a near 1:1 mixture of epimers at the methyl centre, and 
deuterium from 2H2O is equally incorporated into both substrate and product. 
This behaviour is characteristic of ‘one-base’ racemases.210 
 
 
Scheme 4.1: The proposed two-base mechanism of human AMACR where the top panel 
shows the ‘racemisation’ of R-2-methylacyl-CoA ester and the bottom panel shows the 
‘racemisation’ of S-2-methylacyl-CoA ester. The dotted lines show the interactions of the 




In order to study the active site and understand the mechanism of human 
AMACR, a site-directed mutagenesis study on human AMACR 1A was 
performed. Human AMACR 1A was used instead of other spliced variants as 
it is known to be an active enzyme and that it is most commonly over-
expressed in prostate cancer.158 The sequence of human AMACR and 
sequence of MCR were aligned and the chosen residues for site-directed 
mutagenesis were His-122, Asp-152, Met-184 and Glu-237 (Figure 4.1; vide 
supra). All of these AMACR residues were changed to alanine, which is an 
amino acid with a methyl side-chain. Alanine is often used in site-directed 
mutagenesis studies86, 211 because it possesses a small, non-functional side-
chain. Even though glycine is smaller than alanine, it was not considered as it 
is achiral as it lacks a side-chain and therefore could potentially cause 
generalised disruption to the structure.212 Substitution of His-122 with alanine 





Scheme 4.2: Site-directed mutagenesis of His-122 to Ala-122 (H122A mutant). Chemical 
rescue could be performed by adding imidazole to the assay which could potentially 
occupy the empty space left by the missing histidine side-chain. 
 
In addition to alanine residues, mutation of the target residues to other amino 
acids was also considered.  The Asp-152 was mutated to asparagine (D152N) 
and the Glu-237 was changed to glutamine (E237Q) (Scheme 4.3). A change 
from an OH group to a NH2 group introduce the smallest possible structural 
change, but it was expected to affect the acidity of the side-chain and might 










Scheme 4.3: The mutation of Asp-152 and Glu-237 to give the D152N and E237Q 
mutants. 
 
Met-184 in human AMACR 1A was also chosen for site-directed mutagenesis 
as previous studies have shown that Met-188 of MCR has an enolate-
stabilising role in the oxyanion hole (Figure 1.11; vide supra).146 The Met-188 
of the MCR is located in a hydrophobic region of enzyme and is in close 
proximity to Asp-156 according to the X-ray crystallographic structures of the 
enzyme. The sulfur atom of Met-188 interacts directly with Asp-156 and 
modifies its pKa.146 This interaction helps stabilise the enolate intermediate.108 
To study whether Met-184 has the same role in human AMACR, this residue 
was mutated to alanine to give the M184A mutant. 
 
4.2 Production of mutant AMACR 1A plasmids 
4.2.1 Q5® site-directed mutagenesis 
Initially, site-directed mutagenesis was attempted using Q5® site-directed 
mutagenesis kit (Figure 4.2) and non-overlapping primers were used. The 
forward primer had a codon substituted to code for the desired mutation. The 
reverse primer did not have any substitution as it was in the opposite direction 




Figure 4.2: Q5® site-directed mutagenesis protocol. The black arrow on the plasmid 
indicates the forward primer and the cross represents the substitution. The red arrow on 
the plasmid indicates the reverse primer. 
 
After the DNA was amplified and treated according to the protocol, it was 
transformed into competent E.coli and plated onto agar supplemented with 
kanamycin sulfate as the selective agent. No colonies were found in any of the 
LB plates except for the control plate which used the pUC19 vector. This 
showed that the transformation step had worked but the site-directed 
mutagenesis experiment had failed to produce viable mutant plasmids. 
Analysis by agarose gel electrophoresis showed that no DNA band at ~6.6 kb 
(intact plasmid) or ~1.2 kb (AMACR insert) was observed. A control PCR 
reaction was also performed with another polymerase, KOD Hot Start 
polymerase with wild-type plasmid and a DNA fragment of ~1.2 kb was 
observed (Figure 4.3).  The mutagenesis experiment had failed and multiple 
optimisations of the site-directed mutagenesis did not result in a different 
outcome. Hence, further experiments were conducted using KOD Hot Start 




Figure 4.3: PCR products of the site-directed mutagenesis. DNA markers were loaded 
onto the agarose gel and electrophoresed at 95 volts for 1 h. The gel showed DNA 
amplifications of some of the mutants performed using Q5® polymerase except for the 
cDNA control in well 5 (red circle) which was amplified using KOD polymerase. 
 
4.2.2 Optimisations of KOD Hot Start polymerase protocol 
The non-overlapping primers designed using NEB website was used for site-
directed mutagenesis catalysed by KOD Hot Start polymerase. However, no 
colonies were observed following transformation and plating onto the LB agar 
plate containing kanamycin sulfate as the selecting agent. Agarose gel 
electrophoresis showed that no DNA band of ~6.6 kb (corresponding to intact 
plasmid containing AMACR cDNA) was observed.  
 
Primers were phosphorylated in an attempt to establish if prior phosphorylation 
was required for efficient PCR. The DNA was amplified with KOD polymerase, 
template DNA was digested using Dpn1 and the product was purified with 
QIAquick PCR purification kit. The purified DNA was circularised using Quick 
Ligation™ kit and transformed into competent cells. Bacteria containing the 
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plasmids for the H122A, M184A and E237Q mutants formed colonies on LB 
agar plates. Colony PCR was performed on the derived plasmids. No ~1.2 kb 
DNA band from the mutants was observed (Figure 4.4), although bands of 
other sizes were observed. Attempts to express these mutants were 
unsuccessful, which was as expected. 
 
 
Figure 4.4: Wild-type AMACR forward and reverse primers were used in colony PCR to 
screen for the AMACR cDNA. Ca. 1.2 kb DNA bands were expected for all mutants and 
wild-type plasmid. Only wild-type controls (red circle) showed the expected ~1.2 kb band 
but the rest of the mutants either did not show any band or showed bands of incorrect 
sizes. 
 
4.2.3 Site-directed mutagenesis using optimised KOD Hot Start 
polymerase protocol 
Primers were re-designed manually for use with the ‘Stratagene QuickChange 
Method’, where the forward and reverse primers were complementary. Each 
forward primer was ~32 nucleotides with the mutation site in the middle of the 
primer and a run of G or C at the termini of either end. If more than one codon 
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was possible for the amino acid to be substituted, the most common codon in 
E. coli was used. 
 
In addition to the planned substitutions (H122A, M184A, D152A, D152N, 
E237A and E237Q), the H122F and H122L mutants were also produced. They 
were added at a later stage, as it was found that H122A plasmid failed to be 
expressed and produce mutant AMACR (vide infra). 
 
PCR was performed using KOD Hot Start polymerase and the PCR products 
were analysed by agarose gel electrophoresis (Figure 4.5). A band at ~6.6 kb 
was observed, consistent with the presence of a mutant plasmid.  
 
 
Figure 4.5: One of the examples of PCR products amplified by KOD polymerase and 
analysed by agarose gel electrophoresis. Plasmids of ~6.6 kb in wells 2, 3, 4 and 6 (the 
H122A, H122F, H122L and E237A mutants, respectively) were observed. Controls with 
wild-type AMACR plasmid in wells 5 and 10 showed a ~1.2 kb band.  
 
The PCR products were treated with Dpn1 to remove wild-type plasmid, 
purified, and transformed in competent cells. The transformed bacteria with 
wild-type, H122A, H122F, H122L, D152A, D152N, M184A, E237A or E237Q 
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plasmids all formed colonies on LB plates supplemented with kanamycin 
sulfate. Phosphorylation and ligation have been shown to be unnecessary as 
high-efficiency transformation into cells was achieved following purification of 
the PCR product. Colony PCR confirmed the presence of the expected ~1.2 
kb insert. The presence of the required mutations was confirmed by 
sequencing the entire cDNA before protein expression experiments were 
performed, and showed the expected sequences with the required mutations 
and no other changes. 
 
4.2.4 Double mutations on H122A mutant 
As His-122 and Glu-237 are proposed to be working together as a basic dyad 
in deprotonating its substrate,76 a double mutation of these two residues was 
attempted. H122A/E237A and H122A/E237Q mutations were carried in order 
to investigate the effect of losing these two residues together. E237A or E237Q 
forward and reverse primers together with H122A plasmid was used for site-
directed mutagenesis. H122A/E237A and H122A/E23Q mutants formed 
colonies on LB plates. Only H122A/E237A but not H122A/E237Q showed ~1.2 
kb insert in colony PCR (Figure 4.6). Both H122A/E237A and H122A/E237Q 
were sent for sequencing but their sequences could not be confirmed, possibly 
due to the quality of the plasmids. Attempts to re-prepare the plasmids did not 
result in any improvement of the samples and the samples failed to produce a 
clear signal for sequencing. Expression of the double mutants was attempted 





Figure 4.6: Colony PCR for double mutants. H122A/E237A (red circle) showed ~1.2 kb 
insert but H122A/E237Q did not show ~1.2 kb insert upon analysis by agarose gel 
electrophoresis. 
 
4.3 Expression and purification of AMACR 1A enzymes 
Expression experiments were performed on a small scale to find the most 
suitable conditions for protein production from each of the mutated pET 
plasmids. The pET30 Ek/LIC plasmid contains a lac operon where the gene 
expression is inducible by compounds that binds to and releases the lac 
repressor protein (LacI).213 The inducers trialled include the Novagen 
Overnight express™ autoinduction system 1, IPTG and lactose. The Rosetta2 
(DE3) was chosen as the expression strain as this strain has been engineered 
to provide tRNAs that bind to codons common in eukaryotic species that are 
rarely found in normal E. coli, so the expression of eukaryotic cDNA could be 
enhanced.214 
 
Overnight express™ autoinduction system 1 was the preferred inducer as the 
monitoring of cell growth was not required. It contains a specific blend of 
glucose and lactose where the glucose will allow uninduced cell growth and 
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later, the protein expression would be induced by lactose once the glucose 
source is used up. Autoinduction system 1 successfully induced the 
expression of most of the enzymes (wild-type, the M184A, E237A and E237Q 
mutants) with good yield. The H122A, H122F, H122L, D152A and D152N 
mutants were not expressed with autoinduction system 1. 
 
Leaky expression was observed for wild-type enzyme at 37 °C so the 
temperature of the initial growth phase was lowered. Besides preventing leaky 
expression, a lower temperature could also minimise the formation of inclusion 
bodies (misfolded and insoluble proteins).215 The problem of inclusion bodies 
could arise when the production of recombinant proteins is greater than 50% 
of the host proteins. This leads to a higher rate of protein aggregation 
compared to the rate of protein folding.215 A lower temperature reduces the 
rate of transcription and translation and hence a lower protein production rate, 
which will help minimise the formation of inclusion bodies.215 However, the 
bacteria culture will be dormant at low temperature, and protein expression 
can not be induced (if glucose in Autoinduction system is not used up by the 
dormant culture, lactose will not be used to induce protein expression). Hence, 
a compromised temperature of 28 °C was chosen to allow sufficient growth of 
bacteria culture and also to promote correct protein folding. 
 
IPTG (0.25 mM) and lactose (2 mM, 5 mM or 10 mM) were trialled as 
alternative inducers. Lactose is the natural occurring inducer for the lac operon 
and has the advantages of being cheap and non-toxic.216 IPTG is a synthetic 
form of a lactose metabolite (allolactose) and has been widely used as an 
inducer of the lac operon.217, 218 AMACR 1A containing the H122L and D152N 
mutations were expressed with IPTG whilst the H122A, H122F and D152A 
mutants failed to express with all three inducers that were trialled. As a result, 
the planned chemical rescue by adding imidazole to the H122A mutant protein 
could not be carried out. The expression of double mutants was also not 
pursued further as their sequences were not confirmed and their expression 




Once the optimum conditions of expression for each mutant proteins were 
established, they were expressed on a large scale. A consistent temperature 
of 28 °C was used in growing and expressing all mutant proteins regardless of 
the type of inducer used. Attempted mutations and success in the expression 
of mutant enzymes were summarised in Table 4.1. 
 











Table 4.1: Mutations attempted and success in expressing mutant proteins 
 
The histidine-tagged recombinant proteins were purified using nickel-chelate 
chromatography. The proteins were eluted with imidazole which displaced the 
bound proteins from the nickel ions chelated to the column. The eluted 
fractions containing purified protein (Figure 4.7) were combined and dialysed 
into 10 mM NaH2PO4-NaOH, pH 7.4 buffer. All combined purified enzymes 
were analysed by SDS-PAGE (Figure 4.8). The concentration of the enzymes 





Figure 4.7: SDS-PAGE of different purification fractions of M184A. The standard used 
was wild-type AMACR 1A, followed by crude M184A, wash fraction and different elution 




Figure 4.8: SDS-PAGE of purified wild-type, H122L, D152N, M184A, E237A and E237Q, 
showing a strong band at ~47 kDa. AMACR marker was a purified wild-type AMACR 1A 
protein obtained from MDL lab. 
 
Wild-type and mutant enzymes were purified to ca. 95% purity, as judged by 
SDS-PAGE analyses. The impurities were consistent across all purified 
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proteins and could be due to the contamination from bacterial proteins or 
proteolytic fragments resulting from digestion of the recombinant protein.219 
Additional purifications on the wild-type AMACR 1A have been investigated 
previously by the MDL lab1 but this has been proven to be challenging and did 
not improve the purity of the protein.  
 
SDS-PAGE was repeated on the samples of purified proteins in order to check 
for protein degradation over time. The result showed that the proteins were 
stable with no change in purity when stored at -80 °C. 
 
4.4 Protein characterisation 
The wild-type AMACR and all of the mutants were characterised using DLS, 
CD and fluorescent study using ANS in order to check the conformation of the 
enzymes and whether there was any dissociation of dimeric proteins (i.e., that 
dimerisation was intact). 
 
4.4.1 Dynamic light scattering (DLS) 
DLS, also known as photon correlation spectroscopy can be used to determine 
the size and size distribution of particles in the nanometer region.220 The 
sample is illuminated by laser light and the light is scattered by the Brownian 
motion of particles.220 Fluctuations in the intensity of the scattered light are 
analysed and correlated to the hydrodynamic radii of particles.221 
 
The X-ray crystal structure and the site-directed mutagenesis study on MCR 
have shown that the enzyme is a tight-interlocked dimer with subunits 
connected via their C-termini, and the catalytic centres are at the interface of 
the dimer.86, 146 It is assumed that human AMACR 1A has the same or similar 
catalytic sites, situated at the interface of the dimer. Site-directed mutagenesis 
of human AMACR catalytic residues might affect the stability of the enzyme. 
The His-122 residue is thought to be contributed by the large domain and the 
Glu-237 residue is thought to be contributed by the small domain and they 
work together as a catalytic dyad. Mutations of these residues could potentially 
lead to the dissociation of the dimer and hence reduce enzyme catalytic 
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activity. The integrity of the dimeric state of the protein was therefore 
investigated using DLS. 
 
The results (Table 4.2) showed that the sizes of the enzyme were greater than 
an average size of a protein (which are usually in the low nm range).222 Among 
the enzymes tested, wild-type AMACR, E237A and E237Q had the largest 
sized particle, between ca. 65 nm and ca. 90 nm. These large readings 
suggested that these proteins had formed aggregates instead of existing freely 
as a dimer in the solution. The D152N mutant had the smallest size (12.4 nm) 
and smallest standard deviation, suggesting that it was less likely to form 
aggregates. Instead of probing the dimeric state of the enzyme, the DLS 
experiments indicated that the enzymes have a tendency to aggregate. 
 
AMACR Average size (nm) 
Wild-type 89.3 ± 36.4 
H122L 21.6 ± 6.9 
D152N 12.4 ± 3.8 
M184A 21.5 ± 7.7 
E237A 65.3 ± 15.0 
E237Q 80.0 ± 19.4 
Table 4.2: Average sizes (nine replicates) ± standard deviation of wild-type and mutant 
AMACR estimated by DLS. 
 
4.4.2 Circular dichroism (CD) 
To study if the site-directed mutagenesis had affected the stability and hence 
the folding of the enzyme, CD was used to study the structure of the protein. 
Polarised light of the CD interacts with the protein to give a CD spectrum that 
is specific to that particular protein. The pattern and magnitude of the spectrum 
provides excellent information about the structure of the protein, especially 
secondary structure.223 The H122L, D152N, M184A, E237A and E237Q 
mutants were examined by CD in order to determine if their structures were 




The CD spectra at the far-UV region (200-240 nm) and near-UV region (250-
300 nm) were analysed to examine the protein structure. The far-UV region 
provides information on the secondary structure of the protein. Theoretically, 
this region can go below 180 nm, but in practice, it is difficult to obtain accurate 
readings below 200 nm due to noise from the background.224 This region 
shows various secondary structures such as α-helices, β-sheets and β-
turns.224 The CD spectrum of wild-type AMACR expressed at 22 °C2 was 
compared with the CD spectrum of the same enzyme expressed at 28 °C 
(Figure 4.9). Proteins expressed at different temperatures showed slightly 
different secondary structures. Both enzymes have different Km and Vmax 
values for the same substrate, S-2-methyldecanoyl-CoA 38. Wild-type 
AMACR expressed at 22 °C gives a Km value of 277 µM and Vmax value of 39.3 
nmol min-1 mg-1.2 On the other hand, wild-type AMACR expressed at 28 °C 
(vide infra) gives ca. 3 times smaller Km value (95 µM) and ca. 3 times larger 
Vmax value (108 nmol min-1 mg-1), indicating that 28 °C is a better temperature 
for expressing the protein. 
 
In this study, wild-type and all mutant enzymes were expressed at 28 °C and 
they did not seem to have a gross structural disruption. None of the enzymes 
showed a CD spectrum that looked like the denatured protein (Figure 4.9). The 
results showed that the denatured protein has nearly zero molar ellipticity and 
did not have any characteristic signals of α-helices or β-sheets. All mutant 
enzymes except D152N and M184A showed secondary structures similar to 
wild-type enzyme either expressed at 22 °C or 28 °C (Figure 4.9). The results 
implied that the activity or inactivity of these mutant enzymes was probably 
due to the mutation of a single residue, instead of a gross structural disruption 
of the protein. M184A and D152N mutants seemed to have greater molar 
ellipticities, suggesting that there might be enhanced α-helicity in their 
secondary structures. However, it is probable that these molar ellipticities 
values were affected by different levels of protein aggregation (as shown by 
differences in DLS readings). 
 
The near-UV region (250-300 nm) provides information about the local 
environment of aromatic side-chains and tertiary structure of the protein.224 
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Low molar ellipticity readings could be due to high number of aromatic side-
chains in a protein (positive and negative readings cancel out each other), 
close distances between aromatic side-chains and high mobility of aromatic 
side-chains.225 Wild-type and mutant AMACR proteins all have near zero 
molar ellipticity in this region (Figure 4.9), possibly due to the reasons 
mentioned above. Nevertheless, the near-UV region can act as a fingerprint 
region of the protein and it showed that mutations on AMACR did not cause 
any significant change to the tertiary structure. 






























Figure 4.9: CD spectra of wild-type and mutant AMACR. 
 
4.4.3 Fluorescence study using 8-anilino-1-naphthalenesulfonic acid 
(ANS) 
ANS 148 is a fluorescent probe (Figure 4.10) that can be used to study protein 
folding.226 The fluorescence intensity of ANS 148 will increase when it binds 
to hydrophobic surface of protein instead of existing freely in a solution.227 
Hence, it is used to study if the site-directed mutagenesis has disrupted the 
structure of mutant enzymes and exposed their hydrophobic cores. It could 
also reveal if the dimerisation is intact as dimers are predominantly held 
together by hydrophobic interactions. The results of the CD study have shown 



























structures compared with wild-type AMACR. The ANS fluorescence 
experiment would complement the CD study and reveal if there were indeed 
any changes in the overall structure of these proteins. 
 
 
Figure 4.10: Structure of 8-anilino-1-naphthalenesulfonic acid (ANS). 
 
The results showed that the fluorescence intensity of ANS 148 was 
substantially low (almost a flat line) for denatured wild-type AMACR (Figure 
4.11). One might expect that a denatured protein would have its hydrophobic 
core exposed and should bind well with the ANS 148. To explain this, it is 
important to understand interactions between the fluorescent probe 148 with 
a protein. Besides having aromatic rings that could interact with hydrophobic 
residues of a protein, the ionised form of the fluorescent probe (sulfonate 
anion) could form ionic interactions with positively charged amino acids.228 
Both ionic interactions and hydrophobic interactions are required in order for 
the probe to bind stably with a protein to give a strong fluorescence intensity.229 
A fully denatured protein will not form a stable interaction with ANS, so the 
fluorescence intensity of denatured AMACR is very low. 
 
Wild-type enzymes (both expressed at 22 °C and 28 °C), and mutant enzymes 
(H122L, D152N, E237A and E237Q) have similar emission spectra (Figure 
4.11), suggesting that their hydrophobic surfaces were similar. Even though 
CD results suggested that the D152N mutant might have a different secondary 
structure (vide supra), it did not seem to have a huge impact to the overall 
structure of this enzyme. Its ANS emission spectrum was almost identical to 
the emission spectrum of wild-type AMACR expressed at 28 °C. The only 
protein with significantly different fluorescent spectra was the M184A mutant 
(Figure 4.11), with much higher fluorescence intensity. It was obvious that the 
M184A mutant was not fully denatured because if it has been totally unfolded, 
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it would have very low fluorescence intensity just like the denatured wild-type 
AMACR. Assays on the M184A mutant (vide infra) have shown that the 
enzyme was not inactive. On the contrary, it has reasonably good activity, 
suggesting that the M184A mutant has maintained an intact structure. As ANS 
148 does not just bind to hydrophobic surface of a protein, but also interacts 
with positively charged amino acids, high fluorescence intensity alone does 
not indicate that the protein is not folded correctly.230, 231  


















Figure 4.11: The ANS fluorescence emission spectra of denatured wild-type AMACR, 
wild-type enzymes expressed at 22 °C and 28 °C and mutant enzymes expressed at 28 
°C. 
 
4.4 The study of ‘racemisation’ reaction using the deuterium wash-in 
assay 
The activity of wild-type and mutant enzymes were first tested using the 
deuterium wash-in assay as previously described.1, 2 Both the R- 44 and S- 2-
methydecanoyl-CoA 38 were used as substrates in the enzyme assay to 
determine if the site-directed mutagenesis has any effect on the ability of the 
wild-type and mutant enzymes to remove the α-proton and exchange it for 
deuterium from 2H2O. As the Asp-152 residue was thought to be involved in 


























thought to be involved in the deprotonation of the S-substrate, both R- 44 and 
S- 38 substrates were tested with these enzymes to examine their behaviour. 
 
1H NMR was used to analyse the α-proton exchange by quantifying the 
conversion of the 2-methyl peak from a doublet (at ca. 1.00 ppm) to a single 
peak (at ca. 1.00 ppm). The results showed that wild-type AMACR fully 
exchanged the α-proton to α-deuterium of the R- 44 (Figure 4.12) and S- 2-
methyldecanoyl-CoA 38. Under identical conditions, the M184A mutant 
showed 43% conversion of S-2-methyldecanoyl-CoA 38 and 40% conversion 
of R-2-methyldecanoyl-CoA 44. All other mutants did not catalyse significant 




























Figure 4.12: 1H NMR of R-2-methyldecanoyl-CoA 44 with its 2-methyl peak at 1.00 ppm. 
A) The substrate was dissolved in 2H2O prior to the enzyme assay; B) The substrate (final 
assay concentration 100 µM) incubated with heat-inactivated enzyme (final assay 
concentration 0.12 mg mL-1; 2.55 µM); C) The substrate (final concentration 100 µM) 
incubated with active wild-type AMACR (final assay concentration 0.12 mg mL-1; 2.55 
µM). 
 
As the wild-type AMACR and M184 mutant were active using the deuterium 
wash-in assay, kinetic analyses were performed on these two enzymes using 
R- 44 and S-2-methyldecanoyl-CoA 38. As expected, these two acyl-CoA 
esters were shown to be good substrates for wild-type AMACR, results were 
comparable to previous data.1, 2 The Km value for R-2-methyldecanoyl-CoA 44 
from the Direct Linear Plot was 124 µM and Vmax value was 107 nmol min-1 
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was 677 M-1 s-1.  For S-2-methyldecanoyl-CoA 38 the Km value was 95 µM, 
Vmax was 108 nmol min-1 mg-1, kcat was 0.085 s-1 and kcat/Km was 895 M-1 s-1 
(Appendix 3).  
 
Data from the kinetic assay on M184A mutant with S-2-methyldecanoyl-CoA 
38 could not be fitted using the Michaelis-Menten kinetic model. Even though 
the Direct Linear Plot estimated a Km value of 95 µM and Vmax value of 0.77 
nmol min-1 mg-1, the plot was of poor quality and many of the lines did not 
properly converge (Appendix 4). Multiple preliminary assays were performed 
on M184A mutant using R-2-methyldecanoyl-CoA 44 to establish the 
appropriate enzyme concentration for the kinetic analysis. However, the 
results showed a high degree of scatter so kinetic analysis on the M184A 
mutant with R-2-methyldecanoyl-CoA 44 could not be performed. Hence, the 
effects of the mutation could not be quantified using the deuterium wash-in 
assay. 
 
4.5 The study of wild-type and mutant enzymes using the fluoride 
elimination assay 
The deuterium wash-in assay suffers from the problem of overlapping doublet 
and singlet peaks of the 2-methyl group from the substrate and product. If the 
enzyme has low activity, the 1H NMR peaks that are produced would be very 
similar to negative controls and the quantification of enzyme activity is difficult. 
An alternative assay to study the enzyme activity is the fluoride elimination 
reaction recently described (vide supra).3 The reaction is irreversible, and is 
more efficient than the ‘racemisation’ reaction performed by AMACR.3 The 
fluorine of the 3-fluoro-2-methylacyl-CoA esters is eliminated to form a 
corresponding unsaturated product and fluoride anion (Scheme 4.4). The 2-
methyl group of the saturated substrate 114 and unsaturated product 117 have 
very different chemical shifts in the 1H NMR spectrum (Figure 4.13) and hence 
conversion levels can be determined much more accurately. As the α-proton 
is removed in the elimination reaction, the effect of site-directed mutagenesis 





Scheme 4.4: The elimination reaction of (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 to 





Figure 4.13: 1H NMR of the fluoride elimination assay of (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA substrate 114. The 2-methyl peak of the substrate 114 is highlighted 
in red, at ca. 1.00 ppm and the 2-methyl peak of the unsaturated product 117 is highlighted 
in green, at ca. 1.65 ppm. A) The substrate was dissolved in 2H2O prior to the enzyme 
assay; B) The substrate (final assay concentration 100 µM) incubated with heat-
inactivated enzyme (final assay concentration 0.12 mg mL-1; 2.55 µM); C) The substrate 
(final concentration 100 µM) incubated with active wild-type AMACR (final assay 
concentration 0.12 mg mL-1; 2.55 µM). 
 
A  
B   
 
 




(2R,3R)-3-Fluoro-2-methyldecanoyl-CoA 114 substrate was incubated with 
wild-type and mutant enzymes. They were initially tested with a single time 
point assay, where the enzymes were heat-inactivated after one-hour 
incubation. The 1H NMR analysis (Figure 4.13) showed that wild-type AMACR 
eliminated 49% of the substrate after 1 h (Figure 4.14). The most active mutant 
was M184A, which eliminated 8.0% of the substrate, followed by the D152N 
(6.7%), E237Q (5.5%), H122L (4.1%) and E237A (3.3%) mutants (Figure 
4.14). The results were consistent with the deuterium wash-in assay where the 
most active mutant was M184A.  









Figure 4.14: Results of single-time-point elimination assay on wild-type and mutant 
enzymes. Data are mean values (n = 3) ± standard deviation. 
 
As the elimination levels were low for mutant enzymes, it was very difficult to 
perform kinetic analysis using 1H NMR. Instead, the elimination of (2R,3R)-3-
fluoro-2-methyldecanoyl-CoA 114  was further investigated by following the 
reaction at 30 °C using the 1H NMR spectrometer over ~16 h (Figure 4.15). 
After 4 h, the elimination reaction by wild-type AMACR was almost near to 
completion but the reactions were relatively slow for all mutants. The results 
were consistent with the single time point assay, where M184A was the most 




























methyldecanoyl-CoA 114, achieving 39% conversion after 15.5 h. This was 
followed by D152N mutant, with 23% conversion after 15.5 h. The E237A and 
H122L mutants were almost inactive, with conversion levels of ca. 4% and 
these did not seem to change much with time. The result did not support the 
hypothesis that Asp-152 deprotonates the α-proton of a 2R-substrate and Met-
184 is involved in stabilising the enolate intermediate (vide supra).86, 108, 146 
The observation that the D152N and M184A mutants were the two most active 
mutants completely opposes this hypothesis. 














Figure 4.15: 1H NMR time course of wild-type and mutants enzymes (final assay 
concentration 0.12 mg mL-1; 2.55 µM) with (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 
(final assay concentration 100 µM) as substrate. The conversion at 30 °C was measured 
every hour. 
 
To further investigate the proposed hypothesis, the (2S,3S)-3-fluoro-2-
methyldecanoyl-CoA 147 was synthesised using an analogous protocol to that 
previously described.3 The results showed that it was still the D152N and 
M184A mutants that were active in eliminating the 2S-substrate 147, whilst 
H122L, E237A, E237Q mutants were almost completely dead (Figure 4.16). 
The only difference compared to the 2R-substrate 114 was that D152N mutant 
was more active in eliminating the 2S-substrate 147 than the M184A mutant 






























mechanism where Asp-152 deprotonates the R-substrate and His-122 and 
Glu-237 dyad from another face deprotonates the S-substrate (Figure 4.17).86, 
108, 146 In both experiments, the M184A and D152N mutants were active, 
suggesting that human AMACR works by a ‘one-base’ mechanism.  













Figure 4.16: 1H NMR time course of wild-type and mutants enzymes (final assay 
concentration 0.12 mg mL-1; 2.55 µM) with (2S,3S)-3-fluoro-2-methyldecanoyl-CoA 147 




Figure 4.17: The proposed ‘two-base’ mechanism of human AMACR. The Asp-152 
residue stabilised by Met-184 residue deprotonates the R-2-methylacyl-CoA ester as 
shown on the left panel, whilst the His-122/Glu-237 dyad deprotonates the S-2-






























In order to ensure that the results were reproducible, experiments on wild-type 
AMACR, D152N and M184A mutants were repeated. The experiments using 
(2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 and (2S,3S)-3-fluoro-2-
methyldecanoyl-CoA 147 were run in parallel in order to allow direct 
comparison of reaction rates. As the acquisition with 1H NMR was alternating 
between the R- and S- substrate, the temperature was set at 20 °C for the 
reaction to occur at a constant temperature within and outside the NMR 
spectrometer (room temperature was ca. 20 °C). At 20 °C, wild-type AMACR 
took much longer (10 h instead of 4 h) for substrate conversion to go to near 
completion. Even though the overall rates were much lower for both wild-type 
and mutant enzymes at 20 °C, a consistent trend of conversion was observed 
(Figure 4.18). The M184A mutant was more active (24% conversion) than 
D152N mutant (3% conversion) when the R-substrate 114 was used. D152N 
mutant was more active (35% conversion) than the M184A mutant (4% 
conversion) when the S-substrate 147 was used. These results were 
consistent with the above observations and showed that human AMACR is 
unlikely to work by a ‘two-base’ mechanism. The results also showed that 
these two mutant enzymes did not have a gross structural disruption as they 
were active and showed opposite levels of conversion for substrates with 





















Figure 4.18: 1H NMR time course of wild-type AMACR, D152N and M184A mutants (final 
assay concentration 0.12 mg mL-1; 2.55 µM) with (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 
114 or (2S,3S)-3-fluoro-2-methyldecanoyl-CoA 147 as substrate (final assay 
concentration 100 µM). The temperature was set at 20 °C and the acquisition by 1H NMR 
was alternated between the R- and S- substrate for each mutant. 
 
A subset of racemases catalyse their substrates by the 
deprotonation/reprotonation reaction and they usually operate via a ‘two-base’ 
or ‘one-base’ mechanism. For a ‘two-base’ mechanism, the proton is removed 
by a catalytic base and the intermediate is reprotonated by a catalytic residue 
from the opposite face, resulting in a product with the opposite stereochemical 
configuration from the substrate. Examples of ‘two-base’ racemases include 
alanine racemase,232 glutamate racemase,152, 233 mandelate racemase208, 234 
and proline racemase.209, 235 As there are two catalytic bases involved in the 
racemisation reaction, the mutation of one of these two residues will inactivate 
the enzyme as a racemase. For example, Tanner et al. showed that mutation 
of the Cys-73 or Cys-184 residues of the glutamate racemase results in 
mutants with no detectable racemase activity.152 These mutants were further 
tested to determine if they could perform an elimination reaction, where only 






























chloroglutamate substrate.152 Each mutant was shown to be active against 
one of the two diasteromers of the substrate, indicating that each of the 
mutants have a specific requirement for a particular stereochemical 
configuration of substrate.152 Their inability to racemise glutamate is because 
two catalytic bases are required for the racemisation reaction, a behaviour that 
fits a ‘two-base’ mechanism.152 The results from our study are not consistent 
with a ‘two-base’ mechanism. The His-122 and Glu-237 mutants were not 
active when eliminating either the R- 114 or S-fluoro-methyldecanoyl-CoA 147 
substrates, whilst the D152N mutant was active in eliminating both the R- and 
S- substrates.  
 
For a ‘two-base’ mechanism, a separate catalytic base is responsible in 
reprotonating the deprotonated intermediate. If the reaction occurs in heavy 
water such as in 2H2O, the deuterium will be incorporated into the product but 
little will be incorporated into the substrate. The chiral inversion will occur at 
the same time as the exchange of deuterium. This is not what happened in the 
‘racemisation’ reaction performed by human AMACR. Darley et al. showed 
that the product of human AMACR is in nearly 1:1 racemic mixture and that 
deuterium is incorporated in both substrate and product, consistent with a 
‘one-base’ mechanism.1 The ‘one-base’ mechanism, as the name suggests, 
involves only a single catalytic base in deprotonating substrate and 
reprotonating the intermediate, and results in a product that is a near racemic 
mixture. Enzymes operating with a ‘one-base’ mechanism are relatively rare, 
examples include α-amino-ε-caprolactam racemase210 and possibly acyl-CoA 
dehydrogenase.236 
 
The observation by Darley et al.1 supports the results from our site-directed 
mutagenesis study where mutants showed similar activities (or inactivity) 
towards both the R- and S-substrate. In the ‘racemisation’ assay, the D152N, 
H122L, E237A and E237Q mutants were all inactive towards both the 2R- and 
2S- substrate. This is probably because after the first cycle of reaction, the 
catalytic bases are in an inappropriate protonation state. In the elimination 
assay, the mutants do not discriminate between R- or S- substrates. Their 
catalytic activities were significantly reduced but all showed ability in 
131 
 
eliminating both R- and S-substrates, suggesting that deprotonation can occur 
when the α-proton is either on the same side or opposite side of the catalytic 
residue. The ability to deprotonate the substrate with both configurations is 
consistent with a ‘one-base’ mechanism. 
  
Even though the crystal structures of MCR, the homologous enzyme of human 
AMACR, have suggested that the enzyme works by a ‘two-base’ 
mechanism,86, 108, 146 our study using site-directed mutagenesis showed that 
human AMACR is more likely to work by a ‘one-base’ mechanism. Human 
AMACR appears to be atypical, as it does have two catalytic bases, one on 
each side of the substrate, which is usually consistent with the mechanism of 
a ‘two-base’ enzyme. This observation may have contributed to the false 
assumption that human AMACR works by a ‘two-base’ mechanism. The 
phenomenon where AMACR has two catalytic bases but work as a ‘one-base’ 
mechanism can be explained by the existence of water molecules in the active 
site. Instead of the catalytic bases directly deprotonate the substrate and 
reprotonate the intermediate, water molecules act as the intermediaries, which 
are the actual bases to the substrate. It is a ‘one-base’ mechanism because 
the water molecule is the only base that deprotonates the substrate and 
reprotonates the enolate intermediate. The presence of a hydrogen-bonding 
network including water molecules allows deprotonation and reprotonation 
from opposite sides by one base. 
 
The crystal structure of MCR has shown that there are two conserved water 
molecules in the active site which form a hydrogen-bonding network with 
multiple residues including side-chain of Asp127 and main chain of Leu-151, 
Leu-153, Val-154 and Gly-155 (Figure 4.19).146 They may have a role in acting 
as the intermediaries in deprotonating and reprotonating the substrate, but this 
is unlikely as they are anchored to the enzyme residues (via hydrogen bonds) 
and are situated quite far from the substrate (Figure 4.19).146 An other possible 
source of water molecules could be disordered waters from outside of the 
active site, i.e., the bulk solvent.108 These water molecules may also form 
hydrogen bonds with the main-chain and side-chains of active-site residues, 
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been protonated and deprotonated by the catalytic bases and in turn reacting 
with the substrate from both faces.  
 
 
Figure 4.19: The active site of MCR according to the X-ray crystal structure.146 The S-2-
methylacyl-CoA substrate is highlighted in red and the two conserved water molecules 
(W1 and W2) are in blue. Hydrogen bonds are shown as dotted lines. 
 
The site-directed mutagenesis on human AMACR changed the side-chains of 
the catalytic residues and hence affected electrostatic charges and hydrogen 
bonds between the residues and water molecules, which might disrupt the 
whole hydrogen-bonding network. This in turn affects proton transfer between 
catalytic residues and water molecules, and reduces the ability of water 
molecules to deprotonate the substrate and reprotonate the enolate 
intermediate. Similar observations have also been reported in other enzymes, 
catalysing proton transfer reactions, such as carbonic anhydrase II.237-239 
When His-64 residue is mutated to alanine in carbonic anhydrase II, the 
hydrogen-bonding network is disrupted and the proton transfer is affected, 




4.6 The study of wild-type and mutant enzymes using the multi-well 
colorimetric assay 
The kinetic study using the fluoride elimination assay was not conducted as 
the levels of enzyme activity of mutants were low. 1H NMR would not be very 
sensitive in detecting activity at low substrate concentrations and it would be 
too laborious to measure enzyme activity at a range of substrate 
concentrations for each mutant. Hence, the multi-well colorimetric assay (vide 
supra) using 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 as the 
substrate was used to measure the kinetic parameters of mutant enzymes as 
it is more sensitive and allows continuous monitoring of the reaction. 
 
In order to study the ability of mutant enzymes in eliminating the substrate, 
and to confirm that AMACR works by a ‘one-base’ mechanism, substrates 
ideally have to be tested in R- and S- configurations instead of a racemic 
mixture. The substrate, 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135, 
synthesised by Dr Maksims Yevglevskis is a 1:1 mixture of 2-methyl 
epimers.197 Chiral resolutions were attempted in order to resolve the substrate 
135 for use in the enzyme assay. 
 
4.6.1 Attempts to resolve 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA  
The racemic substrate 135 was first synthesised by Dr Maksims Yevglevskis 
using the route described in Scheme 4.5.197 The reaction between 1-fluoro-
2,4-dinitrobenzene 149 and a diol produced alcohol 150. The alcohol 150 was 
oxidised to the corresponding carboxylic acid 151 using Jones oxidation.240 
The acid 151 was activated using carbonyldiimidazole 71 and coupled with 






Scheme 4.5: Synthesis of the racemic substrate 135 as described by Dr Maksims 
Yevglevskis.197 Reagents and conditions: i) Na metal, 2-methyl-1,3-propanediol, rt, 6 h; 
80 °C, 2 h; then rt overnight; ii) H2O, H2SO4,  CrO3, acetone, 0 °C, overnight; iii) DCM, 




, rt, 18 h. 
 
To obtain a single enantiomer, a chiral reagent was investigated to resolve the 
alcohol 150. The same route using 1-fluoro-2,4-dinitrobenzene 149 and 2-
methyl-1,3-propanediol was used to synthesise the alcohol 150 (Scheme 4.5). 
The alcohol 150 was reacted with a chiral acid, S-2-acetoxy-2-phenylacetic 
acid 152 to produce diastereomers (153 and 154) which could potentially be 
separated (Scheme 4.6). This commercially available chiral auxillary 152 has 
previously been used in the esterification of racemic alcohols to produce 
diastereomers that could be separated by chromatography.241, 242 
Unfortunately, in our case, the diastereomers produced failed to separate 
using traditional column chromatography, automated chromatography 
(Teledyne Isco CombiFlash Rf) and HPLC (possibly due to the use of an 





Scheme 4.6: Attempted resolution of alcohol 150 using a chiral acid 152. Reagents and 
conditions: i) DCC, DMAP, DCM, rt, 18 h. 
 
Another chiral resolving agent, (1S)-10-camphorsulfonyl chloride 155 was 
therefore coupled to the racemic alcohol 150 to produce diastereomers 
(Scheme 4.7). It encountered the same problem as the chiral acid 152, the 
diastereomeric products could not be separated.  
 
 
Scheme 4.7: Attempted resolution of alcohol 150 using (1S)-10-camphorsulfonyl chloride 
155. Reagents and conditions: i) pyridine, -5 °C then 0 °C, 2 h. 
 
The third chiral resolving agent to be investigated was an Evans’ chiral 
auxillary 158. The alcohol 150 was first substituted with bromine to give a 
brominated product 159 before it was coupled with the Evans’ auxillary 158 
(Scheme 4.8). However, the coupling failed and no desired products (160 and 
161) were formed. 
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Scheme 4.8: Attempted resolution of alcohol 150 using an Evans’ chiral auxillary 158. 
Reagents and conditions: i) CBr4, PPh3, DCM, 1.5 h; ii) NaH, DMF, rt, 18 h. 
 
Attempts to resolve the racemic substrate 135 were therefore unsuccessful 
either due to the failure to produce the required diastereomers or failure to 
separate them. Instead of resolving the compound, an enantioselective 
synthesis was attempted using an enantiomerically pure starting material. 
 
4.6.2 Attempted enantioselective synthesis 
A chiral alcohol 162 was chosen as the starting material for the 
enantioselective synthesis (Scheme 4.9). The OH group of methyl S-3-
hydroxy-2-methylpropanoate 162 was protected with a tert-butyldiphenylsilyl- 
group. The methyl ester 163 was reduced to alcohol 164. The reduction was 
first attempted with LiAlH4, but the reducing agent was too strong and removed 
the silyl protecting group. DIBAL was then used as the reducing agent to 
produce a reduced OH group with an intact silyl-protecting group at its 
opposite end 164. Sequential protection and deprotection of the OH groups at 
two ends of the molecule should allow the chirality of the methyl group to be 
maintained. The reduced alcohol 164 was reacted with 1-chloro-2,4-
dinitrobenzene to introduce a dinitrophenol group into the compound 165. The 
silyl-protected alcohol at the opposite end was then deprotected. The 
deprotected alcohol 166 was oxidised to the carboxylic acid 167 which could 
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be coupled with CoA-Li3 to form the S-acyl-CoA ester 168. Unfortunately, the 
chirality was unexpectedly lost during the synthesis. Compounds were 
optically active until the deprotected alcohol 166 was produced, which had 
zero optical rotation. The removal of silyl-protecting group is unlikely to remove 
the chirality of the compound. It is unknown if the chirality had been lost in 
earlier steps. The measured optical rotations have been low for compounds 
from earlier steps, where protected alcohol 164 has [α]D20 value of +8.7 (c 1.50 
in CHCl3) [lit. [α]D20 +6.1 (c 0.93 in CHCl3)]243 and the dinitrophenol compound 
165 has [α]D21 value of +11.9 (c 1.09 in CHCl3). Such low optical rotation values 
are susceptible to experimental errors. These compounds might have lost their 
chirality but were unnoticed until later steps. 
 
Scheme 4.9: Attempted enantioselective synthesis of S-acyl-CoA ester 168. Reagents 
and conditions: i) TBDPSCl, imidazole, DCM, 0 °C then 20 °C, 2.5 h; ii) DIBAL, DCM, 0 
°C, 3 h, then Rochelle’s salt, rt, 18 h; iii) NaH, 1-chloro-2,4-dinitrobenzene, DMF, 60 °C, 
2 days; iv) TBAF, THF, rt, 18 h; v) CrO3, H2SO4, acetone, 0 °C, 1.5 h, then rt, 2 h. 
 
The same synthetic route was used to produce the R-acyl-CoA ester 169, 
starting from R-3-hydroxy-2-methylpropanoate 170 (Scheme 4.10). The same 
problem of losing chirality was encountered. This time, the dinitrophenol 
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compound 173 was shown to be optically inactive, confirming the possibility 
that chirality could have been lost during the earlier steps in the synthesis. 
 
Scheme 4.10: Attempted enantioselective synthesis of R-acyl-CoA ester 169. Reagents 
and conditions: i) TBDPSCl, imidazole, DCM, 0 °C then 20 °C, 2.5 h; ii) DIBAL, DCM, 0 
°C, 4 h, then Rochelle’s salt, rt, 18 h; iii) NaH, 1-chloro-2,4-dinitrobenzene, DMF, 60 °C, 
1 day, then 50 °C, 2 days; iv) TBAF, THF, rt, 18 h; v) CrO3, H2SO4, acetone, 0 °C, 1.5 h, 
then rt, 2 h. 
 
To confirm that the acids (167 and 175) were indeed racemic mixture, they 
were derivatised with a chiral amine. The derivatisation method was reported 
by Darley et al. who coupled the R- 176 and S- 2-methyldecanoic acid 177 
with S-1-phenylethylamine 178 to form diastereomers (Scheme 4.11) and their 
chemical shifts were analysed with the 1H NMR.1 The 2-methyl peak of the R-
derivative 179 has chemical shift of 1.11 ppm and the 2-methyl peak of S-
derivative 180 has a chemical shift of 1.13 ppm.1 The work was repeated and 
the (1S,2R)- 179 and (1S,2S)- 180 diastereomers were shown to have 
consistently different chemical shifts on 1H NMR (Figure 4.20). The 
derivatisation of an acid using a chiral amine is a useful method to distinguish 
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whether the acid is a single enantiomer and its enantiomeric excess or whether 
it is a racemic mixture. 
 
Scheme 4.11: Derivatisation of R- 176 and S- 2-methyldecanoic acid 177 with a chiral 





Figure 4.20: 1H NMR of (2R)-2-methyl-N-[(1S)-1-phenylethyl]decanamide 179 (Panel A) 
and (2S)-2-methyl-N-[(1S)-1-phenylethyl]decanamide 180 (Panel B) resulted from the 
derivatisation with a chiral amine. The 2-methyl peaks (highlighted in red) show different 
chemical shifts, where the (1S,2R)-product 179 is at 1.10 ppm and (1S,2S)-product 180 







Acids (167 and 175) resulted from the enantioselective synthesis (vide supra) 
were derivatised with chiral amine 178 using the same procedure described 
by Darley et al.1 (Scheme 4.12). Both acid derivatives showed the same 
chemical shifts on 1H NMR (Figure 4.21). This confirmed that both acids have 
indeed been racemised during the synthesis. 
 
 
Scheme 4.12: Derivatisation of acids (with an unknown stereochemical configuration) 
with a chiral amine. Reagents and conditions: i) oxalyl chloride, DCM, DMF, rt, 45 min. 
 
 
Figure 4.21: 1H NMR of 3-(2,4-dinitrophenoxy)-2-methyl-N-[(1S)-1-
phenylethyl]propanamide 181, the derivative of acids 167 (Panel A) and 175 (Panel B). 









4.6.3 Assay using racemic 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-
CoA as substrate 
Due to the failure to produce the R- and S- enantiomers, racemic 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate was used to assay the 
activity of wild-type and mutant AMACR enzymes. The enzymes were tested 
with a time-course assay over 10 h in order to understand their activities in 
eliminating the 2,4-dinitrophenolate 137 from 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 135 substrate (Figure 4.22). As expected, the wild-type 
enzyme was the most active of all enzymes. Surprisingly, the E237Q mutant 
showed high activity, achieving half of the absorbance of wild-type AMACR 
after 10 h of reaction time. Previous assays based on deuterium wash-in and 
fluoride elimination showed that E237Q mutant was almost inactive, showing 
barely any activity. This result showed that the mutants were not dead, but that 
they have different activities with different substrates. On the other hand, the 
M184A mutant showed very low activity in this assay, which is very different 
from its behaviour in deuterium wash-in assay and fluoride elimination assay 
where the M184A mutant had much higher activity compared to most of the 
other mutants.  
 
Figure 4.22: Time-course multi-well colorimetric assays of wild-type and mutant enzymes 
over 10 h. 























4.6.4 Kinetic studies on wild-type and mutants enzymes using multi-well 
colorimetric assay 
As the eliminated product of 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 
135 substrate absorbs in the UV range, its absorbance can be measured using 
a multi-well format. This convenient, high-throughput assay allows the kinetic 
parameters of wild-type and mutant enzymes to be easily measured. Wild-type 
and mutant enzymes were titrated to determine the appropriate concentrations 
to use in order to measure their initial reaction rate. Once the final 
concentrations of the enzyme were determined, the substrate 135 at a range 
of concentrations were used to determine the Km, Vmax and kcat values (Table 
4.3). However, the Direct Linear Plots of mutant enzymes do not converge and 
the data fits poorly to the Michaelis-Menten model (Appendix 6-10). Hence, it 
is rather difficult to interpret the data accurately and to draw a conclusion 
based on the kinetic parameters obtained. 
 
Enzyme Km (μM) Vmax (nmol min-1 mg-1) kcat (s-1) kcat/Km (M-1 s-1) 
Wild-type 27 274 0.2150 7963 
H122L 1.3  1.5 0.0012 923 
D152N 6.8  1.9 0.0015 221 
M184A 1.3 0.3 0.0002 154 
E237A 0.2  1.8 0.0014 7000 
E237Q 2.0  2.7 0.0021 1050 
Table 4.3: The kinetic parameters of wild-type and mutant AMACR enzymes obtained 
from Direct Linear Plots. 
 
The 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate used in the 
kinetic analysis was racemic and this might be the reason for the poor fitting 
of data in the Michaelis-Menten model. Since the substrate was racemic, the 
result obtained could not be used to deduce if AMACR operates with a ‘one-
base’ or ‘two-base’ mechanism. Nevertheless, the result was rather interesting 
as it showed that the same mutant enzyme has very different levels of activity 
with two different substrates even though wild-type AMACR has been shown 
to be able to eliminate both of them with similar efficiencies. The Km values of 
wild-type AMACR with (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 and 3-
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(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 were similar, 21 µM3 and 58 
µM, respectively. The Vmax values were not very different either, 96.5 nmol 
min-1 mg-1 for (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 1143 and 274 nmol min-
1 mg-1 for 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135. On the other 
hand, the trends were different for mutant enzymes. The fluoride elimination 
assay has shown that D152N and M184A mutants were the most active 
mutant enzymes compared to the H122L, E237A and E237Q mutants, which 
were almost inactive (vide supra). However, the multi-well colorimetric assay 
based on the elimination of 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 
135 showed that the D152N and E237Q mutants were the most active mutant 
enzymes whilst the activity for the M184A mutant was very low (Figure 4.22). 
The results suggest that the low activity of the mutant enzymes is not due to 
them been denatured. Their lack of activity in some of the assays was due to 
the mutation of a specific residue. The difference in the activity of mutants 
might be explained by the size of the leaving group of the substrates. 3-Fluoro-
2-methyldecanoyl-CoA is a substrate with long alkyl chain and a fluorine 
leaving group whilst 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 does 
not have a long alkyl chain but has an aromatic dinitrophenol leaving group. 
The dinitrophenol group is a much larger group than fluorine, and the side-
chains might bind in different conformations to different mutants as their 
catalytic residues have been mutated. As Met-184 residue is important in 
stabilising the enolate intermediate in the oxyanion pocket, different types of 
leaving group could have a profound effect in the ability of the M184A mutant 
enzyme to stabilise the enolate intermediate. M184A mutant might still 
stabilise the intermediate of (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 to a 
greater extent whilst the intermediate produced from 3-(2,4-dinitrophenoxy)-2-





5 Conclusions and future work 
A range of novel compounds have been designed based on the structure of 
fenoprofenoyl-CoA 13. Transition-state mimics (structures with an electron-
withdrawing group at the β-position) and substrate mimics (structures with an 
electron-donating group at the β-position) were produced. There is no 
statistically difference in the potency of inhibition of the transition-state mimics 
and substrate mimics. The IC50 and Ki values are not hugely different when the 
structures have an electron-donating oxygen group or an electron-withdrawing 
sulfide (or sulfone) group next to the 2-methyl group. The same trend occurs 
in side-chains with meta- and para- substituents, no statistically difference in 
their potency is observed. However, aromatic side-chains tend to have lower 
IC50 and Ki values compared to alkyl side-chains, possibly due to π-
interactions from aromatic rings. The 2-methyl group was designed to have a 
R- or S- stereochemical configuration and the results showed that they act as 
competitive inhibitors with similar potency.  
 
The results showed that the methionine-rich hydrophobic surface of AMACR 
can accept a wide spectrum of side-chains. Minimal changes on the side-
chains (such as changing the orientation of the substituents or the substitution 
of a single group) do not bring in a huge difference in the potency of a 
compound when inhibiting AMACR. The results also showed that the 2-methyl 
group and the acyl-CoA moiety are important for the binding with AMACR. 
Compounds designed by Professor Paul Groundwater do not have these two 
moieties and they were shown to be very poor AMACR inhibitors (almost no 
inhibition was observed). This research confirmed that to be a good AMACR 
inhibitor, the compound needs to have a 2-methyl group, an acyl-CoA moiety 
and a hydrophobic side-chain, ideally aromatic groups. As the enzyme can 
tolerate a huge change in the side-chain of the compound, future designs need 
to be less conservative in order to bring a large change in IC50 and Ki values. 
This research acts as a starting point for the SAR study of side-chains of 
AMACR inhibitors but a larger range of compounds will be need to be designed 
and evaluated in the future in order to fully explore the SAR. A potent AMACR 
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inhibitor will act as a lead for producing a drug that can inhibit AMACR which 
is an important treatment strategy for castrate-resistant prostate cancer. 
It has been difficult to produce a convenient assay to measure the potency of 
AMACR inhibitors due to the fact that the enzyme is a racemase. The fluoride 
elimination reaction has been shown as a viable method for measuring the 
potency of AMACR inhibitors. The potency of an inhibitor corresponds to the 
reduction in the conversion of (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 
substrate to an unsaturated product 117 and fluoride anion 118, measured 
using 1H and 19F NMR. However, it has been difficult to turn the fluoride 
elimination assay into a high-throughput method. Several fluoride sensors 
have been trialled to detect the fluoride anion in order to develop the assay so 
that product can be quantified fluorescently. The tert-butyldimethylsilyl-
protected fluorescein 128 and the boronate-based fluorescent sensor 131 
were attempted to react with fluoride anions to produce a fluorescent read-out. 
However, these attempts resulted in readings that were poorly reproducible, 
possibly due to the contamination of fluoride from external sources or the high 
levels of hydration experienced by fluoride in an aqueous environment. 
Nevertheless, the fluoride elimination assay based on 1H and 19F NMR is a 
proof of concept that the reaction can be used to measure the potency of 
AMACR inhibitors. A different type of sensor may be needed to turn the 
reaction into a high-throughput assay. 
 
On the other hand, the multi-well colorimetric assay using the 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 was a success. This is the very 
first high-throughput AMACR assay that does not require complicated sample 
preparation. It allows the screening of multiple inhibitors in a plate. The assay 
takes much less than half an hour to perform and this includes the time needed 
for pre-incubation of inhibitors with enzyme. Compared to the laborious 1H 
NMR study that scans a single sample at a time and manages to investigate 
just a few samples in a day, this assay potentially allows the screening of 
hundreds of compounds in a day. With this assay, a large compound library 
could be screened in order to look for potent AMACR inhibitors that could be 
used as treatment for castrate-resistant prostate cancer. Following this 
research, the MDL group has started the screening of libraries of small, drug-
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like molecules obtained from the MRC Technology and several hits have been 
found. The assay can also be used to screen in-house libraries of 
pharmaceutical companies and our research group can collaborate with these 
companies to turn hits into drugs targeting AMACR. Further research should 
be able to turn the multi-well colorimetric assay into a fluorescent assay, which 
is more sensitive and will be useful to screen drugs with much higher potency. 
 
The site-directed mutagenesis study is the first extensive study on human 
AMACR which investigates the role of various residues reported to-date. There 
have been several studies on MCR, the homologous enzyme of human 
AMACR, including the X-ray crystal structure108, 153 and site-directed 
mutagenesis studies.86 However, there have been a limited number of studies 
on human AMACR, possibly due to the inherent difficulties in producing and 
handling the enzyme. In this research, a lot of protocol optimisations have 
been carried out in order to mutate and express the mutant human AMACR 
enzymes. This study has established optimal protocols for the production of 
mutant AMACR enzymes and these protocols will be useful when mutating 
other residues of human AMACR in the future. 
 
This research showed that His-122, Asp-152, Met-184 and Glu-237 are 
important residues for the catalytic function of human AMACR. By mutating 
these residues, the activity of the enzyme decreased in both terms of 
‘racemisation’ and elimination of its substrate. This study also showed that 
human AMACR is unlikely to work by a ‘two-base’ mechanism. This discovery 
is very significant as it had always been assumed that as the enzyme has two 
catalytic bases at two different sites it works by a ‘two-base’ mechanism. 
However, human AMACR has been shown to be an atypical enzyme that has 
catalytic centres at two sides of the substrate but operates with a ‘one-base’ 
mechanism (Scheme 5.1). It is likely that water molecules, possibly the 
disordered water molecules found within the active site, act as intermediaries 
in transferring protons within hydrogen-bonding networks. Besides providing 
insight into the mechanism of human AMACR, the results also inform the 
importance of these hydrogen-bonding networks. The knowledge obtained 
from this research is useful in the future design of AMACR inhibitors to be used 
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as drugs. Designing compounds that can interfere with hydrogen-bonding 






Scheme 5.1: The ‘one-base’ mechanism of human AMACR where water molecules act 
as intermediaries in transferring protons within the active site. The top panel shows the 
‘racemisation’ of R-2-methylacyl-CoA ester and the bottom panel shows the 




The next step will involve the use of molecular modelling to visualise water 
molecules and hydrogen-bonding networks, which will supplement the data 
from this research. In addition, there should be further attempts to synthesise 
enantiomerically pure R- and S- 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-
CoA substrate in order to better characterise mutant AMACR enzymes and to 







6.1 General (inhibitor syntheses and assays) 
Chemicals were sourced from the Sigma-Aldrich Chemical Co. or Fisher 
Scientific Ltd. and were used without further purification unless otherwise 
stated. Coenzyme A, trilithium salt was purchased from Calbiochem, 
oxazolidinone chiral auxiliaries were purchased from Fluorochem and 
deuterated solvents were obtained from Goss Scientific. (2S,3R)-3-Fluoro-2-
methyldecanoic acid,3, 183 fluorescent ligand 134, racemic 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 were provided by Dr Maksims 
Yevglevskis from the MDL lab. 3-(Hexylsulfanyl)-2-methylpropanoic acid 107 
and 3-(hexylsulfonyl)-2-methylpropanoic acid 108 were obtained from Dr 
Daniel Darley from the MDL lab. The boronate-based fluorescence sensor 131 
was obtained from Dr Xiaolong Sun from the group of Professor Tony James, 
Department of Chemistry, University of Bath.192 Small molecules identified by 
structure-based design were sent by Professor Paul Groundwater from the 
Faculty of Pharmacy, University of Sydney, Australia. Argon gas was used for 
reactions requiring anhydrous conditions. Organic solvents were removed 
using a Stuart RE300 rotary evaporator at 40 °C [except for acyl-CoA esters 
where a water bath at ambient room temperature (ca. 20 °C) was used]. All IR 
spectra were obtained on a Perkin-Elmer Spectrum RXI FT-IR spectrometer 
using KBr or NaCl discs and are reported in cm-1. All mass spectra were 
obtained on a Bruker micrOTOF™ ESI-TOF mass spectrometer (Bruker 
Daltonics, Bremen). All NMR spectra were obtained on Bruker Avance III 
spectrometers. Chemical shifts are reported in parts per million (ppm) 
referenced to residual solvent (CDCl3, 2H2O or DMSO-d6). Assignments of 
spectra were confirmed using COSY, NOESY, HSQC and HMBC data. 
Coupling constants (J) are reported in Hertz (Hz) to a single decimal place. 
Multiplicities are abbreviated as: s (singlet), br s (broad singlet), d (doublet), 
dd (doublet of doublets), dt (doublet of triplets), t (triplet), td (triplet of doublets), 
tt (triplet of triplets), q (quartet), qd (quartet of doublets) and m (multiplet). 
Optical rotations were obtained using an Optical Activity Ltd. AA-10 
polarimeter with a 5 mL cell of 1 dm path length. Values of [α]D are given in 10-
1 deg cm2 g-1 and concentrations are reported in 0.01 g cm-3. Melting points 
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(uncorrected) were determined using a Reichert-Jung heated-stage 
microscope. Thin-layer chromatography was performed on Merck aluminium-
backed silica plates (silica gel 60 F254) and visualised using UV light ( = 254 
nm), phosphomolybdic acid, iodine or potassium permanganate. Column 
chromatography was carried out on Fisher silica gel (35-70 µm) unless 
otherwise stated. Fluorescent spectra were obtained using a Perkin-Elmer 
Luminescence LS 50B Spectrometer. Fluorescence intensity and absorbance 
detections were performed using a FLUOstar Omega plate reader (BMG 
Labtech). Purification of acyl-CoA esters was carried out using solid-phase 
extraction cartridges (Oasis HLB, 6cc, Water Corporation). The acyl-CoA 
esters were eluted from the cartridges with water, and 10%, 20%, 40% and 
50% (v/v) acetonitrile in water. For enzyme assays, all acyl-CoA ester stock 
solutions were vortex-mixed for 5 min before being diluted to their desired 
concentrations. The diluted solutions have to vortex-mixed for 2 min before 
being added to the enzyme. Solutions for enzyme assays were prepared using 
water from a Nanopure Diamond system and was of 18.2 Mega-Ω.cm-1 quality. 
The pH of buffers was adjusted using 5.0 M NaOH aq. or concentrated HCl aq. 
as appropriate and measured using a Corning pH meter 240 at room 
temperature, calibrated with standard commercial buffers at pH 7.0 and pH 4.0 
or pH 10.0. 
 
6.2 Synthesis of novel AMACR inhibitors 
6.2.1 Synthesis of 3-sulfide inhibitors 
O-4-Phenoxyphenyl-N,N-dimethylthiocarbamate (68) 
 
NaH [60% (w/w) dispersion in mineral oil, 1.20 g, 30.0 mmol] was added slowly 
to a solution of 4-phenoxyphenol 67 (5.59 g, 30.0 mmol) in DMF (27 mL) at 10 
°C. N,N-dimethylthiocarbamoyl chloride (5.78 g, 46.8 mmol) was added to the 
stirred solution once hydrogen gas formation had ceased. The reaction mixture 
was stirred at 70 °C for 21 h, and then cooled to ambient temperature. Water 
(100 mL) was added and the mixture was extracted with chloroform (3 x 50 
mL). The organic layers were combined, washed with KOH aq. (50 mL, 0.89 
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M), brine (50 mL), dried over MgSO4 and evaporated in vacuo to give a yellow 
oil. The crude product was purified by column chromatography [silica, 5:1 (v/v) 
PE:EtOAc] to afford a white solid (7.12 g, 86.8%). Rf = 0.50 [5:1 (v/v) 
PE:EtOAc]. 1H and 13C spectra and mass of the product were consistent with 
previously reported data.174 δH (400.04 MHz; CDCl3) 7.37-7.30 (2 H, m, Ar 3’-
H), 7.11 (1 H, t, J = 7.4 Hz, Ar 4’-H), 7.04 (2 H, d, J = 7.7 Hz, Ar 2’-H), 7.02-
6.97 (4 H, m, Ar 2-H and Ar 3-H), 3.46 (3 H, s, NCH3) and 3.34 (3 H, s, NCH3); 
δC (100.59 MHz; CDCl3) 187.89 (C=S), 156.95 (Ar 1’-C), 154.88 (Ar 1-C or Ar 
4-C), 149.31 (Ar 1-C or Ar 4-C), 129.75 (Ar 3’-C), 123.80 (Ar 2-C or Ar 3-C), 
123.42 (Ar 4’-C), 119.03 (Ar 2-C or Ar 3-C), 119.02 (Ar 2’-C), 43.29 (NCH3) 





O-4-Phenoxyphenyl-N,N-dimethylthiocarbamate 68 (7.10 g, 25.9 mmol) was 
heated at 280 °C under an argon atmosphere for 1 h 40 min. The crude dark 
yellow oil was purified by column chromatography [silica, gradient elution with 
19:1, 9:1, 5:1, 3:1 (v/v) PE:EtOAc] to give a pale yellow solid (2.59 g, 36.4%) 
that eluted in 3:1 (v/v) PE:EtOAc. Rf = 0.30 [5:1 (v/v) PE:EtOAc]. 1H and 13C 
NMR spectra and mass of the product were consistent with previously reported 
data.174 δH (400.04 MHz; CDCl3) 7.42-7.50 (2 H, m, Ar 2-H), 7.38-7.30 (2 H, 
m, Ar 3’-H), 7.16-7.11(1 H, m, Ar 4’-H), 7.10-7.04 (2 H, m, Ar 2’-H), 7.03-6.98 
(2 H, m, Ar 3-H) and 3.03 (6 H, br s, N(CH3)2); δC (100.59 MHz; CDCl3) 166.77 
(C=O), 158.33 (Ar 4-C), 156.06 (Ar 1’-C), 137.14 (Ar 2-C), 129.59 (Ar 3’-C), 
123.63 (Ar 4’-C), 122.03 (Ar 1-C), 119.32 (Ar 2’-C), 118.42 (Ar 3-C) and 36.55 










NaOH aq. (4.0 mL, 2.50 M, 10.0 mmol) was added to a solution of 
S-4-phenoxyphenyl-N,N-dimethylcarbamothioate 69 (957 mg, 3.5 mmol) in 
methanol (9 mL), and the reaction mixture was heated at reflux for 4 h. The 
reaction mixture was cooled to ambient temperature, acidified to pH 1 by 
addition of 1.0 M HCl aq. and the aqueous layer was extracted with chloroform 
(3 x 50 mL). The organic layers were combined, washed with brine (50 mL), 
dried over MgSO4 and evaporated in vacuo to afford a yellow oil. The crude 
product was purified by column chromatography [silica, 10:1 (v/v) PE:EtOAc] 
to give a pale yellow oil (618 mg, 87.2%). The product was estimated to be 
90% pure (by 1H NMR) and used without further purification. Rf = 0.78 [5:1 
(v/v) PE:EtOAc]. 1H and 13C NMR spectra and mass of the product were 
consistent with previously reported data.174 δH (400.04 MHz; CDCl3) 7.45-7.36 
(2 H, m, Ar 3’-H), 7.35-7.29 (2 H, m, Ar 2-H), 7.21-7.15 (1 H, m, Ar 4’-H), 7.12-
7.05 (2 H, m, Ar 2’-H), 7.00-6.95 (2 H, m, Ar 3-H) and 3.50 (1 H, s, SH); δC 
(100.59 MHz; CDCl3) 156.89 (Ar 1’-C), 155.61 (Ar 4-C), 131.64 (Ar 2-C), 
129.66 (Ar 3’-C), 123.72 (Ar 1-C), 123.24 (Ar 4’-C), 119.51 (Ar 3-C) and 118.62 
(Ar 2’-C); ESI-MS m/z calcd. for [M-H]- C12H9OS: 201.0374 found 201.0379. 
 
Ethyl 2-[(4-phenoxyphenyl)thio]propanoate (59) 
 
Anhydrous potassium carbonate (367 mg, 2.65 mmol) was added to a solution 
of 4-phenoxybenzenethiol 58 (534 mg, 2.64 mmol) in anhydrous acetonitrile 
(4.9 mL) at -45 °C and the resulting mixture was stirred for 15 min. Acetonitrile 
(1.8 mL) was added to the mixture, followed by a solution of ethyl 2-
bromopropionate (0.35 mL, 2.64 mmol) in acetonitrile (1.2 mL). The reaction 
mixture was warmed to ambient temperature and stirred for 20 h. The mixture 
was filtered through celite and concentrated in vacuo to give a pale yellow oil. 
The crude product was purified by column chromatography [silica, 30:1 (v/v) 
153 
 
PE:EtOAc] to afford a colourless oil (630 mg, 78.9%). Rf = 0.51 [10:1 (v/v) 
PE:EtOAc]; IR max/cm-1 1731 (C=O); δH (400.04 MHz; CDCl3) 7.46-7.41 (2 H, 
m, Ar 2-H), 7.37-7.31 (2 H, m, Ar 3’-H), 7.13 (1 H, tt, J = 7.4, 1.1 Hz, Ar 4’-H), 
7.04-6.98 (2 H, m, Ar 2’-H), 6.95-6.90 (2 H, m, Ar 3-H), 4.15-4.07 (2 H, m, 
OCH2), 3.68 (1 H, q, J = 7.1 Hz, CH), 1.45 (3 H, d, J = 7.1 Hz, CHCH3) and 
1.20 (3 H, t, J = 7.1 Hz, CH2CH3); δC (100.59 MHz and CDCl3) 172.54 (C=O), 
158.04 (Ar 4-C), 156.37 (Ar 1’-C), 135.99 (Ar 2-C), 129.84 (Ar 3’-C), 126.16 
(Ar 1-C), 123.82 (Ar 4’-C), 119.38 (Ar 2’-C), 118.68 (Ar 3-C), 61.05 (OCH2), 
45.76 (CH), 12.20 (CHCH3) and 14.07 (CH2CH3); ESI-MS m/z calcd. for 
[M+Na]+ C17H18O3SNa: 325.0869, found 325.0991. 
 
2-[(4-Phenoxyphenyl)thio]propanoic acid (60) 
 
NaOH aq. [1.5 mL, 2.50 M, 3.75 mmol] was added to a solution of ethyl 2-[(4-
phenoxyphenyl)thio]propanoate 59 (387 mg, 1.28 mmol) in methanol (4.0 mL), 
and the resulting mixture was stirred at ambient temperature for 1.5 h. The 
volatiles were evaporated and the remaining solution was acidified to pH 1 by 
addition of 1.0 M HCl aq. Water (100 mL) was added and the mixture was 
extracted with chloroform (3 x 50 mL). The combined organic extracts were 
washed with brine (100 mL), dried over MgSO4 and evaporated in vacuo to 
afford a colourless oil (339 mg, 96.5%) which was found to be ca. 99% pure 
(by 1H NMR) and used in the next step without further purification. Rf = 0.49 
[10% (v/v) methanol in DCM]; IR max/cm-1 3038 (OH), 1705 (C=O); δH (400.04 
MHz; CDCl3) 11.89 (1 H, br s, OH), 7.47 (2 H, d, J = 8.8 Hz, Ar 2-H), 7.36 (2 
H, t, J = 7.9 Hz, Ar 3’-H), 7.15 (1 H, t, J = 7.4 Hz, Ar 4’-H), 7.03 (2 H, d, J = 7.6 
Hz, Ar 2’-H), 6.94 (2 H, d, J = 8.8 Hz, Ar 3-H), 3.69 (1 H, q, J = 7.2 Hz, CH) 
and 1.48 (3 H, d, J = 7.2 Hz, CH3); δC (100.59 MHz; CDCl3) 179.17 (C=O), 
158.33 (Ar 4-C), 156.25 (Ar 1’-C), 136.09 (Ar 2-C), 129.88 (Ar 3’-C), 125.56 
(Ar 1-C), 123.93 (Ar 4’-C), 119.52 (Ar 2’-C), 118.76 (Ar 3-C), 45.73 (CH) and 






CDI (36 mg, 0.22 mmol) was added in one portion to a solution of 2-[(4-
phenoxyphenyl)thio]propanoic acid 60 (30 mg, 0.11 mmol) in anhydrous DCM 
(2 mL), and the resulting mixture was stirred at ambient temperature for 1 h. 
DCM (3 mL) was added to the reaction mixture which was then washed with 
water (5×2 mL), brine (2 mL), dried over MgSO4 and evaporated in vacuo to 
afford the crude intermediate. NaHCO3 aq. (1 mL, 0.10 M), followed by CoA-Li3 
(17 mg, 0.02 mmol) was added to the solution of crude intermediate in THF (1 
mL), and the resulting mixture was stirred at ambient temperature under an 
argon atmosphere for 18 h. The volatile organics were evaporated in vacuo 
and the remaining solution was acidified to ca. pH 3 by addition of 1.0 M HCl 
aq. The mixture was diluted with water (2 mL) and extracted with EtOAc (5×3 
mL). The crude aqueous product was freeze-dried and purified by solid phase 
extraction to afford a white solid (5.8 mg). δH (500.13 MHz, 2H2O) 8.60 (1 H, s, 
adenosine CH), 8.32 (1 H, s, adenosine CH), 7.39-7.30 (4 H, m, Ar-H), 7.14 
(1 H, t, J = 6.5 Hz, Ar-H), 7.00-6.94 (2 H, m, Ar-H), 6.91-6.85 (2 H, m, Ar-H), 
6.12 (1 H, d, J = 5.0 Hz, adenosine CH), 4.82-4.75 (1 H, m, adenosine CH), 
4.52 (1 H, br s, adenosine CH), 4.18 (2 H, br s, adenosine CH2), 4.04-3.97 (1 
H, m, CH), 3.96 (1 H, s, adenosine CH), 3.83-3.74 (1 H, m, CoA(OCHa)), 3.55-
3.46 (1 H, m, CoA(OCHb)), 3.41-3.30 (2 H, m, CoA(CH2)), 3.24-3.11 (2 H, m, 
CoA(CH2)), 2.96-2.80 (2 H, m, CoA(SCH2)), 2.33 (2 H, t, J = 6.5 Hz, 
CoA(CH2)), 1.36 (3 H, d, J = 7.0 Hz, CH3), 0.85 (3 H, d, J = 4.0 Hz, CoA(CH3)) 
and 0.70 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M-H]- C36H47N7O18P3S2: 







O-(3-Phenoxyphenyl) dimethylthiocarbamate (74) 
 
Compound 74 was prepared from 3-phenoxyphenol 73 (1.86 g, 10.0 mmol) 
using the same procedure as for compound 68. The crude product was purified 
by column chromatography [silica, 5:1 (v/v) PE:EtOAc] to afford a colourless 
oil (1.86 g, 68.1%). Rf = 0.68 [2:1 (v/v) PE:EtOAc]; IR max/cm-1 1139 (C=S); 
δH (400.04 MHz; CDCl3) 7.38-7.30 (3 H, m, Ar 5-H and Ar 3’-H), 7.15-7.05 (3 
H, m, Ar 2’-H and Ar 4’-H), 6.95-6.90 (1 H, m, Ar 4-H or Ar 6-H), 6.87-6.82 (1 
H, m, Ar 4-H or Ar 6-H), 6.78 (1 H, t, J = 2.0 Hz, Ar 2-H), 3.40 (3 H, s, NCH3) 
and 3.26 (3 H, s, NCH3); δC (100.59 MHz; CDCl3) 187.26 (C=S), 157.90 (Ar 1-
C or Ar 3-C), 156.59 (Ar 1’-C), 154.98 (Ar 1-C or Ar 3-C), 129.92 (Ar 3’-C), 
129.80 (Ar 5-C), 123.74 (Ar 4’-C), 119.24 (Ar 2’-C), 117.56 (Ar 4-C or Ar 6-C), 
116.01 (Ar 4-C or Ar 6-C), 113.64 (Ar 2-C), 43.24 (NCH3), 38.75 (NCH3); ESI-




Compound 75 was prepared from O-3-Phenoxyphenyl-N,N-
dimethylthiocarbamate 74 (1.76 g, 6.43 mmol) using the same procedure as 
for compound 69 to give a brown oil (664 mg, 37.8%). Rf = 0.61 [2:1 (v/v) 
PE:EtOAc]; IR max/cm-1 1671 (C=O); δH (400.04 MHz; CDCl3) 7.39-7.30 (3 H, 
m, Ar 5-H and Ar 3’-H), 7.29-7.24 (1 H, m, Ar 4-H), 7.20 (1 H, t, J = 2.2 Hz, Ar 
2-H), 7.12 (1 H, tt, J = 7.4, 1.0 Hz, Ar 4’-H), 7.09-7.01 (3 H, m, Ar 2’-H and Ar 
6-H) and 3.02 (6 H, br s, N(CH3)2); δC (100.59 MHz; CDCl3) 166.01 (C=O), 
157.09 (Ar 3-C), 156.46 (Ar 1’-C), 130.10 (Ar 4-C), 129.98 (Ar 1-C), 129.63 (Ar 
5-C), 129.59 (Ar 3’-C), 125.37 (Ar 2-C), 123.32 (Ar 4’-C), 119.14 (Ar 6-C), 
118.91 (Ar 2’-C) and 36.60 (NCH3); ESI-MS m/z calcd. for [M+H]+ 







Compound 76 was prepared from S-(3-phenoxyphenyl)-N,N-
dimethylcarbamothioate 75 (254 mg, 0.93 mmol) using the same procedure 
as for compound 58. The crude brown oil was purified by column 
chromatography [silica, 40:1 (v/v) PE:EtOAc] to give a colourless oil (98 mg, 
52.1%). Rf = 0.43 [30:1 (v/v) PE:EtOAc]. The product was estimated to be ca. 
85% pure (by 1H NMR) and used without further purification. δH (400.04 MHz; 
CDCl3) 7.40-7.30 (2 H, m, Ar 3’-H), 7.21-7.10 (2 H, m, Ar 5-H and Ar 4’-H), 
7.05-6.96 (3 H, m, Ar 6-H and Ar 2’-H), 6.92 (1 H, t, J = 2.1 Hz, Ar 2-H), 6.83-
6.76 (1 H, m, Ar 4-H) and 3.47 (1 H, s, SH); δC (100.59 MHz; CDCl3) 157.76 
(Ar 3-C), 156.55 (Ar 1’-C), 132.51 (Ar 1-C), 130.16 (Ar 5-C), 129.80 (Ar 3’-C), 
123.75 (Ar 6-C), 123.63 (Ar 4’-C), 119.20 (Ar 2’-C), 119.08 (Ar 2-C) and 115.83 
(Ar 4-C); ESI-MS m/z calcd. for [M-H]- C12H9OS: 201.0374 found 201.0376. 
 
Ethyl 2-[(3-phenoxyphenyl)thio]propanoate (77) 
 
Compound 77 was prepared from 3-phenoxybenzenethiol 76 (94 mg, 0.47 
mmol) using the procedure as for compound 59 to afford a colourless oil (94 
mg, 66.8%). Rf = 0.51 [10:1 (v/v) PE:EtOAc]; IR max/cm-1 1732 (C=O); δH 
(400.04 MHz; CDCl3) 7.38-7.30 (2 H, m, Ar 3’-H), 7.25 (1 H, t, J = 8.0 Hz, Ar 
5-H), 7.20-7.07 (3 H, m, Ar 2-H, 6-H and Ar 4’-H), 7.04-6.97 (2 H, m, Ar 2’-H), 
6.94-6.89 (1 H, m, Ar 4-H), 4.10 (2 H, q, J = 7.2 Hz, OCH2), 3.78 (1 H, q, J = 
7.2 Hz, CH), 1.48 (3 H, d, J = 7.2 Hz, CHCH3) and 1.17 (3 H, t, J = 7.2 Hz, 
CH2CH3); δC (100.59 MHz; CDCl3) 172.43 (C=O), 157.49 (Ar 3-C), 156.65 (Ar 
1’-C), 135.08 (Ar 1-C), 129.94 (Ar 5-C), 129.81 (Ar 3’-C), 127.00 (Ar 6-C), 
123.59 (Ar 4’-C), 122.29 (Ar 2-C), 119.06 (Ar 2’-C), 118.09 (Ar 4-C), 61.22 
(OCH2), 44.99 (CH), 17.34 (CHCH3) and 14.02 (CH2CH3); ESI-MS m/z calcd. 




2-[(3-Phenoxyphenyl)thio]propanoic acid (78) 
 
Compound 78 was prepared from ethyl 2-[(3-phenoxyphenyl)thio]propanoate 
77 (87 mg, 0.29 mmol) using the same procedure as for compound 60 to give 
a colourless oil (79 mg, 98.9%). Rf = 0.23 [5% (v/v) methanol in DCM]; IR 
max/cm-1 3064 (O-H), 1707 (C=O); δH (400.04 MHz; CDCl3) 11.24 (1 H, br s, 
OH), 7.38-7.31 (2 H, m, Ar 3’-H), 7.26 (1 H, t, J = 7.9 Hz, Ar 5-H), 7.18 (1 H, 
dt, J = 7.9, 1.4 Hz, Ar 6-H), 7.15-7.09 (2 H, m, Ar 2-H and Ar 4’-H), 7.04-6.97 
(2 H, m, Ar 2’-H), 6.95-6.90 (1 H, m, Ar 4-H), 3.79 (1 H, q, J = 7.2 Hz, CH) and 
1.50 (3 H, d, J = 7.2 Hz, CH3); δC (100.59 MHz; CDCl3) 178.78 (C=O), 157.61 
(Ar 3-C), 156.52 (Ar 1’-C), 134.57 (Ar 1-C), 130.10 (Ar 5-C), 129.83 (Ar 3’-C), 
126.85 (Ar 6-C), 123.66 (Ar 4’-C), 122.18 (Ar 2-C), 119.12 (Ar 2’-C), 118.25 
(Ar 4-C), 44.81 (CH) and 17.17 (CH3); ESI-MS m/z calcd. for [M-H]- C15H13O3S: 




Compound 50 was prepared from 2-[(3-phenoxyphenyl)thio]propanoic acid 78 
(30 mg, 0.11 mmol) using the same procedure as for compound 49 to give a 
white solid (14 mg). δH (500.13 MHz; 2H2O) 8.55 (1 H, s, adenosine CH), 8.24 
(1 H, s, adenosine CH), 7.36-7.25 (2 H, m, Ar-H), 7.20 (1 H, t, J = 8.0 Hz, 
Ar-H), 7.10-7.01 (2 H, m, Ar-H), 7.00-6.79 (4 H, m, Ar-H), 6.06 (1 H, d, J = 5.5 
Hz, adenosine CH), 4.70 (1 H, s, adenosine CH), 4.47 (1 H, br s, adenosine 
CH),  4.13 (2 H, br s, adenosine CH2), 4.03-3.95 (1 H, m, CH), 3.91 (1 H, s, 
adenosine CH), 3.83-3.68 (1 H, m, CoA(OCHa)), 3.50-3.42 (1 H, m, 
CoA(OCHb)), 3.29 (2 H, t, J = 6.5 Hz, CoA(CH2)), 3.14-3.00 (2 H, m, 
CoA(CH2)), 2.83-2.70 (2 H, m, CoA(SCH2)), 2.24 (2 H, t, J = 6.5 Hz, 
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CoA(CH2)), 1.29 (3 H, d, J = 6.3 Hz, CH3), 0.80 (3 H, s, CoA(CH3)) and 0.65 
(3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M-H]- C36H47N7O18P3S2: 
1022.1626, found 1022.1616. 
 
6.2.2 Synthesis of 3-sulfone inhibitors 
Ethyl 2-[(4-phenoxyphenyl)sulfonyl]propanoate (79)42 
 
A solution of OXONE® (470 mg, 1.53 mmol) in water (4.7 mL) was added to a 
solution of ethyl 2-[(4-phenoxyphenyl)thio]propanote 59 (143 mg. 0.47 mmol) 
in 1:1 methanol/THF (4.7 mL), and the resulting mixture was stirred at ambient 
temperature for 4 h. The reaction mixture was filtered through celite and the 
volatiles were evaporated in vacuo. Water (100 mL) was added and mixture 
was extracted with EtOAc (3×50 mL). The organic layers were combined, dried 
over MgSO4 and evaporated in vacuo. The crude product was purified by 
column chromatography [silica, gradient elution with 20:1, 7:1, 5:1, 3:1 (v/v) 
PE:EtOAc] to give a colourless oil (129 mg, 81.8%) that eluted in 3:1 (v/v) 
PE:EtOAc. Rf = 0.59 [2:1 (v/v) PE:EtOAc]; IR max/cm-1 1738 (C=O), 1324 and 
1144 (S=O); δH (400.04 MHz; CDCl3) 7.82-7.77 (2 H, m, Ar 2-H), 7.45-7.37 (2 
H, m, Ar 3’-H), 7.23 (1 H, tt, J = 7.4, 1.1 Hz, Ar 4’-H), 7.10-7.02 (4 H, m, Ar 3-
H and Ar 2’-H), 4.13 (2 H, q, J = 7.2 Hz, OCH2), 4.02 (1 H, q, J = 7.1 Hz, CH), 
1.55 (3 H, d, J = 7.1 Hz, CHCH3) and 1.20 (3 H, t, J = 7.2 Hz, CH2CH3); δC 
(100.59 MHz; CDCl3) 166.36 (C=O), 162.97 (Ar 4-C), 154.65 (Ar 1’-C), 131.69 
(Ar 2-C), 130.22 (Ar 3’-C), 130.04 (Ar 1-C), 125.24 (Ar 4’-C), 120.48 (Ar 2’-C), 
117.15 (Ar 3-C), 65.47 (CH), 62.16 (OCH2), 13.85 (CH2CH3) and 11.93 
(CHCH3); ESI-MS m/z calcd. for [M-H]- C17H17O5S: 333.0797, found 333.0807. 
 
2-[(4-Phenoxyphenyl)sulfonyl]propanoic acid (81) 
 
Compound 81 was prepared from ethyl 
2-[(4-phenoxyphenylsulfonyl]propanoate 79 (105 mg, 0.31 mmol) using the 
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same procedure as for compound 60 to afford a waxy white solid (95 mg, 
99.5%) which was found to be ca. 99 % pure (by 1H NMR). Rf = 0.28 [5% (v/v) 
methanol in DCM]; melting point 119-120 °C; IR max/cm-1 3251 (O-H), 1741 
(C=O), 1306 and 1125 (S=O); δH (400.04 MHz; CDCl3) 7.86-7.79 (2 H, m, Ar 
2-H), 7.64 (1 H, br s, OH), 7.46-7.38 (2 H, m, Ar 3’-H), 7.28-7.21 (1 H, m, Ar 
4’-H), 7.12-7.02 (4 H, m, Ar 3-H and Ar 2’-H), 4.06 (1 H, q, J = 7.2 Hz, CH) and 
1.57 (3 H, d, J = 7.2 Hz, CH3); δC (100.59 MHz; CDCl3) 170.34 (C=O), 163.25 
(Ar 4-C), 154.52 (Ar 1’-C), 131.73 (Ar 2-C), 130.25 (Ar 3’-C), 129.42 (Ar 1-C), 
125.34 (Ar 4’-C), 120.56 (Ar 2’-C), 117.28 (Ar 3-C), 65.19 (CH) and 12.03 




Compound 51 was prepared from 2-[(4-phenoxyphenyl)sulfonyl]propanoic 
acid 81 (30 mg, 0.10 mmol) using the same procedure as for compound 49 to 
give a white solid (6.1 mg). δH (500.13 MHz; 2H2O) 8.61 (1 H, s, adenosine 
CH), 8.33 (1 H, s, adenosine CH), 7.72 (2 H, d, J = 8.5 Hz, Ar-H), 7.40 (2 H, t, 
J = 7.0 Hz, Ar-H), 7.23 (1 H, t, J = 6.5 Hz, Ar-H), 7.14-7.02 (4 H, m, Ar-H), 6.12 
(1 H, d, J = 4.5 Hz, adenosine CH), 4.79 (1 H, s, adenosine CH), 4.52 (1 H, br 
s, adenosine CH), 4.18 (2 H, br s, adenosine CH2), 3.96 (1 H, s, adenosine 
CH), 3.84-3.74 (1 H, m, CoA(OCHa)), 3.53-3.47 (1 H, m, CoA(OCHb)), 3.43-
3.33 (2 H, m, CoA(CH2)), 3.23-3.08 (2 H, m, CoA(CH2)), 2.98-2.83 (2 H, m, 
CoA(SCH2)), 2.36 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.47 (3 H, s, CH3), 0.85 (3 
H, d, J = 4.0 Hz, CoA(CH3)) and 0.71 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. 







Ethyl 2-[(3-phenoxyphenyl)sulfonyl]propanoate (80) 
 
Compound 80 was synthesised from ethyl 
2-[(3-phenoxyphenylthio]propanoate 77 (115 mg, 0.38 mmol) using the same 
procedure as for compound 79. The reaction mixture was stirred for 21 h to 
give a colourless oil (123 mg, 96.9%) which was found to be ˃95% pure (by 
1H NMR) and used in the next step without further purification. Rf = 0.40 [5:1 
(v/v) PE:EtOAc]; IR max/cm-1 1738 (C=O), 1326 and 1139 (S=O); δH (500.13 
MHz; CDCl3) 7.58 (1 H, d, J = 7.5 Hz, Ar 6-H), 7.50 (1 H, t, J = 8.0 Hz, Ar 5-
H), 7.46 (1 H, t, J = 2.0 Hz, Ar 2-H), 7.38 (2 H, t, J = 7.5 Hz, Ar 3’-H), 7.31-7.26 
(1 H, m, Ar 4-H), 7.18 (1 H, t, J = 7.5 Hz, Ar 4’-H), 7.03 (2 H, d, J = 8.0 Hz, Ar 
2’-H), 4.10 (2 H, q, J = 7.3 Hz, OCH2), 4.02 (1 H, q, J = 7.3 Hz, CH), 1.55 (3 
H, d, J = 7.3 Hz, CHCH3) and 1.17 (3 H, t, J = 7.3 Hz, CH2CH3); δC (126 MHz; 
CDCl3) 165.96 (C=O), 158.04 (Ar 3-C), 155.65 (Ar 1’-C), 138.37 (Ar 1-C), 
130.34 (Ar 5-C), 130.10 (Ar 3’-C), 124.52 (Ar 4’-C), 123.86 (Ar 4-C), 123.42 
(Ar 6-C), 119.48 (Ar 2’-C), 118.53 (Ar 2-C), 65.31 (CH), 62.21 (OCH2), 13.78 
(CH2CH3) and 11.63 (CHCH3); ESI-MS m/z calcd. for [M-H]- C17H17O5S: 
333.0797, found 333.0799. 
2-[(3-Phenoxyphenyl)sulfonyl]propanoic acid (82) 
 
NaOH aq. [2.2 mL, 2.50 M, 5.50 mmol] was added to a solution of ethyl 2-[(3-
phenoxyphenyl)sulfonyl]propanoate 80 (638 mg, 1.91 mmol) in methanol (6 
mL), and the resulting mixture was stirred at ambient temperature for 2.5 h. 
The volatile organics were evaporated in vacuo and the remaining solution 
was acidified to pH 1 by addition of 1.0 M HClaq. Water (100 mL) was added 
and the mixture was extracted with chloroform (3 x 50 mL). The combined 
organic extracts were washed with brine (100 mL), dried over MgSO4 and 
evaporated in vacuo to afford a colourless oil (585 mg, 100%) which was found 
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to be ca. 99% pure (by 1H NMR) and used in the next step without further 
purification. Rf = 0.29 [5% (v/v) methanol in DCM]; IR max/cm-1 3073 (OH), 
1742 (C=O); δH (400.04 MHz; CDCl3) 10.92 (1 H, br s, OH), 7.64-7.58 (1 H, 
m, Ar 6-H), 7.55-7.48 (2 H, m, Ar 5-H and Ar 2-H), 7.41-7.34 (2 H, m, Ar 3’-H), 
7.31-7.27 (1 H, m, Ar 4-H), 7.21-7.15 (1 H, m, 4’-H), 7.05-7.00 (2 H, m, Ar 2’-
H), 4.08 (1 H, q, J = 7.2 Hz, CH) and 1.57 (3 H, d, J = 7.2 Hz, CH3); δC (100.59 
MHz, CDCl3) 171.07 (C=O), 158.15 (Ar 3-C), 155.54 (Ar 1’-C), 137.88 (Ar 1-
C), 130.59 (Ar 5-C), 130.15 (Ar 3’-C), 124.60 (Ar 4’-C), 124.13 (Ar 4-C), 123.44 
(Ar 6-C), 119.46 (Ar 2’-C), 118.48 (Ar 2-C), 65.11 (CH) and 11.79 (CH3); ESI-
MS m/z calcd. for [M-H]- C15H13O5S: 305.0484, found 305.0489. 
 
6.2.3 Synthesis of phenoxyphenol side-chain inhibitors 
Methyl (2R)-2-(4-phenoxyphenoxy)propanoate (87) 
 
A solution of DEAD (0.88 mL, 5.6 mmol) in THF (1.3 mL) was added dropwise 
to 4-phenoxyphenol (1.00 g, 5.4 mmol), triphenylphosphine (1.42 g, 5.4 mmol) 
and methyl S-lactate 89 (0.52 mL, 5.4 mmol) in THF (7 mL) over 30 min at 
ambient temperature. The resulting mixture was stirred at ambient 
temperature for 24 h. The volatile organics were evaporated in vacuo and 1:1 
PE/Et2O (200 mL) was added to the residue. The mixture was filtered through 
silica gel-celite and washed with 1:1 PE/Et2O. The filtrate was evaporated in 
vacuo, and the crude product was purified by column chromatography [silica, 
gradient elution with 30:1, 20:1 (v/v) PE:EtOAc] to give a white solid (0.95 g, 
64.4%) that eluted in 20:1 (v/v) PE:EtOAc. Rf = 0.27 [10:1 (v/v) PE:EtOAc]; 
melting point 35-38 °C; [α]D21 +33.3 (c 0.51 in CHCl3); IR max/cm-1 1750 (C=O); 
δH (400.04 MHz, CDCl3) 7.34-7.27 (2 H, m, Ar 3’-H), 7.05 (1 H, tt, J = 7.6, 0.8 
Hz, Ar 4’-H), 6.99-6.93 (4 H, m, Ar 2’-H and Ar 3-H), 6.90-6.84 (2 H, m, Ar 2-
H), 4.73 (1 H, q, J = 6.8 Hz, CH), 3.77 (3 H, s, OCH3) and 1.63 (3 H, d, J = 6.8 
Hz, CH3); δC (100.59 MHz, CDCl3) 172.52 (C=O), 157.99 (Ar 1’-C), 153.58 (Ar 
1-C), 150.95 (Ar 4-C), 129.52 (Ar 3’-C), 122.55 (Ar 4’-C), 120.46 (Ar 3-C), 
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117.78 (Ar 2’-C), 116.25 (Ar 2-C), 73.08 (CH), 52.18 (OCH3) and 18.50 (CH3); 
ESI-MS m/z calcd. for [M-H]- C16H16NaO4: 295.0946 found 295.0944. 
(2R)-2-(4-phenoxyphenoxy)propanoic acid (88) 
 
Compound 88 was prepared from methyl (2R)-2-(4-
phenoxyphenoxy)propanoate 87 (597 mg, 2.19 mmol) using the same 
procedure as for compound 60 to afford a white solid (500 mg, 88.4%) which 
was found to be ca. 99% pure (by 1H NMR) and used in the next step without 
further purification. Rf = 0.23 [10:1 (v/v) DCM:methanol]; melting point 69-70 
°C; [α]D21 +16.3 (c 0.52 in CHCl3); IR max/cm-1 3050 (OH), 1709 (C=O); δH 
(400.04 MHz; CDCl3) 7.34-7.27 (2 H, m, Ar 3’-H), 7.06 (1 H, tt, J = 7.6, 0.8 Hz, 
Ar 4’-H), 7.00-6.93 (4 H, m, Ar 2’-H and Ar 3-H), 6.92-6.85 (2 H, m, Ar 2-H), 
6.75 (1 H, br s, OH), 4.75 (1 H, q, J = 7.0 Hz, CH) and 1.67 (3 H, d, J = 7.0 Hz, 
CH3); δC (100.59 MHz, CDCl3) 177.40 (C=O), 157.96 (Ar 1’-C), 153.29 (Ar 1-
C), 151.35 (Ar 4-C), 129.64 (Ar 3’-C), 122.75 (Ar 4’-C), 120.57 (Ar 3-C), 117.97 
(Ar 2’-C), 116.49 (Ar 2-C), 72.79 (CH) and 18.45 (CH3); ESI-MS m/z calcd. for 




Compound 53 was prepared from (2R)-2-(4-phenoxyphenoxy)propanoic acid 
88 (30 mg, 0.12 mmol) using the same procedure as for compound 49 to give 
a white solid (20 mg). δH (500.13 MHz, 2H2O) 8.57 (1 H, s, adenosine CH), 
8.31 (1 H, s, adenosine CH), 7.34-7.25 (2 H, m, Ar-H), 7.11-7.02 (1 H, m, Ar-
H), 6.95-6.85 (6 H, m, Ar-H), 6.12 (1 H, s, adenosine CH), 5.00-4.90 (1 H, m, 
CH), 4.52 (1 H, br s, adenosine CH), 4.18 (2 H, br s, adenosine CH2), 3.95 (1 
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H, s, adenosine CH), 3.83-3.75 (1 H, m, CoA(OCHa)), 3.55-3.45 (1 H, m, 
CoA(OCHb)), 3.35-3.20 (4 H, m, 2×CoA(CH2)), 3.05-2.93 (2 H, m, 
CoA(SCH2)), 2.33-2.21 (2 H, m, CoA(CH2)), 1.50 (3 H, d, J = 5.5 Hz, CHCH3), 
0.85 (3 H, s, CoA(CH3)) and 0.71 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for 
[M+Na]+ C36H48N7NaO19P3S: 1030.1836, found 1030.1889. 
Methyl (2S)-2-(4-phenoxyphenoxy)propanoate (91) 
 
Compound 91 was prepared from 4-phenoxyphenol (1.00 g, 5.4 mmol) and 
methyl R-lactate 90 (0.52 mL, 5.4 mmol) using the same procedure as for 
compound 87 to give a white solid (1.04 g, 70.7%). [α]D21 -33.6 (c 0.68 in 
CHCl3); 1H and 13C NMR spectra of the compound were consistent with its 
enantiomer 87 (vide supra). δH (400.04 MHz, CDCl3) 7.33-7.24 (2 H, m, Ar 3’-
H), 7.03 (1 H, tt, J = 6.8, 1.2 Hz, Ar 4’-H), 6.98-6.93 (4 H, m, Ar 2’-H and Ar 3-
H), 6.90-6.84 (2 H, m, Ar 2-H), 4.73 (1 H, q, J = 6.8 Hz, CH), 3.76 (3 H, s, 
OCH3) and 1.62 (3 H, d, J = 6.8 Hz, CH3); δC (100.59 MHz, CDCl3) 172.44 
(C=O), 157.95 (Ar 1’-C), 153.54 (Ar 1-C), 150.90 (Ar 4-C), 129.48 (Ar 3’-C), 
122.50 (Ar 4’-C), 120.41 (Ar 3-C), 117.73 (Ar 2’-C), 116.20 (Ar 2-C), 73.00 
(CH), 52.10 (OCH3) and 18.44 (CH3). 
 (2S)-2-(4-phenoxyphenoxy)propanoic acid (92) 
 
Compound 92 was prepared from methyl (2S)-2-(4-
phenoxyphenoxy)propanoate 91 (588 mg, 2.16 mmol) using the same 
procedure as for compound 60 to afford a white solid (556 mg, 99.6%) which 
was found to be ca.  99% pure (by 1H NMR) and used in the next step without 
further purification. [α]D21 -17.7 (c 0.56 in CHCl3); 1H and 13C NMR spectra of 
the compound were consistent with its enantiomer 88 (vide supra). δH (400.04 
MHz; CDCl3) 12.00 (1 H, br s, OH), 7.36-7.29 (2 H, m, Ar 3’-H), 7.08 (1 H, tt, 
J = 7.2, 1.2 Hz, Ar 4’-H), 7.02-6.96 (4 H, m, Ar 2’-H and Ar 3-H), 6.95-6.88 (2 
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H, m, Ar 2-H), 4.78 (1 H, q, J = 6.8 Hz, CH) and 1.70 (3 H, d, J = 6.8 Hz, CH3); 
δC (100.59 MHz, CDCl3) 178.46 (C=O), 157.91 (Ar 1’-C), 153.27 (Ar 1-C), 
151.30 (Ar 4-C), 129.60 (Ar 3’-C), 122.71 (Ar 4’-C), 120.52 (Ar 3-C), 117.93 




Compound 55 was prepared from (2S)-2-(4-phenoxyphenoxy)propanoic acid 
92 (90 mg, 0.35 mmol) using the same procedure as for compound 49 to give 
a white solid (46 mg). δH (500.13 MHz, 2H2O) 8.52 (1 H, s, adenosine CH), 
8.21 (1 H, s, adenosine CH), 7.28 (2 H, t, J = 8.0 Hz, Ar-H), 7.05 (1 H, t, J = 
7.5 Hz, Ar-H), 6.95-6.84 (6 H, m, Ar-H), 6.08 (1 H, d, J =  6.0 Hz, adenosine 
CH), 4.18 (2 H, br s, adenosine CH2), 3.94 (1 H, s, adenosine CH), 3.83-3.73 
(1 H, m, CoA(OCHa)), 3.53-3.45 (1 H, m, CoA(OCHb)), 3.35-3.20 (4 H, m, 
2×CoA(CH2)), 2.97 (2 H, t, J = 6.0 Hz, CoA(SCH2)), 2.26 (2 H, t, J = 6.0 Hz, 
CoA(CH2)), 1.49 (3 H, d, J = 7.0 Hz, CHCH3), 0.82 (3 H, s, CoA(CH3)) and 
0.68 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M-H]- C36H47N7O19P3S: 
1006.1860, found 1006.1882. 
Methyl (2R)-2-(3-phenoxyphenoxy)propanoate (93) 
 
Compound 93 was prepared from 3-phenoxyphenol (0.86 mL, 5.4 mmol) and 
methyl S-lactate 89 (0.52 mL, 5.4 mmol) using the same procedure as for 
compound 87 to give a colourless oil (1.17 g, 79.9%). Rf = 0.30 [10:1 (v/v) 
PE:EtOAc]; [α]D21 +19.4 (c 0.52 in CHCl3); IR max/cm-1 1747 (C=O); δH (400.04 
MHz; CDCl3) 7.39-7.29 (2 H, m, Ar 3’-H), 7.21 (1 H, t, J = 8.0 Hz, Ar 5-H), 7.12 
(1 H, tt, J = 7.6, 0.8 Hz, Ar 4’-H), 7.05-7.00 (2 H, m, Ar 2’-H), 6.67-6.59 (2 H, 
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m, Ar 4-H and Ar 6-H), 6.56 (1 H, t, J = 2.0 Hz, Ar 2-H), 4.74 (1 H, q, J = 6.8 
Hz, CH), 3.74 (3 H, s, OCH3) and 1.61 (3 H, d, J = 6.8 Hz, CH3); δC (100.59 
MHz, CDCl3) 172.29 (C=O), 158.69 (Ar 1-C or Ar 3-C), 158.56 (Ar 1-C or Ar 
3-C), 156.57 (Ar 1’-C), 130.17 (Ar 5-C), 129.65 (Ar 3’-C), 123.46 (Ar 4’-C), 
119.20 (Ar 2’-C), 111.60 (Ar 4-C or Ar 6-C), 109.32 (Ar 4-C or Ar 6-C), 105.71 
(Ar 2-C), 72.39 (CH), 52.20 (OCH3) and 18.38 (CH3); ESI-MS m/z calcd. for 
[M+H]+ C16H17O4: 273.1127, found 273.1150. 
 
(2R)-2-(3-phenoxyphenoxy)propanoic acid (94) 
 
Compound 94 was prepared from methyl (2R)-2-(3-
phenoxyphenoxy)propanoate 93 (566 mg, 2.08 mmol) using the same 
procedure as for compound 60 to afford a white solid (536 mg, 99.8%) which 
was found to be ca. 99% pure (by 1H NMR) and used in the next step without 
further purification. Rf = 0.23 [10:1 (v/v) DCM:methanol]; melting point 51-52 
°C; [α]D21 -7.46 (c 0.54 in CHCl3); IR max/cm-1  3064 (OH), 1710 (C=O); δH 
(400.04 MHz; CDCl3) 11.93 (1 H, br s, OH), 7.39-7.30 (2 H, m, Ar 3’-H), 7.24 
(1 H, t, J = 6.0 Hz, Ar 5-H), 7.13 (1 H, tt, J = 7.2, 1.2 Hz, Ar 4’-H), 7.07-7.01 (2 
H, m, Ar 2’-H), 6.70-6.62 (2 H, m, Ar 4-H and Ar 6-H), 6.60 (1 H, t, J = 2.0 Hz, 
Ar 2-H), 4.78 (1 H, q, J = 6.8 Hz, CH) and 1.67 (3 H, d, J = 6.8 Hz, CH3); δC 
(100.59 MHz, CDCl3) 178.31 (C=O), 158.70 (Ar 3-C), 158.42 (Ar 1-C), 156.46 
(Ar 1’-C), 130.30 (Ar 5-C), 129.72 (Ar 3’-C), 123.60 (Ar 4’-C), 119.30 (Ar 2’-C), 
111.84 (Ar 4-C or Ar 6-C), 109.23 (Ar 4-C or Ar 6-C), 105.80 (Ar 2-C), 71.89 







Compound 54 was prepared from (2R)-2-(3-phenoxyphenoxy)propanoic acid 
94 (90 mg, 0.35 mmol) using the same procedure as for compound 49 to give 
a white solid (43 mg). δH (500.13 MHz, 2H2O) 8.59 (1 H, s, adenosine CH), 
8.31 (1 H, s, adenosine CH), 7.31 (2 H, t, J = 8.0 Hz, Ar-H), 7.21 (1 H, t, J = 
8.0 Hz, Ar-H), 7.11 (1 H, t, J = 8.0 Hz, Ar-H), 6.92 (2 H, d, J = 8.0 Hz, Ar-H), 
6.69-6.57 (2 H, m, Ar-H), 6.48-6.39 (1 H, m, Ar-H), 6.11 (1 H, d, J = 5.0 Hz, 
adenosine CH), 4.19 (2 H, br s, adenosine CH2), 3.95 (1 H, s, adenosine CH), 
3.85-3.75 (1 H, m, CoA(OCHa)), 3.58-3.47 (1 H, m, CoA(OCHb)), 3.30 (2 H, t, 
J = 6.5 Hz, CoA(CH2)), 3.25-3.15 (2 H, m, CoA(CH2)),  2.93 (2 H, t, J = 6.5 Hz, 
CoA(SCH2)), 2.27 (2 H, t, J = 5.0 Hz, CoA(CH2)), 1.46 (3 H, d, J = 6.5 Hz, 
CCH3), 0.85 (3 H, s, CoA(CH3)) and 0.71 (3 H, s, CoA(CH3)); ESI-MS m/z 
calcd. for [M+Na]+ C36H48N7NaO19P3S: 1030.7779, found 1030.7315. 
Methyl (2S)-2-(3-phenoxyphenoxy)propanoate (95) 
 
Compound 95 was prepared from 3-phenoxyphenol (0.86 mL, 5.4 mmol) and 
methyl R-lactate 90 (0.52 mL, 5.4 mmol) using the same procedure as for 
compound 87 to give a colourless oil (1.02 g, 69.1%). [α]D21 -21.6 (c 0.56 in 
CHCl3); 1H and 13C NMR spectra of the compound were consistent with its 
enantiomer 93 (vide supra). δH (400.04 MHz; CDCl3) 7.38-7.30 (2 H, m, Ar 3’-
H), 7.21 (1 H, t, J = 8.4 Hz, Ar 5-H), 7.12 (1 H, tt, J = 7.2, 1.2 Hz, Ar 4’-H), 
7.06-7.01 (2 H, m, Ar 2’-H), 6.66-6.60 (2 H, m, Ar 4-H and Ar 6-H), 6.57 (1 H, 
t, J = 2.0 Hz, Ar 2-H), 4.74 (1 H, q, J = 6.8 Hz, CH), 3.73 (3 H, s, OCH3) and 
1.61 (3 H, d, J = 6.8 Hz, CH3); δC (100.59 MHz, CDCl3) 172.15 (C=O), 158.63 
(Ar 1-C or Ar 3-C), 158.47 (Ar 1-C or Ar 3-C), 156.50 (Ar 1’-C), 130.09 (Ar 5-
167 
 
C), 129.57 (Ar 3’-C), 123.37 (Ar 4’-C), 119.11 (Ar 2’-C), 111.50 (Ar 4-C or Ar 
6-C), 109.24 (Ar 4-C or Ar 6-C), 105.62 (Ar 2-C), 72.28 (CH), 52.06 (OCH3) 
and 18.27 (CH3). 
 
(2S)-2-(3-phenoxyphenoxy)propanoic acid (96) 
 
Compound 96 was prepared from methyl (2S)-2-(3-
phenoxyphenoxy)propanoate 95 (566 mg, 2.08 mmol) using the same 
procedure as for compound 60 affording a white solid (536 mg, 99.8%) which 
was found to be ca. 99% pure (by 1H NMR) and used in the next step without 
further purification. [α]D21 +5.38 (c 0.56 in CHCl3); 1H and 13C NMR spectra of 
the compound were consistent with its enantiomer 94 (vide supra). δH (400.04 
MHz; CDCl3) 11.44 (1 H, br s, OH), 7.38-7.30 (2 H, m, Ar 3’-H), 7.23 (1 H, t, J 
= 8.0 Hz, Ar 5-H), 7.12 (1 H, tt, J = 7.2, 1.2 Hz, Ar 4’-H), 7.06-7.00 (2 H, m, Ar 
2’-H), 6.68-6.60 (2 H, m, Ar 4-H and Ar 6-H), 6.58 (1 H, t, J = 2.0 Hz, Ar 2-H), 
4.77 (1 H, q, J = 7.0 Hz, CH) and 1.66 (3 H, d, J = 7.0 Hz, CH3); δC (100.59 
MHz, CDCl3) 178.15 (C=O), 158.75 (Ar 3-C), 158.44 (Ar 1-C), 156.51 (Ar 1’-
C), 130.34 (Ar 5-C), 129.76 (Ar 3’-C), 123.64 (Ar 4’-C), 119.35 (Ar 2’-C), 
111.90 (Ar 4-C or Ar 6-C), 109.28 (Ar 4-C or Ar 6-C), 105.85 (Ar 2-C), 71.96 




Compound 56 was prepared from (2S)-2-(3-phenoxyphenoxy)propanoic acid 
96 (90 mg, 0.35 mmol) using the same procedure as for compound 49 to give 
a white solid (51 mg). δH (500.13 MHz, 2H2O) 8.55 (1 H, s, adenosine CH), 
8.25 (1 H, s, adenosine CH), 7.31 (2 H, t, J = 7.5 Hz, Ar-H), 7.21 (1 H, t, J = 
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8.5 Hz, Ar-H), 7.11 (1 H, t, J = 7.5 Hz, Ar-H), 6.93 (2 H, d, J = 8.5 Hz, Ar-H), 
6.68-6.56 (2 H, m, Ar-H), 6.46-6.39 (1 H, m, Ar-H), 6.09 (1 H, d, J = 5.0 Hz, 
adenosine CH), 4.88 (1 H, q, J = 7.0 Hz, CH), 4.82-4.75 (1 H, m, adenosine 
CH), 4.51 (1 H, br s, adenosine CH), 4.18 (2 H, br s, adenosine CH2), 3.96 (1 
H, s, adenosine CH), 3.85-3.72 (1 H, m, CoA(OCHa)), 3.55-3.45 (1 H, m, 
CoA(OCHb)), 3.30 (2 H, t, J = 6.0 Hz, CoA(CH2)), 3.23 (2 H, t, J = 6.0 Hz, 
CoA(CH2)),  3.00-2.85 (2 H, m, CoA(SCH2)), 2.27 (2 H, t, J = 6.5 Hz, 
CoA(CH2)), 1.46 (3 H, d, J = 6.5 Hz, CCH3), 0.84 (3 H, s, CoA(CH3)) and 0.69 
(3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M-H]- C36H47N7O19P3S: 1006.1860, 
found 1006.1879. 
 
6.2.4 Synthesis of long-chain inhibitors 
3-(Hexylsulfanyl)-2-methylpropanoyl-CoA (109) 
 
Compound 109 was prepared from 3-(hexylsulfanyl)-2-methylpropanoic acid 
107 (90 mg, 0.44 mmol) using the same procedure as for compound 49 to give 
a white solid (48 mg). δH (500.13 MHz, 2H2O) 8.61 (1 H, s, adenosine CH), 
8.30 (1 H, s, adenosine CH), 6.14 (1 H, d, J = 6.0 Hz, adenosine CH), 4.18 (2 
H, br s, adenosine CH2), 3.97 (1 H, s, adenosine CH), 3.83-3.72 (1 H, m, 
CoA(OCHa)), 3.57-3.45 (1 H, m, CoA(OCHb)), 3.39 (2 H, t, J = 6.5 Hz, 
CoA(CH2)), 3.26 (2 H, t, J = 6.0 Hz, CoA(CH2)), 3.02-2.85 (3 H, m, CoA(SCH2) 
and CHCH3), 2.75-2.66 (1 H, m, SCHa), 2.64-2.55 (1 H, m, SCHb), 2.46 (2 H, 
t, J = 7.5 Hz, SCH2), 2.37 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.50-1.39 (2 H, m, 
CH2), 1.30-1.07 (9 H, m, 3×CH2 and CHCH3), 0.85 (3 H, s, CoA(CH3)), 0.75 (3 
H, t, J = 7.0 Hz, CH2CH3) and 0.72 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for 








Compound 110 was prepared from 3-(hexylsulfonyl)-2-methylpropanoic acid 
108 (53 mg, 0.23 mmol) using the same procedure as for compound 49 to give 
a white solid (10 mg). δH (500.13 MHz, 2H2O) 8.62 (1 H, s, adenosine CH), 
8.37 (1 H, s, adenosine CH), 6.16 (1 H, d, J = 5.5 Hz, adenosine CH), 4.25-
4.12 (2 H, m, adenosine CH2), 3.97 (1 H, s, adenosine CH), 3.85-3.75 (1 H, 
m, CoA(OCHa)), 3.72-3.60 (1 H, m, CHCH3), 3.57-3.48 (1 H, m, CoA(OCHb)), 
3.38 (2 H, t, J = 6.5 Hz, CoA(CH2)), 3.36-3.20 (4 H, m, CoA(CH2) and 
CoA(SCH2)), 3.07-2.90 (2 H, m, CHCHa and CHCHb), 3.13 (2 H, t, J = 8.0 Hz, 
OSOCH2), 2.37 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.75-1.62 (2 H, m, CH2), 1.40-
1.10 (9 H, m, 3×CH2 and CHCH3), 0.87 (3 H, s, CoA(CH3)), 0.78 (3 H, t, J = 
7.0 Hz, CH2CH3) and 0.74 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M-H]- 
C31H53N7O19P3S2: 984.2050, found 984.2070. 
 
6.3 Synthesis of known AMACR ligands 
6.3.1 Synthesis of (2R)-2-methydecanoyl-CoA 
(4R)-4-benzyl-3-decanoyl-1,3-oxazolidin-2-one (182) 
 
The oxazolidinone 182 was synthesised using the protocol previously 
described.1 n-Butyl lithium (2.5 M in hexanes, 5.8 mL, 14.4 mmol) was added 
dropwise to R-4-benzyloxazolidin-2-one (2.50 g, 14.1 mmol) in THF (25 mL) 
at -78 °C over 15 min. Decanoyl chloride (3.3 mL, 15.6 mmol) was then added 
and the mixture was stirred at -78 °C for 1 h. It was allowed to reach ambient 
room temperature and stirred for further 2 h. Saturated NH4Cl aq. (25 mL) was 
added to quench the reaction. The mixture was extracted with DCM (3×20 
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mL). The organic layers were combined, washed with 1.0 M K2CO3 aq. (100 
mL) and brine (100 mL), dried over MgSO4 and evaporated in vacuo to give a 
colourless oil. The oil crystallised on standing to give a colourless solid (4.66 
g, 99.8%) which was found to be ˃90 % pure (by 1H NMR) and used in the 
next step without further purification. Rf = 0.41 [10:1 (v/v) PE:EtOAc]. 1H and 
13C NMR spectra of the product were consistent with previously reported data.1 
δH (400.04 MHz; CDCl3) 7.36-7.14 (5 H, m, Ar-H), 4.70-4.60 (1 H, m, 4-H), 
4.20-4.10 (2 H, m, 5-H), 3.27 (1 H dd, J = 13.4, 3.2 Hz, ArCHa), 3.01-2.82 (2 
H, m, 2’-H), 2.76 (1 H, dd, J = 13.4, 9.6, ArCHb), 1.73-1.58 (2 H, m, 3’-H), 1.42-
1.17 (12 H, m, 6×CH2) and 0.87 (3 H, t, J = 6.8 Hz, 10’-H); δC (100.59 MHz, 
CDCl3) 173.26 (1’-C), 153.32 (2-C), 135.25 (Ar-C), 129.30 (Ar-C), 128.79 (Ar-
C), 127.17 (Ar-C), 66.00 (5-C), 55.00 (4-C), 37.78 (ArCHaHb), 35.41 (2’-C), 
31.75 (CH2), 29.33 (CH2), 29.29 (CH2), 29.16 (CH2), 29.02 (CH2),  24.15 (3’-
C), 22.55 (CH2) and 13.99 (10’-C); ESI-MS m/z calcd. for [M+H]+ C20H30NO3: 




The oxazolidinone 183 was synthesised using the protocol previously 
described.1 A solution of (4R)-4-benzyl-3-decanoyl-1,3-oxazolidin-2-one 182 
(1.60 g, 4.85 mmol) in THF (20 mL) at 0 °C was added dropwise to sodium 
bis(trimethylsilyl)amide (1.0 M in THF, 5.4 mL, 5.34 mmol) at -78 °C. After 
stirring the mixture at -78 °C for 1 h, iodomethane (1.5 mL, 24.25 mmol) in 
THF (0.8 mL) at -78 °C was added. The mixture was stirred for 1 h at -78 °C 
and allowed to reach ambient temperature. It was further stirred for 30 min at 
room temperature before being quenched with saturated NH4Cl aq. (20 mL). 
The mixture was extracted with DCM (3×20 mL). The organic layers were 
combined, washed with 1.0 M Na2SO3 aq., dried over MgSO4 and evaporated 
in vacuo to give a light yellow oil. The crude product was purified by column 
chromatography [silica, 10:1 (v/v) PE: EtOAc] to afford a colourless oil (1.09 
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g, 59.0%). Rf = 0.45 [10:1 (v/v) PE:EtOAc]. 1H and 13C NMR spectra of the 
product were consistent with previously reported data.1 δH (400.04 MHz; 
CDCl3) 7.35-7.15 (5 H, m, Ar-H), 4.70-4.60 (1 H, m, 4-H), 4.20-4.09 (2 H, m, 
5-H), 3.74-3.64 (1 H, m, 2’-H), 3.24 (1 H, dd, J = 13.2, 3.2 Hz, ArCHa), 2.76 (1 
H, dd, J = 13.2, 9.2, ArCHb), 1.80-1.65 (1 H, m, 3’-Ha), 1.45-1.35 (1 H, m, 3’-
Hb), 1.34-1.18 (15 H, m, 6×CH2 and CH3CH) and 0.86 (3 H, t, J = 6.8 Hz, 10’-
H); δC (100.59 MHz, CDCl3) 177.17 (1’-C), 152.90 (2-C), 135.24 (Ar-C), 129.31 
(Ar-C), 128.74 (Ar-C), 127.14 (Ar-C), 65.84 (5-C), 55.18 (4-C), 37.72 
(ArCHaHb), 37.56 (2’-C), 33.28 (3’-C), 31.71 (CH2), 29.52 (CH2), 29.32 (CH2), 
29.11 (CH2), 27.12, (CH2),  22.51 (CH2), 17.22 (CH3CH) and 13.97 (10’-C); 
ESI-MS m/z calcd. for [M+H]+ C21H32NO3: 346.2382, found 346.2381. 
 
(2R)-2-methyldecanoic acid (184) 
 
The acid 184 was synthesised using the protocol previously described.1 H2O2 
aq. [30% (w/w), 0.94 mL, 8.3 mmol] and lithium hydroxide monohydrate (110 
mg, 2.54 mmol) were added to (4R)-4-benzyl-3-[(2R)-2-methyldecanoyl]-1,3-
oxazolidin-2-one 183 (439 mg, 1.27 mmol) in THF (18 mL) and water (6 mL). 
The mixture was stirred at 0 °C for 3 h. Na2SO3 aq. (1.5 M, 10 mL, 15.0 mmol) 
was added to the reaction mixture, which was then acidified with HCl aq. (1.0 
M) to pH 1. The mixture was extracted with DCM (3×20 mL). The organic 
layers were combined, dried over MgSO4 and evaporated in vacuo to afford a 
mixture of colourless oil and white solid. The crude product was purified by 
column chromatography [silica, 1:2 (v/v) PE: EtOAc] to afford a colourless oil 
(160 mg, 67.4%). Rf = 0.84 [2:1 (v/v) PE:EtOAc]. [α]D20 -15.5 (c 1.32 in 
methanol); lit. [α]D20 -16.3 (c 1.00 in methanol);1 1H and 13C NMR spectra of 
the product were consistent with previously reported data.1 δH (400.04 MHz; 
CDCl3) 12.05 (1 H, s, OH), 2.50-2.38 (1 H, m, 2-H), 1.74-1.60 (1 H, m, 3-Ha), 
1.50-1.37 (1 H, m, 3-Hb), 1.37-1.20 (12 H, m, 6×CH2), 1.16 (3 H, d, J = 6.8 Hz, 
2-CH3), and 0.87 (3 H, t, J = 6.4 Hz, 10-H); δC (100.59 MHz, CDCl3) 183.82 
(C=O), 39.42 (2-C), 33.51 (3-C), 31.84 (CH2), 29.49(CH2), 29.41 (CH2),  29.24 
(CH2), 27.12 (CH2),  22.64 (CH2),  16.77 (2-CH3), and 14.05 (10-C); ESI-MS 





Compound 44 was prepared from (2R)-2-methyldecanoic acid 184 (90 mg, 
0.48 mmol) using the same procedure as for compound 49 to give a white solid 
(31 mg). The 1H NMR spectrum of the product was consistent with previously 
reported data.1 δH (500.13 MHz, 2H2O) 8.60 (1 H, s, adenosine CH), 8.22 (1 H, 
s, adenosine CH), 6.10 (1 H, d, J = 6.0 Hz, adenosine CH), 4.52 (1 H, br s, 
adenosine CH), 4.17 (2 H, br s, adenosine CH2), 3.95 (1 H, s, adenosine CH), 
3.84-3.70 (1 H, m, CoA(OCHa)), 3.55-3.45 (1 H, m, CoA(OCHb)), 3.36 (2 H, t, 
J = 7.0 Hz, CoA(CH2)), 3.25 (2 H, t, J = 6.0 Hz, CoA(CH2)), 3.00-2.84 (2 H, m, 
CoA(SCH2)), 2.70-2.55 (1 H, m, CHCH3), 2.34 (2 H, t, J = 7.0 Hz, CoA(CH2)), 
1.54-1.41 (1 H, m, CHCHa), 1.36-1.23 (1 H, m, CHCHb), 1.20-1.05 (12 H, m, 
6×CH2), 1.01 (3 H, d, J = 6.5 Hz, CHCH3), 0.82 (3 H, s, CoA(CH3)), 0.74 (3 H, 
t, J = 5.0 Hz, CH2CH3) and 0.69 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for 
[M+Na-2H]- C32H54N7NaO17P3S: 956.2407, found 956.2378. 
 
6.3.2 Synthesis of (2S)-2-methydecanoyl-CoA 
(4S)-4-benzyl-3-decanoyl-1,3-oxazolidin-2-one (185) 
 
Compound 185 was prepared from S-4-benzyloxazolidin-2-one (5.00 g, 28.2 
mmol) using the same procedure1 as compound 182 to give a colourless oil 
that crystallised on standing to give a colourless solid (9.24 g, 98.8%). The 
crude product was taken forward to the next step without purification. 1H and 
13C NMR spectra of the product were consistent with previously reported data.1 
δH (400.04 MHz; CDCl3) 7.34-7.15 (5 H, m, Ar-H), 4.69-4.59 (1 H, m, 4-H), 
4.20-4.09 (2 H, m, 5-H), 3.26 (1 H dd, J = 13.4, 3.2 Hz, ArCHa), 3.01-2.81 (2 
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H, m, 2’-H), 2.75 (1 H, dd, J = 13.4, 9.6, ArCHb), 1.73-1.58 (2 H, m, 3’-H), 1.43-
1.17 (12 H, m, 6×CH2) and 0.87 (3 H, t, J = 6.8 Hz, 10’-H); δC (100.59 MHz, 
CDCl3) 173.18 (1’-C), 153.26 (2-C), 135.22 (Ar-C), 129.25 (Ar-C), 128.73 (Ar-
C), 127.11 (Ar-C), 65.95 (5-C), 54.93 (4-C), 37.71 (ArCHaHb), 35.35 (2’-C), 
31.71 (CH2), 29.29 (CH2), 29.24 (CH2), 29.11 (CH2), 28.98 (CH2),  24.11 (3’-
C), 22.50 (CH2) and 13.94 (10’-C); ESI-MS m/z calcd. for [M+Na]+ 




Compound 186 was prepared from (4S)-4-benzyl-3-decanoyl-1,3-oxazolidin-
2-one 185 (3.65 g, 11.0 mmol) using the same procedure1 as compound 183. 
The crude product was purified by column chromatography [silica, 10:1 (v/v) 
PE: EtOAc] to afford a colourless oil (2.60 g, 68.4%). 1H and 13C NMR spectra 
of the product were consistent with previously reported data.1 δH (400.04 MHz; 
CDCl3) 7.34-7.16 (5 H, m, Ar-H), 4.70-4.60 (1 H, m, 4-H), 4.20-4.10 (2 H, m, 
5-H), 3.75-3.62 (1 H, m, 2’-H), 3.24 (1 H, dd, J = 13.2, 3.2 Hz, ArCHa), 2.76 (1 
H, dd, J = 13.2, 9.6, ArCHb), 1.80-1.65 (1 H, m, 3’-Ha), 1.45-1.35 (1 H, m, 3’-
Hb), 1.34-1.17 (15 H, m, 6×CH2 and CH3CH) and 0.86 (3 H, t, J = 6.8 Hz, 10’-
H); δC (100.59 MHz, CDCl3) 177.16 (1’-C), 152.90 (2-C), 135.23 (Ar-C), 129.30 
(Ar-C), 128.74 (Ar-C), 127.14 (Ar-C), 65.84 (5-C), 55.17 (4-C), 37.72 
(ArCHaHb), 37.55 (2’-C), 33.28 (3’-C), 31.71 (CH2), 29.52 (CH2), 29.32 (CH2), 
29.11 (CH2), 27.12, (CH2),  22.51 (CH2), 17.21 (CH3CH) and 13.96 (10’-C); 
ESI-MS m/z calcd. for [M+H]+ C21H32NO3: 346.2382, found 346.2398. 
 
(2S)-2-methyldecanoic acid (187) 
 
Compound 187 was prepared from (4S)-4-benzyl-3-[(2S)-2-methyldecanoyl]-
1,3-oxazolidin-2-one 186 (1.36 g, 3.94 mmol) using the same procedure1 as 
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compound 184. The crude product was purified by column chromatography 
[silica, 1:2 (v/v) PE: EtOAc] to afford a colourless oil (665 mg, 90.6%). Rf = 
0.84 [2:1 (v/v) PE:EtOAc]. [α]D20 +14.9 (c 1.28 in methanol); lit. [α]D20 +15.8 (c 
1.00 in methanol).1 1H and 13C NMR spectra of the product were consistent 
with previously reported data.1 δH (400.04 MHz; CDCl3) 12.24 (1 H, s, OH), 
2.50-2.35 (1 H, m, 2-H), 1.73-1.58 (1 H, m, 3-Ha), 1.50-1.36 (1 H, m, 3-Hb), 
1.36-1.18 (12 H, m, 6×CH2),  1.16 (3 H, d, J = 6.8 Hz, 10’-H, 2-CH3), and 0.87 
(3 H, t, J = 6.4 Hz, 10-H);  δC (100.59 MHz, CDCl3) 183.89 (C=O), 39.44 (2-C), 
33.52 (3-C), 31.86 (CH2), 29.51(CH2), 29.43 (CH2),  29.26 (CH2), 27.14 (CH2),  
22.65 (CH2),  16.74 (2-CH3), and 14.03 (10-C); ESI-MS m/z calcd. for [M-H]- 




Compound 38 was prepared from (2S)-2-methyldecanoic acid 187 (90 mg, 
0.48 mmol) using the same procedure as for compound 49 to give a white solid 
(14 mg). The 1H NMR spectrum of the product was consistent with previously 
reported data.1 δH (500.13 MHz, 2H2O) 8.61 (1 H, s, adenosine CH), 8.23 (1 H, 
s, adenosine CH), 6.10 (1 H, d, J = 6.5 Hz, adenosine CH), 4.52 (1 H, br s, 
adenosine CH), 4.16 (2 H, br s, adenosine CH2), 3.96 (1 H, s, adenosine CH), 
3.84-3.70 (1 H, m, CoA(OCHa)), 3.53-3.44 (1 H, m, CoA(OCHb)), 3.37 (2 H, t, 
J = 7.0 Hz, CoA(CH2)), 3.26 (2 H, t, J = 5.5 Hz, CoA(CH2)), 3.00-2.82 (2 H, m, 
CoA(SCH2)), 2.70-2.56 (1 H, m, CHCH3), 2.34 (2 H, t, J = 7.0 Hz, CoA(CH2)), 
1.53-1.42 (1 H, m, CHCHa), 1.36-1.25 (1 H, m, CHCHb), 1.20-1.05 (12 H, m, 
6×CH2), 1.01 (3 H, d, J = 6.5 Hz, CHCH3), 0.82 (3 H, s, CoA(CH3)), 0.75 (3 H, 
t, J = 6.5 Hz, CH2CH3) and 0.69 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for 





6.3.3 Synthesis of N-dodecyl-N-methylcarbamoyl-CoA 
N-dodecyl-N-methyl-1H-imidazole-1-carboxamide (188) 
 
N-Methyldodecylamine (2.00 g, 10.0 mmol) was added dropwise over 15 min 
to CDI (1.78 g, 11.0 mmol) in DCM (16 mL) at 0 °C. The mixture was allowed 
to reach room temperature and was then stirred for 24 h. Water (25 mL) was 
added and the mixture was extracted with DCM (3 x 25 mL). The combined 
organic extracts were dried over MgSO4 and evaporated in vacuo to afford a 
pale yellow oil. The crude product was purified by column chromatography 
[silica, 10:1 (v/v) DCM:methanol] to afford a colourless oil (2.33 g, 79.5%). Rf 
= 0.77 [10:1 (v/v) DCM:methanol]. 1H and 13C NMR spectra of the product 
were consistent with previously reported data.145 δH (400.04 MHz; CDCl3) 7.78 
(1 H, s, 2’-H), 7.12 (1 H, t, J = 1.6 Hz, 5’-H), 6.99-6.94 (1 H, m, 4’-H), 3.30 (2 
H, t, J = 7.6 Hz, 1-H), 2.96 (3 H, s, NCH3), 1.60-1.48 (2 H, m, 2-H), 1.25-1.17 
(18 H, m, 3-H to 11-H) and 0.77 (3 H, t, J = 6.8 Hz, 12-H); δC (100.59 MHz, 
CDCl3) 151.33 (C=O), 136.55 (2’-C), 129.15 (4’-C), 117.65 (5’-C), 50.33 (1-C), 
35.93 (NCH3), 31.60 (10-C), 29.40-28.80 (4-C to 9-C), 26.96 (2-C), 26.27 (3-
C), 22.38 (11-C) and 13.82 (12-C); ESI-MS m/z calcd. for [M+H]+ C17H32N3O: 
294.2545, found 294.2719. 
 
1-[Dodecyl(methyl)carbamoyl]-3-methyl-1H-imidazol-3-ium iodide (189) 
 
 
Methyl iodide (1.7 mL, 26.66 mmol) was added to N-dodecyl-N-methyl-1H-
imidazole-1-carboxamide 188 (978 mg, 3.33 mmol) in acetonitrile (15 mL), and 
the resulting mixture was stirred at room temperature overnight. The mixture 
was filtered and filtrate was evaporated in vacuo. The crude gummy yellow 
solid was purified via trituration from petroleum ether to give a gummy dark-
yellow solid (972 mg, 67.0%). Rf = 0.53 [10:1 (v/v) DCM:methanol]. 1H and 13C 
NMR spectra of the product were consistent with previously reported data.145 
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δH (400.04 MHz; CDCl3) 10.18 (1 H, s, 2’-H), 7.71 (2 H, s, 4’-H and 5’-H), 4.25 
(3 H, s, N+CH3), 3.45 (2 H, t, J = 9.0 Hz, 1-H), 3.26 (3 H, s, NCH3), 1.71-1.58 
(2 H, m, 2-H), 1.35-1.10 (18 H, m, 3-H to 11-H) and 0.84 (3 H, t, J = 6.5 Hz, 
12-H); δC (100.59 MHz, CDCl3) 146.74 (C=O), 136.77 (2’-C), 124.02 (4’-C), 
121.02 (5’-C), 51.50 (1-C), 38.04 (NCH3 and N+CH3), 31.75-22.53 (C-2 to C-
11) and 13.98 (12-C); ESI-MS m/z calcd. for [M]+ C18H34N3O: 308.2702, found 




1-[Dodecyl(methyl)carbamoyl]-3-methyl-1H-imidazol-3-ium iodide 189 (40 
mg, 0.09 mmol) was dissolved in THF (1 mL) at room temperature. NaHCO3 
aq. (1 mL, 0.10 M), followed by CoA-Li3 (17 mg, 0.02 mmol) was added to the 
solution. The resulting mixture was stirred at ambient temperature under an 
argon atmosphere for 18 h. The volatile organics were evaporated in vacuo 
and the remaining solution was acidified to ca. pH 3 by addition of 1.0 M HCl 
aq. The mixture was diluted with water (2 mL) and extracted with EtOAc (5×3 
mL). The crude aqueous product was freeze-dried and purified by solid phase 
extraction to afford a white solid (7 mg). δH (500.13 MHz, 2H2O) 8.62 (1 H, s, 
adenosine CH), 8.35 (1 H, s, adenosine CH), 6.15 (1 H, d, J = 6.0 Hz, 
adenosine CH), 4.53 (1 H, br s, adenosine CH), 4.18 (2 H, br s, adenosine 
CH2), 3.97 (1 H, s, adenosine CH), 3.84 (3 H, s,NCH3), 3.81-3.76 (1 H, m, 
CoA(OCHa)), 3.53-3.47 (1 H, m, CoA(OCHb)), 3.39 (2 H, t, J = 6.5 Hz, NCH2), 
3.35-3.22 (3 H, m, CoA(CHOH)) and CoA(CH2)), 2.95-2.82 (4 H, m, CoA(CH2) 
and CoA(SCH2)), 2.38 (2 H, t , J = 6.5 Hz, CoA(CH2)), 1.55-1.35 (2 H, m, CH2), 
1.25-1.05 (18 H, m, 9×CH2), 0.87 (3 H, s, CoA(CH3)), 0.76 (3 H, t, J = 7.0 Hz, 
CH2CH3) and 0.72 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M+2Na-3H]- 




6.3.4 Synthesis of acyl-CoA esters of 2-APA 
Fenoprofenoyl-CoA (13) 
 
Fenoprofen calcium salt hydrate (1.00 g, 1.91 mmol) was treated with excess 
1.0 M HCl aq. and was extracted with chloroform to obtain fenoprofen (acid). 
Compound 13 was prepared from fenoprofen (acid) (93 mg, 0.38 mmol) using 
the same procedure as for compound 49 to give a white solid (48 mg). The 1H 
NMR spectrum of the product was consistent with previously reported data.2 
δH (500.13 MHz, 2H2O) 8.57 (1 H, s, adenosine CH), 8.28 (1 H, s, adenosine 
CH), 7.32-7.18 (3 H, m, Ar-H), 7.05 (1 H, t, J = 7.5 Hz, Ar-H), 7.00 (1 H, d, J = 
7.5 Hz, Ar-H), 6.94-6.78 (4 H, m, Ar-H), 6.09 (1 H, d, J = 5.0 Hz, adenosine 
CH), 4.49 (1 H, br s, adenosine CH), 4.15 (2 H, br s, adenosine CH2), 4.00-
3.85 (2 H, m, CHCH3 and CoA(OCHa)), 3.81-3.71 (1 H, m, CoA(OCHb)), 3.52-
3.42 (1 H, m, CoA(OHCH)), 3.30-3.10 (4 H, m, 2×CoA(CH2)), 2.95-2.89 (1 H, 
m, CoA(SCH)), 2.87-2.78 (1 H, m, CoA(SCH)), 2.26-2.07 (2 H, m, CoA(CH2)), 
1.33 (3 H, d, J = 6.5 Hz, CHCH3), 0.82 (3 H, s, CoA(CH3)) and 0.66 (3 H, s, 
CoA(CH3)); ESI-MS m/z calcd. for [M+4Na-3H]+ C36H45N7Na4O18P3S: 










Compound 119 was prepared from ibuprofen (90 mg, 0.43 mmol) using the 
same procedure as for compound 49 to give a white solid (49 mg). The 1H 
NMR spectrum of the product was consistent with previously reported data.2 
δH (500.13 MHz, 2H2O) 8.58 (1 H, s, adenosine CH), 8.31 (1 H, s, adenosine 
CH), 7.13 (2 H, d, J = 7.8 Hz, Ar-H), 7.06 (2 H, d, J = 7.8 Hz, Ar-H), 6.11 (1 H, 
d, J = 5.5 Hz, adenosine CH), 4.50 (1 H, br s, adenosine CH), 4.16 (2 H, br s, 
adenosine CH2), 3.95-3.85 (2 H, m, CHCH3 and CoA(OCHa)), 3.82-3.71 (1 H, 
m, CoA(OCHb)), 3.53-3.43 (1 H, m, CoA(OHCH)), 3.28-3.13 (4 H, m, 
2×CoA(CH2)), 2.99-2.88 (1 H, m, CoA(SCH)), 2.87-2.78 (1 H, m, CoA(SCH)), 
2.32 (1 H, d, J = 6.7 Hz, CH2CH(CH3)2), 2.20-2.08 (2 H, m, CoA(CH2)), 1.66 
(1 H, nonet, J = 6.7 Hz, CH2CH(CH3)2), 1.35 (3 H, d, J = 7.0 Hz, CHCH3), 0.83 
(3 H, s, CoA(CH3)), 0.72 (6 H, d, J = 6.7 Hz, CH2CH(CH3)2) and 0.69 (3 H, s, 





Compound 120 was prepared from ketoprofen (90 mg, 0.35 mmol) using the 
same procedure as for compound 49 to give a white solid (37 mg). The 1H 
NMR spectrum of the product was consistent with previously reported data.2 
δH (500.13 MHz, 2H2O) 8.57 (1 H, s, adenosine CH), 8.30 (1 H, d, J = 2.0 Hz, 
adenosine CH), 7.75-7.55 (6 H, m, Ar-H), 7.52-7.38 (3 H, m, Ar-H), 6.09 (1 H, 
d, J = 5.5 Hz, adenosine CH), 4.17 (1 H, br s, adenosine CH), 4.11-4.02 (1 H, 
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m, CHCH3), 3.94 (1 H, s, adenosine CH), 3.82-3.74 (1 H, m, CoA(OCHa)), 
3.55-3.45 (1 H, m, CoA(OCHb)), 3.23 (4 H, t, J = 6.0 Hz, 2×CoA(CH2)), 3.03-
2.94 (1 H, m, CoA(SCH)), 2.93-2.84 (1 H, m, CoA(SCH)), 2.25-2.11 (2 H, m, 
CoA(CH2)), 1.46-1.40 (3 H, 2×d overlapping, J = 7.0 Hz, CHCH3), 0.84 (3 H, 
s, CoA(CH3)) and 0.69 (3 H, s, CoA(CH3)); ESI-MS m/z calcd. for [M+Na-2H]- 




Compound 121 was prepared from naproxen (90 mg, 0.39 mmol) using the 
same procedure as for compound 49 to give a white solid (17 mg). δH (500.13 
MHz, 2H2O) 8.43 (1 H, s, adenosine CH), 8.00 (1 H, s, adenosine CH), 7.62-
7.52 (2 H, m, Ar-H), 7.36 (1 H, s, Ar-H), 7.28 (1 H, d, J = 8.5 Hz, Ar-H), 7.05 
(1 H, s, Ar-H), 6.98 (1 H, d, J = 9.0 Hz, Ar-H), 5.95 (1 H, d, J = 5.0 Hz, 
adenosine CH), 4.50 (1 H, br s, adenosine CH), 4.17 (2 H, br s, adenosine 
CH2), 4.08 (1 H, q, J = 7.0 Hz, CHCH3), 3.88 (1 H, s, adenosine CH), 3.80 (3 
H, s, OCH3), 3.77-3.69 (1 H, m, CoA(OCHa)), 3.48-3.39 (1 H, m, CoA(OCHb)), 
3.27-3.16 (2 H, m, CoA(CH2)), 3.12-3.01 (2 H, m, CoA(CH2)), 3.01-2.93 (1 H, 
m, CoA(SCH)), 2.89-2.79 (1 H, m, CoA(SCH)), 2.10-1.95 (2 H, m, CoA(CH2)), 
1.48 (3 H, d, J = 7.0 Hz, CHCH3), 0.77 (3 H, s, CoA(CH3)) and 0.63 (3 H, s, 
CoA(CH3)); ESI-MS m/z calcd. for [M+2Na-3H]- C35H45N7Na2O18P3S: 






Compound 122 was prepared from flurbiprofen (90 mg, 0.37 mmol) using the 
same procedure as for compound 49 to give a white solid (13 mg). The 1H 
NMR spectrum of the product was consistent with previously reported data.2 
δH (500.13 MHz, 2H2O) 8.61 (1 H, s, adenosine CH), 8.55 (1 H, s, adenosine 
CH), 7.51-7.29 (6 H, m, Ar-H), 7.22-7.10 (2 H, m, Ar-H), 6.11-6.04 (1 H, m, 
adenosine CH), 4.17 (2 H, br s, adenosine CH2), 4.10-4.01 (1 H, m, CHCH3), 
3.92 (1 H, d, J = 5.5 Hz, adenosine CH), 3.81-3.75 (1 H, m, CoA(OCHa)), 3.53-
3.45 (1 H, m, CoA(OCHb)), 3.32-3.16 (4 H, m, 2×CoA(CH2)), 3.08-2.98 (1 H, 
m, CoA(SCH)), 2.95-2.85 (1 H, m, CoA(SCH)), 2.24-2.12 (2 H, m, CoA(CH2)), 
1.46 (3 H, d, J = 7.0 Hz, CHCH3), 0.82 (3 H, s, CoA(CH3)) and 0.67 (3 H, s, 
CoA(CH3)); ESI-MS m/z calcd. for [M+2Na-3H]- C36H41FN7Na2O17P3S: 
1036.1507, found 1036.1673. 
 




The oxazolidinone 190 was synthesised using the protocol previously 
described.3, 143 (S)-(+)-4-benzyl-3-propionyl-2-oxazolidinone (3.00 g, 12.9 
mmol) in DCM (30 mL) was cooled to -78C. Dibutylboron triflate in DCM (1.00 
M, 13.0 mL, 12.9 mmol) and diisopropylethylamine (2.3 mL, 13.2 mmol) were 
added to the solution, and the resulting mixture was stirred for 30 min. Octanal 
(1.4 mL, 9.2 mmol) was dissolved in DCM (9 mL) and the solution was added 
dropwise to the reaction mixture at -78 °C. It was stirred for 30 min at -78 °C, 
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allowed to reach room temperature and further stirred for 2 h. 0.1 M NaH2PO4-
NaOH, pH 7.0 (100 mL) was slowly added to the mixture to quench the 
reaction. The organic layer was washed with HCl aq. (1.0 M, 100 mL), saturated 
NaHCO3 aq. (100 mL) and brine (100 mL), dried over MgSO4 and evaporated 
in vacuo. The crude product was purified by column chromatography [silica, 
gradient elution with 10:1, 6:1 (v/v) PE:EtOAc] to give a colourless oil (2.53 g, 
76.2%) that eluted in 6:1 (v/v) PE:EtOAc. Rf=0.25 [1:1 (v/v) PE:Et2O]; [α]D21 
+51.4 (c 0.74 in CHCl3); IR max/cm-1 3517 (OH), 1780 (C=O) and 1692 (C=O); 
δH (500.13 MHz; CDCl3) 7.26-7.07 (5 H, m, Ar-H), 4.65-4.55 (1 H, m, 4-H), 
4.16-4.05 (2 H, m, 5-H), 3.89-3.80 (1 H, m, 3’-H), 3.68 (1 H, qd J = 7.0, 3.0 Hz, 
2’-H), 3.14 (1 H, dd, J = 13.0, 3.0 Hz, ArCHa), 2.92 (1 H, s, OH), 2.70 (1 H, dd, 
J = 13.0, 9.0 Hz, ArCHb), 1.50-1.10 (15 H, m, 6×CH2 and CH3CH) and 0.79 (3 
H, t, J = 6.5 Hz, 10’-H); δC (125.76 MHz, CDCl3) 177.23 (1’-C), 152.87 (2-C), 
134.92 (Ar-C), 129.24 (Ar-C), 128.73 (Ar-C), 127.18 (Ar-C), 71.35 (3’-C), 65.96 
(5-C), 54.91 (4-C), 42.02 (2’-C), 37.53 (ArCHaHb), 33.77 (CH2), 31.62 (CH2), 
29.35 (CH2), 29.05 (CH2), 25.84 (CH2), 22.45 (CH2), 13.90 (CH3CH) and 10.31 






The oxazolidinone 191 was synthesised using the protocol previously 
described.3, 143 DAST (0.5 mL, 3.87 mmol) in DCM (10 mL) was added 
dropwise to (4S)-4-benzyl-3-[(2S,3R)-3-hydroxy-2-methyldecanoyl]-1,3-
oxazolidin-2-one 190 (1.40 g, 3.87 mmol) in DCM (20 mL) at -78C. The 
mixture was stirred at -78 °C for 2 h, then allowed to reach room temperature 
and stirred for a further 2 h. Water (50 mL) was added slowly to the reaction 
mixture and it was extracted with DCM (50 mL). The organic layer was washed 
with saturated NaHCO3 aq. (100 mL), brine (100 mL), dried over MgSO4 and 
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evaporated in vacuo to afford a colourless oil. The crude product was purified 
by column chromatography [silica, 30:1 (v/v) PE:EtOAc] to give a colourless 
oil (490 mg, 35.0%). Rf = 0.63 [5:1 (v/v) PE:EtOAc]; [α]D21 +49.2 (c 0.63 in 
CHCl3); IR max/cm-1 1782 (C=O) and 1700 (C=O); δH (500.13 MHz; CDCl3) 
7.27-7.06 (5 H, m, Ar-H), 4.76-4.57 (2 H, m, 4-H and 3’-H), 4.15-3.96 (3 H, m, 
5-H and 2’-H), 3.17 (1 H, dd, J = 13.5, 3.5 Hz, ArCHa), 2.72 (1 H, dd, J = 13.5, 
9.5 Hz, ArCHb), 1.70-1.14 (12 H, m, 6×CH2), 1.10 (3 H, d, J = 7.0 Hz, CH3CH) 
and 0.80 (3 H, t, J = 6.5 Hz, 10’-H); δC (125.76 MHz, CDCl3) 174.37 (d, J = 2.8 
Hz, 1’-C), 153.12 (2-C), 135.25 (Ar-C), 129.47 (Ar-C), 128.93 (Ar-C), 127.37 
(Ar-C), 94.89 (d, J = 169.8 Hz, 3’-C), 66.19 (5-C), 55.38 (4-C), 42.03 (d, J = 
20.9 Hz, 2’-C), 37.85 (ArCHaHb), 32.04 (d, J = 20.9 Hz, CH2), 31.79 (CH2), 
29.37 (CH2), 29.16 (CH2), 24.57 (d, J = 2.8 Hz, CH2), 22.64 (CH2), 14.10 (10’-
C) and 13.62 (d, J = 8.5 Hz, 2’-CH3); δF (470.59 MHz, CDCl3) -179.67; ESI-MS 
m/z calcd. for [M+Na]+ C21H30FNNaO3: 386.2107, found 386.2126. 
 
(2R,3S)-3-Fluoro-2-methyldecanoic acid (192) 
 
The acid 192 was synthesised using the protocol previously described.3, 143 
H2O2 aq. [30% (w/w), 0.7 mL, 6.2 mmol] and LiOH (62 mg, 2.60 mmol) were 
added to (4S)-4-benzyl-3-[(2R,3S)-3-fluoro-2-methyldecanoyl]-1,3-oxazolidin-
2-one 191 (472 mg, 1.3 mmol) in THF (14 mL) at 0 °C. The mixture was stirred 
for 20 h and saturated Na2SO3 aq. (14 mL) was added to quench the reaction. 
THF was evaporated and the mixture was acidified with 1.0 M HCl aq. to pH 1 
and extracted with DCM (100 mL). The organic layer was washed with water 
(75 mL) and brine (75 mL), dried over MgSO4 and evaporated in vacuo to 
afford a colourless oil. The crude product was purified by column 
chromatography [silica, 5:1 (v/v) PE: EtOAc] to afford a white solid (245 mg, 
92.4%). Rf = 0.40 [5:1 (v/v) PE:EtOAc]; melting point 64-65 °C; [α]D21 -7.8 (c 
0.51 in CHCl3); IR max/cm-1 2925 (OH) and 1693 (C=O); δH (400.04 MHz; 
CDCl3) 10.89 (1 H, br s, OH), 4.58-4.50 (1 H, m, 3-H), 2.58-2.52 (1 H, m, 2-H), 
1.75-1.23 (12 H, m, 6×CH2), 1.20 (3 H, d, J = 7.2 Hz, CH3CH) and 0.88 (3 H, 
t, J = 6.8 Hz, 10-H); δC (100.59 MHz, CDCl3) 180.02 (d, J = 5.6 Hz, C=O), 94.28 
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(d, J = 172.2 Hz, 3-C), 44.37 (d, J = 22.0 Hz, 2-C), 31.74 (d, J = 21.1 Hz, CH2), 
31.74 (CH2), 29.30 (CH2), 29.12 (CH2), 24.82 (d, J = 3.0 Hz, CH2), 22.61 (CH2), 
14.05 (10-C) and 12.56 (d, J = 6.6 Hz, 2-CH3); δF (470.59 MHz, CDCl3) -




Compound 147 was prepared from (2R,3S)-3-fluoro-2-methyldecanoic acid 
192 (30 mg, 0.15 mmol) using the same procedure as for compound 49 to give 
a white solid (14 mg). δH (500.13 MHz, 2H2O) 8.63 (1 H, s, adenosine CH), 
8.38 (1 H, s, adenosine CH), 6.16 (1 H, d, J = 6.0 Hz, adenosine CH), 4.30-
4.10 (2 H, br s, adenosine CH2), 3.97 (1 H, s, adenosine CH), 3.85-3.72 (1 H, 
m, CoA(OCHa)), 3.58-3.47 (1 H, m, CoA(OCHb)), 3.39 (2 H, t, J = 6.5 Hz, 
CoA(CH2)), 3.29 (2 H, t, J = 6.0 Hz, CoA(CH2)), 3.08-2.90 (3 H, m, CoA(SCH2) 
and CHCH3), 2.36 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.68-1.44 (2 H, m, CHa and 
CHb), 1.39-1.12 (10 H, m, 5×CH2), 1.07 (3 H, d, J = 7.0 Hz, CHCH3), 0.87 (3 
H, s, CoA(CH3)) and 0.81-0.70 (6 H, m, CH2CH3 and CoA(CH3)); δF (470.59 
MHz, 2H2O) -181.11; ESI-MS m/z calcd. for [M-2H]2- C32H53FN7O17P3S: 













6.5 Synthesis of substrate for fluoride elimination assay to evaluate 
potential AMACR inhibitors 
(2R,3R)-3-Fluoro-2-methyldecanoyl-CoA (114) 
 
Compound 114 was prepared from (2S,3R)-3-fluoro-2-methyldecanoic acid 
(30 mg, 0.15 mmol) using the same procedure as for compound 49 to give a 
white solid (18 mg). δH (500.13 MHz, 2H2O) 8.43 (1 H, s, adenosine CH), 8.13 
(1 H, s, adenosine CH), 6.04 (1 H, d, J = 6.5 Hz, adenosine CH), 4.55-4.51 (1 
H, m, CHF), 4.49 (1 H, br s, adenosine CH), 4.11 (2 H, br s, adenosine CH2), 
3.90 (1 H, s, adenosine CH), 3.77-3.67 (1 H, m, CoA(OCHa)), 3.47-3.38 (1 H, 
m, CoA(OCHb)), 3.32 (2 H, t, J = 6.5 Hz, CoA(CH2)), 3.22 (2 H, t, J = 5.0 Hz, 
CoA(CH2)), 2.98-2.80 (3 H, m, CoA(SCH2) and CHCH3), 2.29 (2 H, t, J = 6.5 
Hz, CoA(CH2)), 1.58-1.35 (2 H, m, CHa and CHb), 1.30-1.04 (10 H, m, 5×CH2), 
1.00 (3 H, d, J = 7.0 Hz, CHCH3), 0.77 (3 H, s, CoA(CH3)), 0.71 (3 H, t, J = 6.5 
Hz, CH2CH3) and 0.63 (3 H, s, CoA(CH3)); δF (470.59 MHz, 2H2O) -181.15; 
ESI-MS m/z calcd. for [M-H]- C32H54FN7O17P3S: 952.2494, found 952.2528. 
 




2,6-Dimethylpyridine (2.2 mL, 18.8 mmol) was added to a solution of 
fluorescein (2.50 g, 7.52 mmol) in DCM (40 ml). tert-Butyldimethylsilyl triflate 
(4.6 ml, 20.0 mmol) was added dropwise and the mixture was stirred for 4.5 h 
at room temperature. Water (100 mL) was added and the mixture was 
extracted with DCM (3 x 50 mL). The combined organic extracts were washed 
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with brine (100 mL), dried over MgSO4 and evaporated in vacuo to afford a 
dark brown oil. The crude product was purified by column chromatography 
[silica, 30:1 (v/v) PE: EtOAc] to afford a white solid (2.79 g, 66.2%). Rf = 0.82 
[4:1 (v/v) PE:EtOAc]. 1H and 13C NMR spectra were consistent with previously 
reported data.191 δH (400.04 MHz; CDCl3) 8.01 (1 H, d, J = 7.6 Hz, Ar-H), 7.66 
(1 H, td, J = 7.6, 1.2 Hz, Ar-H), 7.60 (1 H, td, J = 7.6, 1.2 Hz, Ar-H), 7.18 (1 H, 
d, J = 7.6 Hz, Ar-H), 6.73 (2 H, d, J = 2.4 Hz, Ar-H), 6.64 (2 H, d, J = 8.8 Hz, 
Ar-H), 6.52 (2 H, dd, J = 8.8, 2.4 Hz, Ar-H), 0.98 (18 H, s, 2×(CH3)3), 0.23 (6 
H, s, 2×Si-CH3) and 0.22 (6 H, s, 2×Si-CH3); δc (100.59 MHz; CDCl3) 169.4 
(C=O), 157.5 (Ar-C), 153.1 (Ar-C), 152.3 (Ar-C), 134.9 (Ar-C), 129.6 (Ar-C), 
128.9 (Ar-C), 126.8 (Ar-C), 124.9 (Ar-C), 123.9 (Ar-C), 116.5(Ar-C), 112.0 (Ar-
C), 107.6 (Ar-C), 83.2 (COC), 25.6 (CCH3), 18.1 (SiC) and -4.5 (Si-CH3); ESI-
MS m/z calcd. for [M+H]+ C32H41O5Si2: 561.2493, found 561.2594. 
 
6.7 Deuterium wash-in assay to measure exchange of potential AMACR 
inhibitors 
The deuterium wash-in assay was performed using the protocol previously 
described.1, 2, 184 Acyl-CoA esters were dissolved in 2H2O and their 
concentrations were determined by 1H NMR.2 The vortex-mixed acyl-CoA 
ester (100 µM final concentration in the assay) was incubated with human 
recombinant AMACR (0.18 mg mL-1; 3.82 µM) in 50 mM NaH2PO4-NaOH, pH 
7.4 and 2H2O in a final volume of 550 µL. There was ca. 85% (v/v) 2H2O in the 
reaction mixture. The assay mixture was incubated at 30°C for 1 h before the 
enzyme was heat-inactivated at 60 °C for 30 min. R-2-methyldecanoyl-CoA 
was used as a positive control and heat-inactivated AMACR was used as a 
negative control. 1H NMR (2H2O, 500.13 MHz) was used to analyse α-proton 
exchange by quantifying the conversion of the 2-methyl peak from a doublet 
(at ca. 1.34 ppm) to an unresolved single peak (at ca. 1.33 ppm). 
 
6.8 Fluoride elimination 
6.8.1 Fluoride elimination assay (trial/initial protocol) 
The vortex-mixed (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 in 2H2O (100 
µM final concentration) and the potential AMACR inhibitor in 2H2O (100 µM 
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final concentration) were incubated with human recombinant AMACR (0.12 
mg mL-1; 2.55 µM) in 50 mM NaH2PO4-NaOH, pH 7.4 and 2H2O in a final 
volume of 550 µL. The reaction mixture contained ca. 87% (v/v) 2H2O. The 
mixture was incubated at 30°C for 1 h before the enzyme was inactivated by 
heating at 60 °C for 30 min. The positive control lacked an inhibitor whilst the 
negative control contained heat-inactivated AMACR. Each inhibitor was tested 
in duplicate. 1H NMR (2H2O, 500.13 MHz) was used to analyse the elimination 
of substrate by quantifying the conversion from the saturated 2-methyl group 
(a doublet at ca. 1.10 ppm) to an unsaturated product (a singlet at ca. 1.75 
ppm). 
 
6.8.2 Fluoride elimination assay (optimised protocol for the evaluation of 
AMACR inhibitors)  
Potential AMACR inhibitors were dissolved in 2H2O or deuterated dimethyl 
sulfoxide (DMSO) if they were not water soluble. A potential AMACR inhibitor 
(200 µM in the incubation phase) was incubated with human recombinant 
AMACR (0.24 mg mL-1; 5.10 µM in the incubation phase) in NaH2PO4-NaOH, 
pH 7.4 and 2H2O in a volume of 275 µL. The mixture was incubated for 10 min 
at room temperature. An equal volume (275 µL) of (2R,3R)-3-fluoro-2-
methyldecanoyl-CoA 114 substrate in the same buffer and 2H2O was added to 
the pre-incubated mixture to a make a final 1× concentration of substrate (100 
µM), inhibitor (100 µM) and enzyme (0.12 mg mL-1; 2.55 µM). The final mixture 
also contained 50 mM NaH2PO4-NaOH, pH 7.4 and ca. 87% (v/v) 2H2O. It was 
incubated at 30 °C for 1 h before the enzyme was inactivated by heating at 60 
°C for 30 min. The positive control lacked an inhibitor while the negative control 
contained heat-inactivated AMACR. Each inhibitor was tested in duplicate. 1H 
NMR (2H2O, 500.13 MHz) was used to analyse the elimination of substrate by 
quantifying the conversion from the saturated 2-methyl group (a doublet at ca. 
1.10 ppm) to an unsaturated product (a singlet at ca. 1.75 ppm). 
 
For potential inhibitors 123, 124, 125, 126 and 127 designed by Professor Paul 
Groundwater, the same protocol as above applied but the final concentration 
of (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 114 substrate was 20 µM and the 
enzyme was 0.01 mg mL-1 (0.21 µM). As the potential inhibitors were not water 
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soluble, they were dissolved in deuterated DMSO [2% (v/v) final concentration 
in the assay]. AMACR was shown not to be inhibited by 2% (v/v) DMSO.  
 
6.8.3 Calibration of fluorescence intensity against fluoride concentration 
using protected fluorescein 
The calibration was carried out using the protocol as described by Rydzik et 
al.191 with some modifications of the concentrations. tert-Butyldimethylsilyl-
protected fluorescein was dissolved in DMSO and its concentration was 
determined using 1H NMR. The protected fluorescein (80 μL, final 
concentration 256 μM) was added to solutions of fluoride anion (NaF solution; 
20 µL; final concentrations 0, 2.5, 5, 10, 20, 40, 80, 160, 320, and 640 μM) in 
50 mM Tris-HCl, pH 7.5. The buffer was prepared using highly purified water. 
The mixture was incubated in a solid black 96-well plate at room temperature 
in the dark for 1 h. 50 mM HEPES-NaOH buffer, pH 7.0 (50 μL) was added to 
the mixture after 1 h and the samples were further incubated for 2 min. The 
fluorescence was measured using FLUOstar Omega plate reader (BMG 
Labtech) with an excitation wavelength of 480 nm and an emission wavelength 
of 520 nm. Quadruplicate reactions were performed in a 96-well plate. 
Triplicate readings of each reaction were taken and the readings were 
corrected by subtracting the baseline signal (control with 0 µM fluoride). The 
readings were averaged and the standard deviation of the sample was 
calculated using Microsoft Excel. 
 
6.8.4 Calibration of fluorescence intensity against fluoride concentration 
using boronate-based fluorescent sensor 
The boronate-based fluorescence sensor 131 was dissolved in deuterated 
methanol and its concentration was determined by 1H NMR. The sensor was 
diluted in acetonitrile and the solution (160 μL, final concentration 2 µM) was 
added to NaF (40 µL, final concentrations 0, 9.375, 18.75, 37.5, 75, 150 and 
300 μM) in 50 mM NaH2PO4-NaOH, pH 7.4. The buffer was prepared using 
highly purified water. The final concentration of acetonitrile was ~80% (v/v).  
 
For experiment that used 100% (v/v) acetonitrile, TBAF instead of NaF was 
used, and the final concentrations of the sensor and fluoride anion were the 
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same as above. For experiment with final concentration of ~95% (v/v) 
acetonitrile, the sensor (190 μL, final concentration 2 µM) and NaF solution 
(10 µL, final concentrations 0, 6.25, 12.5, 25, 50, 100, 200 µM) were in the 
assay. 
 
The 200 µL solution was mixed in a solid black 96-well plate at room 
temperature for 3 min. The 96-well plate was measured with FLUOstar Omega 
plate reader (BMG Labtech) with an excitation wavelength of 350 nm and an 
emission wavelength of 520 nm. Duplicate reactions were performed in a 96-
well plate and triplicate readings were taken. The readings were averaged and 
the standard deviation of the sample was calculated using Microsoft Excel. 
 
6.9 Fluorescence-based competitive binding assay 
The fluorescent ligand, 2-methyl-3-(3-(2-(6-morpholino-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)ethoxy)phenyl)-3-oxopropanoyl-CoA 134 (5 
μM) was incubated with human recombinant AMACR (0.049 mg mL-1; 1.04 
μM) in 50 mM NaH2PO4-NaOH, pH 7.4. Water was added to a final volume of 
1000 μL. The mixture was incubated at room temperature for 10 min. Potential 
inhibitor at various concentrations (0, 0.1, 1, 5, 10, 50 and 100 μM, except 
potential inhibitors 49 and 50 where the final concentrations were 0, 0.1, 1, 10 
and 100 µM) was added and incubated for another 10 min. The fluorescence 
intensity was measured using a Perkin-Elmer Luminescence LS 50B 
Spectrometer, with an excitation wavelength of 400 nm and an emission 
wavelength between 450 and 650 nm (Excitation slit: 10 nm; Emission slit: 10 
nm). IC50 values were calculated with SigmaPlot 12.3, using the four 
parameter logistic equation. Ki values were calculated using the Ki calculator 
(website: http://sw16.im.med.umich.edu/software/calc_ki/).195, 196 
 
In order to test for slow-binding of inhibitors, the order of addition of the 
fluorescent ligand and potential AMACR inhibitor was reversed. The potential 
inhibitor was pre-incubated with human recombinant AMACR at room 
temperature for 10 min. The fluorescent ligand was added and incubated for 
another 10 min before the fluorescence intensity was measured. The final 
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concentrations of reactants remained the same. Readings were obtained and 
data was analysed as above. 
 
6.10 Multi-well colorimetric assay 
The potential inhibitor (150 µL; final assay concentrations 100.00, 33.33, 
11.11, 3.70, 1.23, 0.41, 0.14, 0.05 μM; except for N-dodecyl-N-
methylcarbamoyl-CoA 30 which had final assay concentrations of 411.5, 
137.2, 45.7, 15.2, 5.1, 1.7, 0.6, 0.2 nM) in 50 mM NaH2PO4-NaOH, pH 7.4, 
supplemented with 8% (v/v) DMSO was incubated with human recombinant 
AMACR (150 µL; final assay concentration 0.035 mg mL-1, 0.74 µM) in a 96-
well plate at room temperature for 10 min. The 300 µL mixture was split into 
three (100 µL each) and the substrate 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 135 (100 µL, final assay concentration 40 µM) was 
added after 10 min. The reaction was measured immediately using FLUOstar 
Omega plate reader (BMG Labtech) at 30 °C. The absorbance was measured 
at 354 nm and 390 nm every 5 min for 15 min. The positive control lacked an 
inhibitor while the negative control lacked active enzyme (buffer as the 
substitute). Each assay was performed in triplicate. The absorbance readings 
at 10 min were averaged and plotted against inhibitor concentration. IC50 
values were calculated with SigmaPlot 12.3, using four parameter logistic 
equation. Ki values were calculated from IC50 values using the Cheng-Prusoff 
equation for competitive inhibition.200 
 
6.10.1 Multi-well colorimetric assay (mode of binding: experiment 1) 
The potential inhibitor (150 µL; pre-incubation phase 20× IC50) in 50 mM 
NaH2PO4-NaOH, pH 7.4, supplemented with 8% (v/v) DMSO was pre-
incubated with human recombinant AMACR (150 µL; pre-incubation 
concentration 0.07 mg mL-1, 1.48 µM) in a 96-well plate at room temperature 
for 10 min. The 300 µL mixture was split into three (100 µL in each well). The 
3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate (100 µL, final 
assay concentration 40 µM) was added to the potential inhibitor (final assay 
concentration 10× IC50) and the enzyme (final assay concentration 0.035 mg 
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mL-1, 0.74 µM) mixture. The reaction was measured immediately using 
FLUOstar Omega plate reader (BMG Labtech) at 30 °C.  
 
Each assay was performed in triplicate. The absorbance was measured at 354 
nm and 390 nm every min for 60 min. The positive control lacked an inhibitor 
while the negative control lacked active AMACR. The absorbance readings at 
354 nm were averaged and plotted against time. If an inhibitor absorbed at 
354 nm, then absorbance at 390 nm was plotted. 
 
6.10.2 Multi-well colorimetric assay (mode of binding: experiment 2) 
The potential inhibitor (6 µL; pre-incubation concentration 20× IC50) in 50 mM 
NaH2PO4-NaOH, pH 7.4, supplemented with 8% (v/v) DMSO was pre-
incubated with human recombinant AMACR (6 µL; pre-incubation 
concentration 1.75 mg mL-1, 37 µM) in a 96-well plate at room temperature for 
10 min. The 12 µL mixture was split into three (4 µL in each well). The 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate (196 µL, final assay 
concentration 40 µM) was added to the potential inhibitor (final assay 
concentration 0.4× IC50) and enzyme (final assay concentration 0.035 mg mL-
1, 0.74 µM) mixture. The reaction was measured immediately in a plate reader 
using the condition as experiment 1 (vide supra).85 Each assay was performed 
in triplicate. 
 
6.10.3 Multi-well colorimetric assay (mode of binding: experiment 3) 
The potential inhibitor (50 µL; 4× stock, final assay concentration 10× IC50) in 
50 mM NaH2PO4-NaOH, pH 7.4, supplemented with 8% (v/v) DMSO was 
incubated with substrate 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 
(100 µL, 2× stock, final assay concentration 40 µM) at room temperature for 
10 min. Human recombinant AMACR (50 µL; 4× stock, final assay 
concentration 0.035 mg mL-1, 0.74 µM) was added. The reaction was 
measured immediately in a plate reader using the condition as experiment 1 





6.10.4 Kitz-Wilson analysis  
The procedure was carried out as described by Kitz and Wilson.85, 202 Ebselen 
oxide 35 (10 µL; final concentration 0.00, 0.09, 0.13, 0.30, 0.67 and 1.00 µM) 
in 50 mM NaH2PO4-NaOH, pH 7.4, supplemented with 8% (v/v) DMSO was 
pre-incubated with human recombinant AMACR (10 µL; final assay 
concentration 0.105 mg mL-1, 2.23 µM) in a 96-well plate at room temperature 
for 0, 2, 4, 6, 8 and 10 min. The substrate 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 135 (180 µL, final assay concentration 40 µM) was 
added and the reaction was measured using FLUOstar Omega plate reader 
(BMG Labtech) at 30 °C. The absorbance was measured at 354 nm every min 
for 15 min. The initial reaction rate was calculated from the slope of the straight 
line of absorbance against time. A graph showing the remaining activity (y-
axis) against the time of pre-incubation was plotted. The y-axis was obtained 
by calculating the natural log of the ratio of initial rate with inhibitor and initial 







6.11 General (site-directed mutagenesis) 
Reagents for biological experiments were obtained from the Sigma-Aldrich 
Chemical Co. or Fisher Scientific Ltd. unless otherwise stated and were of 
analytical or molecular biology grade. KOD Hot Start DNA polymerase, 
Overnight Express™ Autoinduction System 1, NovaBlue GigaSingles™ 
competent cells, the Rosetta2 (DE3) expression strain and benzonase were 
purchased from Novagen (Merck Millipore). QIAquick PCR purification kit was 
obtained from Qiagen Ltd. SeeBlue® Plus2 pre-stained protein standard and 
primers were sourced from Invitrogen. Q5® site-directed mutagenesis kit, 100 
bp and 1 kb DNA ladders, DpnI, DNA sample loading buffer (6×), Quick 
Ligation™ kit, dATP solution and T4 polynucleotide kinase were purchased 
from New England Biolabs. Metal-chelate chromatography columns (HisTrap 
FF) were obtained from GE Healthcare. Ebselen and ebselen oxide were 
purchased from Cayman Chemical. The pET30 Ek/LIC vector containing 
wild-type AMACR was obtained from the MDL lab1 and was used as the 
template DNA for site-directed mutagenesis. Solutions were prepared using 
water from a Nanopure Diamond system and was of 18.2 Mega-Ω.cm-1 quality. 
The pH of buffers was adjusted using 5.0 M NaOH aq. or concentrated HCl aq. 
as appropriate and measured using a Corning pH meter 240 at room 
temperature, calibrated with standard commercial buffers at pH 7.0 and pH 4.0 
or pH 10.0. Plasmids were quantified using GeneQuant II RNA/DNA calculator 
(GE Healthcare). The incubation of bacterial culture was performed in a 
shaking incubator (Thermo Scientific MaxQ 4000). Circular dichroism was 
performed using a Chirascan™ CD Spectrometer (Applied Photophysics). 
Dynamic light scattering was measured using the Zetasizer nano series 
instrument (Malvern). Thermo-cycling was performed using a Techne 
Flexigene or Techne Techgene PCR machine. Centrifugation was carried out 
either with an Eppendorf Mini-spin micro-centrifuge (at 13 400 r.p.m. and 
ambient room temperature unless otherwise stated) or a Beckman J2-MC 
centrifuge.  
 
6.12 Microbiological techniques 
All microbiological experiments were conducted under flame using standard 
aseptic technique. Sterilisation of reagents was performed by autoclaving at 
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121 °C, 103 kPa for 15 min or filtering through a 0.2 µm filter for heat-labile 
reagents. Plastic-ware were acquired pre-sterilised or sterilised by autoclaving 
under the conditions above. 
 
LB (Lennox) media was used throughout the experiments for the cultivation of 
E. coli. LB agar was prepared by supplementing the media with 1% (w/v) agar. 
LB media was supplemented with antibiotics as appropriate (Table 6.1). 
 






LB broth Rosetta2 (DE3) culture Chloramphenicol 32  
Rosetta2 (DE3) 
transformed with 
AMACR cDNA plasmid 
Chloramphenicol  32  
Kanamycin sulfate 30  
LB agar Control with pUC19 
vector 
Ampicillin 100 
Cells transformed with 
pET30 Ek/LIC vector  
Kanamycin sulfate 30 
Rosetta2 (DE3) 
transformed with 
AMACR cDNA plasmid 
Chloramphenicol 32 
Kanamycin sulfate 30 
Table 6.1: LB broth and agar were supplemented with different antibiotics as needed. 
 
6.13 Glycerol stocks 
The glycerol stock was made by adding the overnight bacterial culture (1.0 
mL) to sterile glycerol [0.2 mL, 80% (w/v)] and stored in a sterile cryogenic vial 
at -80 °C. 
 
6.14 Site-directed mutagenesis using Q5® mutagenesis kit 
The sequences of AMACR 1A (http://www.uniprot.org/uniprot/, accession 
number Q9UHK6) and sequence of MCR (http://www.uniprot.org/uniprot/, 
accession number O06543) were aligned using Clusterw 
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(http://www.ch.embnet.org/software/ClustalW.html). Potential active site 
residues were chosen for site-directed mutagenesis based on this alignment 
and the known active site residues of MCR.86 
 
The pET30 Ek/LIC vector containing wild-type human AMACR 1A was 
obtained from the MDL lab1 and was used as a template. The Q5® site-directed 
mutagenesis used the non-overlapping primers and the E0554 protocol was 
followed. The circularisation of the PCR product and digestion of the template 
DNA was catalysed by the KLD enzyme mixture (contained kinase, ligase, and 
DpnI). As the template came from bacteria and therefore was methylated, it 
would be digested by DpnI. The mutant plasmid was made by PCR and was 
not methylated, so it would survive the DpnI digestion. The treated PCR 
product was transformed into NEB 5-alpha competent E. coli cells. The cells 
were selected using LB agar plate supplemented with kanamycin sulfate as 
the pET30 Ek/LIC vector contains a kanamycin-resistant gene. 
 
Non-overlapping primers for Q5® mutagenesis (Table 6.2) were designed 








H122A reverse 5’-CGGCAGAAGCTTCCTGAC-3’ 
D152A forward 5’-TCTCCTGGCTGCGTTTGCTGGTGGTGG-3’ 




M184A forward 5’-TGATGCAAATGCGGTGGAAGGAACAG-3’ 
M184A reverse 5’-ATGACCTGACCCTTGCCA-3’ 
E237A forward 5’-TGGAGCAATAGCGCCCCAGTTCTAC-3’ 










Table 6.2: Primers of the pET30Ek/LIC plasmid for Q5® site-directed mutagenesis 
experiments. Mutated codons are shown as bold letters. 
 
Optimal annealing temperatures for each primers given by the 
NEBaseChangerTM webite were used in PCR reactions. Sterile water instead 
of primers was used as a negative control.  
 
6.15 Primer phosphorylation 
Primers were phosphorylated by mixing the following: primer (3 µL, 100 
pmol/µL), dATP (5 µL, 10 mM), T4 polynucleotide kinase reaction buffer (5 µL, 
10×), T4 polynucleotide kinase (1 µL, 10 U µL-1) and water (36 µL). The 
mixture was incubated at 37 °C for 30 min. Heat-inactivated was performed at 
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65 °C for 20 min. Phosphorylation of primer was attempted but subsequently 
was not used in mutagenesis as it was shown that in vitro phosphorylation was 
not required.  
 
6.16 DNA ligation 
DNA ligation was performed by mixing the following: purified DNA (50 ng), 
Quick ligation reaction buffer (10 µL, 2×), Quick T4 DNA ligase (1 µL, 400,000 
units mL-1) and water (to 21 µL). The mixture was incubated at 25 °C for 5 min. 
Heat inactivation was not required. The purified DNA was initially ligated in 
vitro before it was transformed into competent cells. The DNA ligation step 
was subsequently abandoned. It was shown that the in vitro ligation was 
unnecessary and in fact, could jeopardise the success of transformation. 
 
6.17 Site-directed mutagenesis using KOD Hot Start polymerase 
The primers for site-directed mutagenesis with KOD Hot Start polymerase 
were designed manually. The forward and reverse primers were overlapping 





















H122A forward 5'-GCCGGTTAGCTGGCGCGGATATCAACTATTTGGC-3' 
H122A reverse 5'-GCCAAATAGTTGATATCCGCGCCAGCTAACCGGC-3' 
H122F forward 5'-GCCGGTTAGCTGGCTTTGATATCAACTATTTGGC-3' 
H122F reverse 5'-GCCAAATAGTTGATATCAAAGCCAGCTAACCGGC-3' 
H122L forward 5'-GCCGGTTAGCTGGCCTGGATATCAACTATTTGGC-3' 
H122L reverse 5'-GCCAAATAGTTGATATCCAGGCCAGCTAACCGGC-3' 
D152A forward 5’-CTGAATCTCCTGGCTGCGTTTGCTGGTGGTGGC-3’ 
D152A reverse 5’-GCCACCACCAGCAAACGCAGCCAGGAGATTCAG-3’ 
D152N forward 5'-CTGAATCTCCTGGCTAACTTTGCTGGTGGTGGC-3' 
D152N reverse 5'-GCCACCACCAGCAAAGTTAGCCAGGAGATTCAG-3' 
M184A forward 5'-CAGGTCATTGATGCAAATGCGGTGGAAGGAACAGC-
3' 


















Table 6.3: Primers of the pET30Ek/LIC plasmid for site-directed mutagenesis catalysed 
by KOD Hot Start polymerase. Mutated codons are shown as bold letters. 
 
The PCR reaction was carried out by mixing the following on ice: Buffer (5 µL, 
10×); dNTPs (5 µL, 2 mM each); MgSO4 (2 µL, 25 mM); pET30 Ek/LIC plasmid 
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containing AMACR (100 ng); KOD Hot Start polymerase (1 µL, 1 U µL-1); 
forward primer (3.75 µL, 4 µM); reverse primer (3.75 µL, 4 µM) and sterile 
water (to 50.0 µL). The mixture was transferred to a PCR machine and PCR 
amplification was carried out using the following conditions: Initial denaturation 
at 95 °C for 2 min; 25 cycles of: 95 °C, 20 s; 55 °C, 30 s; 68 °C, 8 min 20 s; 
and final extension at 68 °C for 5 min. Control reactions used primers that 
amplified the 1.2 kb wild-type AMACR 1A insert. The presence of the required 
DNA was confirmed by agarose gel electrophoresis. 
 
6.18 Agarose gel electrophoresis 
50× TAE buffer: EDTA (10.0 mL, 0.5 M, pH 8.0), glacial acetic acid (5.71 mL), 
Tris base (24.2 g) and water to 100 mL, pH 8.5 
 
Agarose powder [0.8% (w/v) for DNA ≥1.5 kb or 1.0% (w/v) for DNA ≤1.5 kb] 
was suspended in 1× TAE buffer. The suspension was heated in a microwave 
until fully dissolved into a clear solution. The mixture was poured evenly into 
the casting tray. The comb was inserted and the gel was left to solidify at room 
temperature. The solidified gel was transferred to an electrophoresis cell (Bio-
Rad) and submerged in 1× TAE buffer. All samples [DNA (5 µL) with 6× DNA 
sample loading buffer (2 µL)] were loaded to the gel wells. DNA ladders (100 
bp and 1 kb in 1× DNA sample loading buffer; 0.5 µg each) were added as 
standard markers. The gel was run at 95 volts for 1 h before transfer into 
ethidium bromide solution (~3 µg mL-1 in 1× TAE buffer). They was stained for 
10 min and visualised with a GeneGenius bio-imaging system (Syngene) 
under UV light ( = 312 nm). 
 
6.19 Manipulation of PCR products and transformation 
The PCR product was treated with DpnI (2 µL; 40 units) at 37 °C for 2 h to 
remove the template plasmid. The treated product was purified using the 
QIAquick PCR purification kit using the manufacturers’ procedure and eluted 
into sterile 10 mM Tris-HCl buffer, pH 8.0 (30 µL). The purified DNA (5 µL) was 
transformed into NovaBlue GigaSinglesTM competent cells. The DNA was 
mixed with the cells by flicking gently and incubated on ice for 5 min. The 
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mixture was heat shocked at 42 °C for 30 s and incubated on ice for a further 
2 min. SOC media (250 µL) was added to the mixture and the sample was 
incubated at 37 °C and 220 r.p.m. for 1 h. The bacterial culture (100 µL) was 
placed onto a LB agar plate pre-warmed at 37 °C and supplemented with 
kanamycin sulfate. The plate was incubated at 37 °C overnight. A LB agar 
plate supplemented with ampicillin was used as a positive control with the 
pUC19 plasmid transformed into competent cells. A single colony from the 
agar plate was inoculated into LB broth (6 mL) supplemented with kanamycin 
sulfate. It was incubated at 37 °C and 220 r.p.m. overnight.  Plasmid mini-
preparation was performed from 5 mL bacterial culture (Section 6.20) and the 
remainder was stored as glycerol stock (Section 6.13).  
 
6.20 Plasmid mini-prep procedures 
Overnight bacterial culture was harvested by centrifugation at 13 400 r.p.m. 
for 60 s. Solution I (250 µL; 10 mM EDTA, 50 mM Tris-HCl, pH 8.0 with 50 mM 
glucose and 100 µg mL-1 RNase A) was used to suspend the harvested cells. 
To the suspension, solution II [250 µL; 200 mM NaOH, 1% (w/v) SDS] was 
subsequently added. The mixture was gently inverted five times to give a 
clearer mixture and was left at room temperature for 5 min. Solution III (250 
µL; 2.55 M KOAc-HOAc, pH 5.4) was added and inverted 5 times to mix before 
incubation on ice for 15 min. The mixture was centrifuged at 13 400 r.p.m. for 
30 min and the supernatant was transferred to a sterile Eppendorf tube. 
Isopropanol (525 µL) was added, and the mixture was gently inverted 5 times 
and incubated at room temperature for 5 min. Centrifugation at 13 400 r.p.m. 
for 30 min was carried out and the supernatant was discarded. The 
precipitated DNA pellet was washed with cold ethanol [100 µL, 70% (v/v)] 
twice. The pellet was dried on bench for at least 1 h to get rid of any residual 
ethanol. Sterile water (40 µL) was used to suspend the DNA pellet and the 
mixture was stored at -20 °C until ready to be used.  
 
6.21 Colony PCR 
Colony PCR was performed in order to confirm that the required insert of the 
correct size for AMACR 1A was present. Each PCR reaction contained the 
following: Buffer (2 µL, 10×); dNTPs (2 µL, 2 mM each); MgSO4 (0.8 µL, 25 
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mM); template DNA containing the mutated insert (1 µL); KOD Hot Start 
polymerase (0.4 µL, 1 U µL-1); forward primer (1.5 µL, 4 µM); reverse primer 
(1.5 µL, 4 µM) and sterile water (to 20.0 µL). The mixture was transferred to a 
PCR machine and PCR amplification was carried out using the following 
conditions: Initial denaturation at 95 °C for 2 min; 35 cycles of: 95 °C, 20 s; 52 
°C, 10 s; 70 °C, 24 s; and final extension at 70 °C for 5 min. Agarose gel 
electrophoresis was performed and the gel was stained with ethidium bromide 
(Section 6.18). Once the insert of the correct size was confirmed, the plasmid 
was sent for sequencing to Source BioScience, U.K. in order to confirm that 
the desired mutation was present with no other changes to the sequence. 
 
6.22 Protein expression 
6.22.1 Preparation of competent cell for protein expression  
A thawed glycerol stock of Rosetta2 (DE3)  (200 µL) was inoculated into 1 mL 
SOC media supplemented with chloramphenicol in a 50 mL Falcon tube at 37 
°C and 220 r.p.m. for 90 min. LB media supplemented with chloramphenicol 
(10 mL) was added to the bacterial culture and incubated at 37 °C and 220 
r.p.m. until turbid (usually 3 h).  Cells were harvested by centrifugation (JA-14 
rotor, 10 000 r.p.m., 15 300 g, 10 min). The harvested cells were gently 
suspended in sterile, ice-cold 50 mM CaCl2 aq. (1 mL). The suspension was 
centrifuged again and the supernatant was discarded. The pellet was re-
suspended in sterile, ice-cold 50 mM CaCl2 aq. (0.5 mL). The suspended cells 
were left on ice in the cold room for 30 min or until ready to be used. 
 
6.22.2 Transformation of competent cell for protein expression 
Mini-prep plasmid (2 µL) was cooled on ice and mixed with the freshly 
prepared competent Rosetta2 (DE3) (100 µL) by flicking gently. Cells were 
incubated on ice for 5 min before being spread onto an agar plate that was 
pre-warmed at 37 °C and supplemented with chloramphenicol and kanamycin 
sulfate. Plates were incubated at 37 °C overnight. 
 
6.22.3 Small scale protein expression using IPTG or lactose 
A single colony from the transformation plate (Section 6.22.2) was inoculated 
into 5 mL LB media supplemented with chloramphenicol and kanamycin 
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sulfate. The culture was incubated at 37 °C and 220 r.p.m. until OD600 reached 
~1.5. The culture temperature was lowered to 16 °C for 1 h before IPTG (0.25 
mM) or lactose (2 mM, 5 mM or 10 mM) was added. The induced culture was 
incubated at 16 °C and 220 r.p.m. overnight.  
 
6.22.4 Small scale protein expression using overnight express™ 
autoinduction system 1  
1× autoinduction system 1 (100 µL OnEx™ Solution 1, 250 µL OnEx Solution 
2 and 5 µL OnEx Solution 3) was added to 5 mL LB media supplemented with 
kanamycin sulfate and chloramphenicol. A single colony was inoculated into 
the mixture and incubated at 37 °C and 220 r.p.m. overnight. 
 
6.22.5 Small scale protein sample preparation 
The cells were harvested by centrifugation at 13 400 r.p.m. to give ~30 mg cell 
pellet. Lysozyme (1 mg mL-1) in 20 mM Tris-HCl and 150 mM NaCl, pH 8.0 
buffer (150 µL) was used to re-suspend the centrifuged cell pellet (~30 mg). 
The suspension was incubated at room temperature for 20 min. TritonTM X-
100 solution [10 µL, 10% (v/v)] was added to the mixture which was incubated 
at room temperature for 30 min. To 30 µL of the lysed cells, was added TCA 
aq. [final concentration 10% (w/v)]. The sample was centrifuged at 13 400 r.p.m. 
for 10 min. The supernatant was removed and 30 µL of 1× SDS-PAGE sample 
loading buffer (Section 6.24) was added to the protein pellet. The protein 
sample was heated at 90 °C for 10 min with periodic vortex mixing. 
 
6.22.6 Large scale protein expression  
A single transformed Rosetta2 (DE3) colony (Section 6.22.2) was inoculated 
into 5 mL LB media supplemented with chloramphenicol and kanamycin 
sulfate. The culture was incubated at 28 °C and 220 r.p.m. for 6 h. Fresh LB 
media (12 mL) supplemented with the same antibiotics was added after 6 h 
and the incubation was continued under the same conditions overnight.  
 
The expression of wild-type, M184A, E237A and E237Q were induced using 
the overnight express™ autoinduction system 1. The starter culture produced 
above (15 mL) was inoculated into 500 mL of LB media supplemented with 
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chloramphenicol, kanamycin sulfate and was induced with 1× autoinduction 
system 1 (10 mL OnEx™ Solution 1, 25 mL OnEx Solution 2 and 0.5 mL OnEx 
Solution 3). The induced culture was incubated overnight at 28 °C and 220 
r.p.m. Cells were harvested by centrifugation (JA-10 rotor, 9000 r.p.m., 14 300 
g, 30 min) and stored at -80 °C. 
 
IPTG was used to induce the expression of the H122L and D152N mutants. 
The starter culture (15 mL) was inoculated into 500 mL of LB media 
supplemented with chloramphenicol and kanamycin sulfate and was 
incubated at 28 °C and 220 r.p.m. until OD600 reached ~1.0 (~6 h). IPTG (0.25 
mM) was added and the culture was further incubated under the same 
conditions overnight. Cells were harvested by centrifugation (JA-10 rotor, 9000 
r.p.m., 14 300g, 30 min) and stored at -80 °C. 
 
6.23 Large scale purification of AMACR 
Cell pellet was re-suspended in start buffer (30 mL; 20 mM NaH2PO4-NaOH, 
300 mM NaCl, 10 mM imidazole, pH 7.2) supplemented with 1 mM 
benzamidine-HCl, 1 mM PMSF and 250 U benzonase. The suspension was 
stirred gently at 4 °C until a homogenous mixture was produced. Cells were 
lysed with an One Shot cell disruption system (Constant System Ltd.). The 
lysate was centrifuged (JA-14 rotor, 5000 r.p.m., 3800 g, 5 min) to remove 
excessive bubbles. N-Lauroylsarcosine was added to the lysate dropwise to a 
final concentration of 1.5% (w/v) and stirred gently at 4 °C for 1 h. The treated 
mixture was centrifuged (JA-14 rotor, 10 000 r.p.m., 15 300 g, 10 min). The 
supernatant was passed through a 0.8 µm filter. The filtrate was loaded onto 
a metal-chelate chromatography column (HisTrap FF) which has been 
equilibrated with start buffer supplemented with 0.2 mM PMSF and 0.2 mM 
benzamidine-HCl. The protein was eluted with elution buffer (300 mM 
imidazole in start buffer, pH 7.2) supplemented with 0.2 mM PMSF and 0.2 
mM benzamidine-HCl. Each eluted fractions were analysed by SDS-PAGE 
(Section 6.24). Fractions containing the purified protein were pooled and 
dialysed into 10 mM NaH2PO4-NaOH, pH 7.4 (3× 600 mL). The dialysed 




6.24 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was carried out by the method of Laemmli.244 A 3% stacking gel 
and 10% running gel (to resolve 40 kDa protein) was transferred to a Mini 
Protean III™ apparatus (Bio-Rad) and 1× running buffer was added.  
 
Crude protein samples should be prepared by TCA precipitation (Section 
6.22.5) before they were analysed by SDS-PAGE. TCA precipitation was not 
required for purified protein samples eluted from a metal-chelate 
chromatography column. Protein sample loading buffer (5 µL, 5×) was added 
to the purified sample (20 µL) and was heated at 90 °C for 10 min with periodic 
vortex mixing. 
 
All protein samples with a final concentration of 1×sample loading buffer were 
loaded onto the SDS-PAGE gel. SeeBlue® Plus2 molecular weight markers 
were used as standard. The gel was electrophoresed at 170 volts for ~5 min 
to stack and run at 220 volts afterwards. The gel was removed from 
electrophoresis, washed with water and stained with 0.25% (w/v) Coomassie 
Brilliant Blue R-250 in 50% (v/v) ethanol and 10% (v/v) acetic acid for 10 min. 
The stained gel was washed with water and destained with 10% (v/v) ethanol 
and 5% (v/v) acetic acid. The de-staining with ethanol and acetic acid was 
repeated at least twice to observe protein bands. 
 
Stacking gel (3%): Tris-HCl (400 µL, 1.0 M, pH 6.8), ammonium persulfate 
[160 µL, 1% (w/v)], SDS [32 µL, 10% (w/v)], acrylamide/bis-acrylamide 
solution [37.5:1, 240 µL, 40% (w/v)], tetramethylethylenediamine (TEMED) (5 
µL) and H2O (2.4 mL). 
 
Running gel (10%): Tris-HCl (4.5 mL, 0.75 M, pH 8.8), ammonium persulfate 
[450 µL, 1% (w/v)], SDS [90 µL, 10% (w/v)], acrylamide/bis-acrylamide 
solution [37.5:1, 2.25 mL, 40% (w/v)], TEMED (10 µL) and H2O (1.8 mL). 




5× Protein sample loading buffer: Tris-HCl (2.5 mL, 0.625 M, pH 6.8), 10% 
(v/v) β-mercaptoethanol, 0.01% (w/v) bromophenol blue, 10% (w/v) SDS, 50% 
(w/v) glycerol and H2O. 
 
SeeBlue® Plus2 pre-stained standards: A ready-to use molecular weight 
marker consisting of 10 polypeptides that have been pre-stained (8 blue and 
2 coloured) in the range of 4-250 kDa.: myosin (250 kDa), phosphorylase (148 
kDa, orange), BSA (98 kDa); glutamic dehydrogenase (64 kDa), alcohol 
dehydrogenase (50 kDa), carbonic anhydrase (36 kDa), myoglobin red (22 
kDa, pink), lysozyme (16 kDa), aprotinin (6 kDa) and B-chain insulin (4 kDa). 
 
6.25 Enzyme quantification 
Protein concentrations were quantified using an UV-visible spectrophotometer 
(Helios γ, Unicam) at 280 nm. The concentrations were calculated from the 
extinction coefficients obtained from Protparam 
(http://web.expasy.org/protparam/), which was 35785  M-1 cm-1 for each His-
tag proteins. Proteins in molar concentration was converted to mg mL-1 using 
the molecular weights obtained from Protparam 
(http://web.expasy.org/protparam/): wild-type (47074.8 Da); H122L (47050.8 
Da); D152N (47073.8 Da); M184A (47014.6 Da); E237A (4716.7 Da) and 
E237Q (47073.8 Da). The concentration of wild-type AMACR was 3.48 mg 
mL-1 (73.72 µM), H122L was 1.08 mg mL-1 (22.96 µM), D152N was 0.98 mg 
mL-1 (20.66 µM), M184A was 2.59 mg mL-1 (55.13 µM), E237A was 5.06 mg 
mL-1 (107.56 µM) and E237Q was 3.64 mg mL-1 (77.36 µM). 
 
6.26 Protein characterisation 
6.26.1 Protein characterisation using dynamic light scattering (DLS) 
AMACR (final concentration 1 mg mL-1) in 10 mM NaH2PO4-NaOH buffer, pH 
7.4 was filtered through a 0.2 µm filter. Its size was measured using a DLS 
instrument (Zetasizer nano series instrument, Malvern) at 25 °C. Nine 
measurements were taken to determine the average size of the protein, given 
in number distribution. The readings were averaged and the standard 




6.26.2 Protein characterisation using circular dichroism (CD) 
The CD spectrum of the enzyme was obtained using a Chirascan™ CD 
Spectrometer (Applied Photophysics). The protein (~0.1 mg mL-1) in 10 mM 
NaH2PO4-NaOH buffer, pH 7.4 was placed in a quartz cuvette with a path 
length of 1 cm. The solution was scanned 10 times, and the ellipticity readings 
from 200 to 300 nm at 20 °C were recorded. The spectra were averaged and 
buffer-corrected. The molar ellipticity was calculated using the formula: [θ] = 
100xθ/(Cxl); where θ is the observed ellipticity (degree); C is the concentration 
of the enzyme (M), and l is the path length (cm).245 A denatured wild-type 
enzyme (10-min heating at 95 °C with periodic vortex mixing) was used as a 
negative control. 
 
6.26.3 Protein characterisation with 8-anilino-1-naphthalenesulfonic 
acid (ANS) as a fluorescent probe 
The protein (0.1 mg mL-1) in 50 mM NaH2PO4-NaOH buffer, pH 7.4 was 
incubated with ANS 148 (0.2 mM) in the dark for 20 min. The fluorescent 
spectra were recorded using a Perkin-Elmer Luminescence LS 50B 
Spectrometer with an excitation wavelength of 385 nm and a bandwidth of 5 
nm. The emission spectra were recorded between 420 and 580 nm, with a 
bandwidth of 10 nm. The spectra were corrected by subtracting the baseline 
(ANS 148 in buffer without protein). A denatured wild-type enzyme (10-min 
heating at 95 °C with periodic vortex mixing) was used as a negative control. 
 
6.27 The study of the ‘racemisation’ reaction on wild-type and mutant 
enzymes 
6.27.1 The deuterium wash-in assay  
R- 44 or S- 2-methyldecanoyl-CoA 38 was dissolved in 2H2O and used as a 
substrate for the assay. The vortex-mixed substrate (final concentration 100 
µM) was incubated with wild-type or mutant enzymes (final concentration 0.12 
mg mL-1, 2.55 µM) in 50 mM NaH2PO4-NaOH, pH 7.4 and 2H2O [77% (v/v)] in 
a final volume of 550 µL. The assay mixture was incubated at 30°C for 1 h 
before the enzyme was heat-inactivated at 60 °C for 30 min. 
R-2-Methyldecanoyl-CoA was used as a positive control and heat-inactivated 
AMACR was used as a negative control. 1H NMR (2H2O, 500.13 MHz) was 
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used to analyse α-proton exchange by quantifying the conversion of the 2-
methyl peak from a doublet to an unresolved single peak at ca. 1.00 ppm. 
 
6.27.2 Kinetic studies using the deuterium wash-in assay 
The R- 44 or S- 2-methyldecanoyl-CoA 38 substrate (50, 100, 200, 300, 400 
and 600 µM) was incubated with wild-type AMACR (5.0 µg mL-1, 0.11 µM for 
R-substrate and 2.5 µg mL-1, 0.05 µM for S-substrate) in 50 mM NaH2PO4-
NaOH, pH 7.4 and 2H2O [77% (v/v)] in a final volume of 550 µL. For M184A 
mutant, substrate concentrations were 30, 50, 75, 100, 200 and 250 µM and 
an enzyme concentration of 0.40 mg mL-1 (8.51 µM) was used. Each substrate 
concentration was measured in duplicate. The assay mixture was incubated 
at 30°C for 1 h before the enzyme was heat-inactivated at 60 °C for 30 min. 1H 
NMR (2H2O, 500.13 MHz) was used to analyse α-proton exchange by 
quantifying the conversion of the 2-methyl peak from a doublet to an 
unresolved single peak at ca. 1.00 ppm. Rates were corrected for non-
enzymatic exchange using data from heat-inactivated enzymes. Data was 
analysed with SigmaPlot 12.3 software, using the Direct Linear Plot,203, 204 
Michaelis-Menten Plot,246, 247 Lineweaver-Burk Plot248 and Residual Plot.205 
 
6.25 Fluoride elimination assay on wild-type and mutant enzymes  
6.28.1 Fluoride elimination assay using a single time point 
(2R,3R)-3-Fluoro-2-methyldecanoyl-CoA 114 substrate (final concentration 
100 µM) was incubated with wild-type or mutant enzymes (final concentration 
0.12 mg mL-1; 2.55 µM) in 50 mM NaH2PO4-NaOH, pH 7.4 and 2H2O [77% 
(v/v)] in a final volume of 550 µL. The mixture was incubated at 30 °C for 1 h 
before the enzyme was inactivated by heating at 60 °C for 30 min. Three 
replicates for each enzyme were performed. Rates were corrected for non-
enzymatic elimination using negative controls containing heat-inactivated 
enzyme. 1H NMR (2H2O, 500.13 MHz) was used to analyse the elimination of 
substrate by quantifying the conversion from the saturated 2-methyl group (a 





6.28.2 Time course of fluoride elimination over 16 h using 1H NMR 
(2R,3R)-3-Fluoro-2-methyldecanoyl-CoA 114 or (2S,3S)-3-fluoro-2-
methyldecanoyl-CoA 147 (final concentration 100 µM) was incubated with 
wild-type or mutant enzymes (final concentration 0.12 mg mL-1; 2.55 µM) in 50 
mM NaH2PO4-NaOH, pH 7.4 and 2H2O [77% (v/v)] in a final volume of 715 µL. 
The experiment was performed using a 500.13 MHz 1H NMR spectrometer at 
30 °C (or 20 °C for simultaneous measurements) and the reaction was 
followed for 15.5 h with a one-hour intervals. Rates were corrected for non-
enzymatic elimination using negative controls containing heat-inactivated 
enzyme.  
 
6.29 Multi-well colorimetric assay on wild-type and mutant enzymes 
6.29.1 Time-course multi-well colorimetric assay 
The 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate (100 µL; 
final concentration 40 µM) was incubated with the wild-type or mutant 
enzymes (50 µL; final concentration 0.035 mg mL-1, ~0.74 µM) in 50 mM 
NaH2PO4-NaOH, pH 7.4 in a 96-well plate. The reactions were performed in 
triplicate. Heat-inactivated wild-type AMACR was used as a negative control. 
The absorbance of the 200 µL reaction mixture was measured using FLUOstar 
Omega plate reader (BMG Labtech) at 30 °C. The absorbance was measured 
at 354 nm and 390 nm every 1 h for 10 h. The absorbance readings were 
averaged (using Microsoft Excel) and plotted against time. 
 
6.29.2 The kinetic study using multi-well colorimetric assay 
Wild-type and mutant enzymes were titrated to an appropriate concentration 
in order to determine their activity at the initial reaction rate (linear part of the 
curve). The final concentrations chosen were: wild-type (0.035 mg mL-1, 0.74 
µM); H122L (0.540 mg mL-1, 11.48 µM); D152N (0.326 mg mL-1, 6.93 µM); 
M184A (1.295 mg mL-1, 27.54 µM); E237A (2.528 mg mL-1, 53.77 µM) and 
E237Q (0.450 mg mL-1, 9.56 µM). The 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 135 substrate (50 µL; final concentrations 200, 100, 50, 
25, 12.5, 6.25, 3.125, 1.563 µM) was incubated with each enzyme (50 µL, 
concentration as above) in 50 mM NaH2PO4-NaOH, pH 7.4. The 100 µL 
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reaction mixture was run in a Greiner 96 half area plate and measured using 
FLUOstar Omega plate reader (BMG Labtech) at 30 °C. The absorbance was 
measured at 354 nm and 390 nm every 1 min for 8 min. Rates were 
determined by plotting absorbance against time in SigmaPlot 12.3. Rates in 
absorbance unit min-1 were converted to nmol min-1 mg-1 unit using path length 
of 0.509 cm (determined by the plate-reader) and an extinction coefficient of 
15.3 mM-1 cm-1.199 Data was analysed with SigmaPlot 12.3 software, using the 
Direct Linear Plot,203, 204 Michaelis-Menten Plot,246, 247 Lineweaver-Burk Plot248 
and Residual Plot.205 
 




Sodium (1.50 g, 65 mmol) was stirred with 2-methyl-1,3-propanediol (34.00 g, 
377 mmol) for 3 h at room temperature before 1-fluoro-2,4-dinitrobenzene  (8.4 
mL, 67 mmol) was added to the mixture. The mixture was stirred at 80 °C for 
2 h and left stirring at room temperature for 18 h. The mixture was filtered and 
the filtrate was washed with cold water, dried over MgSO4 and evaporated in 
vacuo to afford a dark brown oil. The crude product was purified by column 
chromatography [silica, gradient elution with 5:1, 3:1, 2:1 (v/v) PE:EtOAc] to 
give a yellow solid (3.60 g, 21.6%) that eluted in 2:1 (v/v) PE:EtOAc. Rf = 0.27 
[1:1 (v/v) PE:EtOAc]; melting point 46-48 °C; IR max/cm-1 3583 (OH), 1528 (N-
O) and 1343 (N-O); δH (400.04 MHz; CDCl3) 8.74 (1 H, d, J = 2.8 Hz, Ar 3’-H), 
8.41 (1 H, dd, J = 9.2, 2.8 Hz, Ar 5’-H), 7.26 (1 H, d, J = 9.2 Hz, Ar 6’-H), 4.29-
4.18 (2 H, m, 3-CH2), 3.74 (1 H, dd, J = 10.8, 4.8 Hz, 1-CHa), 3.68 (1 H, dd, J 
= 10.8, 6.8 Hz, 1-CHb), 2.35-2.19 (2 H, m, 2-CH and OH) and 1.07 (3 H, d, J 
= 6.8 Hz, 2-CH3); δC (100.59 MHz, CDCl3) 156.91 (Ar 1’-C), 139.83 (Ar 4’-C), 
138.36 (Ar 2’-C), 129.30 (Ar 5’-C), 121.97 (Ar 3’-C), 114.38 (Ar 6’-C), 72.82 (3-
CH2), 64.40 (1-CH2), 35.34 (2-CH) and 13.28 (2-CH3); ESI-MS m/z calcd. for 





acetate (racemic mixture of 153 and 154) 
 
(2R,S)-3-(2,4-dinitrophenoxy)-2-methylpropan-1-ol 150 (243 mg, 0.94 mmol) 
was dissolved in DCM (5 mL). DCC (1.0 M in DCM) (1.08 mL, 1.08 mmol) and 
DMAP (11 mg, 0.094 mmol) were added, and the resulting mixture was stirred 
until fully dissolved. (S)-2-Acetoxy-2-phenylacetic acid (202 mg, 1.04 mmol) 
was added to the solution and stirred overnight. The mixture was filtered 
through celite and the filtrate was concentrated in vacuo. The crude product 
was purified by column chromatography [silica, 4:1 (v/v) PE:EtOAc] to afford 
a yellow oil (392 mg, 96.7%) as a mixture of diastereomers. Attempts to 
separate the diastereomers were unsuccessful. Rf = 0.69 [1:1 (v/v) PE:EtOAc]; 
IR max/cm-1 1747 (C=O), 1530 (N-O) and 1343 (N-O); δH (400.04 MHz; CDCl3) 
8.71 (1 H, d, J = 2.8 Hz, Ar 3’’-H), 8.36, 8.35 (1 H, 2×dd overlapping , J = 9.2, 
2.8 Hz, Ar 5’’-H)*, 7.45-7.38 (2 H, m, Ar-H), 7.35-7.28 (3 H, m, Ar-H), 7.05, 
7.01 (1 H, 2×d, J = 9.2 Hz, Ar 6’’-H)*, 5.85, 5.84 (1 H, 2×s, 2-CH)*, 4.33-4.10 
(2 H, m, 1’-CH2), 4.40-3.87 (2 H, m, 3’-CH2), 2.43-2.28 (1 H, m, 2’-CH), 2.16, 
2.15 (3 H, 2×s, COCH3)* and 1.06, 1.03 (3 H, 2×d, J = 7.2 Hz, 2’-CH3)*; δC 
(100.59 MHz, CDCl3) 170.39, 170.35 (CH3C=O)*, 168.54, 168.51 (1-C=O)*, 
156.55, 156.351 (Ar 1’’-C)*, 139.88 (Ar 4’’-C), 138.43 (Ar 2’’-C), 133.52-121.83 
(Ar-C and Ar 5’’-C)*, 121.83, 121.82 (Ar 3’’-C)*, 114.33, 114.32 (Ar 6’’-C)*, 
74.40, 74.34 (2-CH)*, 71.21, 71.17 (3’-CH2)*, 65.70 (1’-CH2), 32.82, 32.74 (2’-
CH)*, 20.55 (COCH3) and 13.30, 13.24 (2’-CH3)*; ESI-MS m/z calcd. for 
[M+Na]+ C20H20N2NaO9: 455.1067, found 455.1074.*overlapping peaks or 









hept-1-yl)methanesulfonate (racemic mixture of 156 and 157) 
 
(1S)-10-camphorsulfonyl chloride (201 mg, 0.80 mmol) was added to a 
solution of (2R,S)-3-(2,4-dinitrophenoxy)-2-methylpropan-1-ol 150 (205 mg, 
0.80 mmol) in pyridine (2.0 mL) at -5°C and then stirred at 0 °C for 2 h. Water 
(50 mL) was added to quench the reaction and the mixture was extracted with 
DCM (3 x 30 mL). The organic layers were combined, dried over MgSO4 and 
evaporated in vacuo to afford a brown oil. The crude product was purified by 
column chromatography [silica, gradient elution with 4:1, 3:1, 2.5:1 (v/v) 
PE:EtOAc] to give a yellow solid (250 mg, 68.5%) that eluted in 2.5:1 (v/v) 
PE:EtOAc as a mixture of diastereomers. Attempts to separate the 
diastereomers were unsuccessful. Rf = 0.63 [1:1 (v/v) PE:EtOAc]; IR max/cm-
1 1745 (C=O), 1530 (N-O) and 1344 (N-O); δH (400.04 MHz; CDCl3) 8.77 (1 H, 
d, J = 2.8 Hz, Ar-H), 8.43 (1 H, dd, J = 9.2, 2.8 Hz, Ar-H), 7.24 (1 H, d, J = 9.2 
Hz, Ar-H), 4.50-4.10 (4 H, m, 2×OCH2), 3.55 (1 H, d, J = 15.2 Hz, OSOCHa), 
2.97 (1 H, dd, J = 15.2, 0.8 Hz, OSOCHb), 2.56-2.25 (3 H, m, CH and 2×bicyclic 
CH), 2.10 (1 H, t, J = 4.4 Hz, bicyclic CH), 2.07-1.95 (1 H, m, bicyclic CH), 1.86 
(1 H, dd, J = 18.4, 2.8 Hz, bicyclic CH), 1.65-1.58 (1 H, m, bicyclic CH), 1.46-
1.36 (1 H, m, bicyclic CH), 1.18, 1.17 (3 H, 2×d, J = 6.8 Hz, CH3)*, 1.06 (3 H, 
s, bicyclic CH3) and 0.84 (3 H, s, bicyclic CH3); δC (100.59 MHz, CDCl3) 214.37. 
214.32 (C=O)*, 156.57 (Ar-C), 140.11 (Ar-C), 138.52 (Ar-C), 129.27 (Ar-CH), 
122.03 (Ar-CH), 114.48 (Ar-CH), 70.82 (OCH2), 70.61 (OCH2), 57.83 (bicyclic 
C), 48.01, 48.00 (bicyclic C)*, 46.73 (OSOCH2), 42.62 (bicyclic CH), 42.40 
(bicyclic CH), 33.39, 33.36 (CH)*, 26.78 (bicyclic CH), 24.84 (bicyclic CH), 
19.58 (bicyclic CH3), 19.54 (bicyclic CH3) and 13.15 (CH3); ESI-MS m/z calcd. 
for [M+Na]+ C20H26N2NaO9S: 493.1257, found 493.1256.*Overlapping peaks 








Tetrabromomethane (470 mg, 1.41 mmol) was added to a solution of (2R,S)-
3-(2,4-dinitrophenoxy)-2-methylpropan-1-ol 150 (295 mg, 1.15 mmol) in DCM 
(3 mL). The mixture was stirred at room temperature for 5 min before dropwise 
addition of triphenylphosphine (333 mg, 1.27 mmol) in DCM (1 mL). The 
reaction mixture was stirred at room temperature for 1.5 h before it was 
quenched with saturated NaHCO3 aq. The mixture was extracted with DCM 
(3×30 mL) and the combined organic extracts were dried over MgSO4 and 
evaporated in vacuo to afford a brown oil. The crude product was purified by 
column chromatography [silica, 4:1 (v/v) PE:EtOAc] to afford an orange oil 
(303 mg, 82.6%). Rf = 0.65 [2:1 (v/v) PE:EtOAc]; IR max/cm-1 1529 (N-O) and 
1344 (N-O); δH (400.04 MHz; CDCl3) 8.73 (1 H, d, J = 2.8 Hz, Ar 3’-H), 8.42 (1 
H, dd, J = 9.2, 2.8 Hz, Ar 5’-H), 7.26 (1 H, d, J = 9.2 Hz, Ar 6’-H), 4.29-4.12 (2 
H, m, 1-CH2), 3.64 (1 H, dd, J = 10.0, 4.4 Hz, 3-CHa), 3.53 (1 H, dd, J = 10.0, 
6.4 Hz, 3-CHb), 2.50-2.33 (1 H, m, 2-CH) and 1.18 (3 H, d, J = 6.8 Hz, 2-CH3); 
δC (100.59 MHz, CDCl3) 156.52 (Ar 1’-C), 139.96 (Ar 4’-C), 138.37 (Ar 2’-C), 
129.23 (Ar 5’-C), 121.88 (Ar 3’-C), 114.42 (Ar 6’-C), 72.24 (1-CH2), 36.26 (3-
CH2), 34.71 (2-CH) and 15.44 (2-CH3). 
 
6.31 Attempts of enantioselective synthesis of 3-(2,4-dinitrophenoxy)-2-
methylpropanoyl-CoA 
Methyl (S)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanoate (163) 
 
Methyl (S)-3-hydroxy-2-methylpropionate (5.10 g, 43.17 mmol) was dissolved 
in DCM (40 mL) at 0° C. Imidazole (6.47 g, 95.04 mmol) and tert-
butyl(chloro)diphenylsilane (12.4 mL, 47.66 mmol) was added. The mixture 
was stirred at room temperature for 2.5 h before it was quenched with 
saturated NaHCO3 aq. (100 mL). It was extracted with DCM (3×100 mL) and 
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the organic extracts were combined, dried over MgSO4 and evaporated in 
vacuo to afford a colourless oil (15.21 g, 98.8%). The oil was found to be ˃ 95% 
pure (by 1H NMR) and was used in next step without purification. Rf = 0.58 
[10:1 (v/v) PE:EtOAc]; [α]D20 +20.5 (c 0.59 in CHCl3); lit. [α]D20 +16.9 (c 1.11 in 
CHCl3);249 IR max/cm-1 1744 (C=O); 1H and 13C NMR spectra of the product 
were consistent with previously reported data.249 δH (400.04 MHz; CDCl3) 
7.78-7.73 (4 H, m, Ar 2’-H), 7.52-7.38 (6 H, m, Ar 3’-H and Ar 4’-H), 3.93 (1 H, 
dd, J = 10.0, 7.2 Hz, 3-CHa), 3.83 (1 H, dd, J = 10.0, 6.0 Hz, 3-CHb), 3.74 (3 
H, s, OCH3), 2.87-2.76 (1 H, m, 2-CH), 1.24 (3 H, d, J = 7.2 Hz, 2-CH3) and 
1.14 (9 H, s, (CH3)3); δC (100.59 MHz, CDCl3) 175.24 (C=O), 135.42 (Ar 2’-C), 
133.31 (Ar 1’-C), 133.25 (Ar 1’-C), 129.56 (Ar 4’-C), 127.56 (Ar 3’-C), 65.78 (3-
CH2), 51.38 (OCH3), 42.24 (2-CH), 26.58 (C(CH3)3), 19.09 (SiC) and 13.31 (2-




Methyl (S)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanoate 163 (5.14 g, 
14.42 mmol) was dissolved in DCM (70 mL) at 0 °C. DIBAL (1.0 M in DCM, 32 
mL, 32.0 mmol) was added dropwise to the solution, and the resulting mixture 
was stirred at 0 °C for 4 h. Saturated aqueous Rochelle’s salt (58 mL) was 
added slowly at 0 °C and stirred at room temperature overnight until a bilayer 
formed. The layers were separated, and the aqueous layer was extracted with 
EtOAc (3×50 mL). The organic layers were combined, dried over MgSO4 and 
evaporated in vacuo to afford a colourless oil. The crude product was purified 
by column chromatography [silica, 12:1 (v/v) PE:EtOAc] to afford a colourless 
oil (3.23 g, 68.1%). Rf = 0.24 [10:1 (v/v) PE:EtOAc]; [α]D20 +8.7 (c 1.50 in 
CHCl3); lit. [α]D20 +6.1 (c 0.93 in CHCl3);243 1H and 13C NMR spectra and mass 
of the product were consistent with previously reported data.243 δH (400.04 
MHz; CDCl3) 7.76-7.68 (4 H, m, Ar 2’-H), 7.50-7.38 (6 H, m, Ar 3’-H and Ar 4’-
H), 3.76 (1 H, dd, J = 10.0, 4.4 Hz, 3-CHa), 3.73-3.68 (2 H, m, 1-CH2), 3.64 (1 
H, dd, J = 10.0, 7.6 Hz, 3-CHb), 2.70 (1 H, br s, OH), 2.10-1.97 (1 H, m, 2-CH), 
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1.11 (9 H, s, (CH3)3) and 0.88 (3 H, d, J = 6.8 Hz, 2-CH3); δC (100.59 MHz, 
CDCl3) 135.52 (Ar 2’-C), 135.50 (Ar 2’-C), 133.15 (Ar 1’-C), 129.71 (Ar 4’-C), 
127.69 (Ar 3’-C), 68.45 (3-CH2), 67.33 (1-CH2), 37.32 (2-CH), 26.79 ((CH3)3), 
19.09 (SiC) and 13.14 (2-CH3); ESI-MS m/z calcd. for [M+H]+ C20H29O2Si: 





A solution of (R)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropan-1-ol 164 (2.63 
g, 8.0 mmol) in DMF (40 mL) and a solution of 1-chloro-2,4-dinitrobenzene 
(3.24 g, 16.0 mmol) in DMF (18 mL) were added to NaH [60% (w/w) dispersion 
in mineral oil, 0.64 g, 16.0 mmol] in DMF (20 mL). The mixture was stirred at 
60 °C for 2 days and was then filtered. The crude product was purified by 
column chromatography [Teledyne Isco CombiFlash Rf, RediSep prepacked 
columns, linear gradient of 0-15% (v/v) EtOAC in PE] to afford a yellow oil (545 
mg, 13.8%). Rf = 0.50 [5:1 (v/v) PE:EtOAc]; [α]D20 +11.9 (c 1.09 in CHCl3); IR 
max/cm-1 1538 (N-O) and 1344 (N-O); δH (400.04 MHz; CDCl3) 8.77 (1 H, d, J 
= 2.8 Hz, Ar 3’’-H), 8.41 (1 H, dd, J = 9.2, 2.8 Hz, Ar 5’’-H), 7.67-7.60 (4 H, m, 
Ar 2’-H), 7.45-7.31 (6 H, m, Ar 3’-H and Ar 4’-H), 7.19 (1 H, d, J = 9.2 Hz, Ar 
6’’-H), 4.28 (1 H, dd, J = 8.8, 5.6 Hz, 3-CHa), 4.20 (1 H, dd, J = 8.8, 5.2 Hz, 3-
CHb), 3.83 (1 H, dd, J = 10.4, 4.4 Hz, 1-CHa), 3.73 (1 H, dd, J = 10.4, 7.2 Hz, 
1-CHb), 2.35-2.23 (1 H, m, 2-CH), 1.10 (3 H, d, J = 7.2 Hz, 2-CH3) and 1.07 (9 
H, s, (CH3)3); δC (100.59 MHz, CDCl3) 157.01 (Ar 1’’-C), 139.75 (Ar 4’’-C), 
138.52 (Ar 2’’-C), 135.44 (Ar 2’-C), 135.41 (Ar 2’-C), 133.34 (Ar 1’-C), 133.30 
(Ar 1’-C), 129.67 (Ar 4’-C), 129.04 (Ar 5’’-C), 127.62 (Ar 3’-C), 121.89 (Ar 3’’-
C), 114.24 (Ar 6’’-C), 71.98 (3-CH2), 64.53 (1-CH2), 35.66 (2-CH), 26.83 
((CH3)3), 19.24 (SiC) and 13.36 (2-CH3); ESI-MS m/z calcd. for [M+Na]+ 




Attempted synthesis of (2S)-3-(2,4-dinitrophenoxy)-2-methylpropan-1-ol 
(166) 
 
TBAF (1.0 M in THF, 2.0 mL, 2.00 mmol) was added to (R)-tert-butyl(3-(2,4-
dinitrophenoxy)-2-methylpropoxy)diphenylsilane 165 (482 mg, 0.98 mmol) in 
THF (10 mL) and was stirred at room temperature for 18 h. Brine (20 mL) was 
added to the reaction mixture and was extracted with chloroform (3×20 mL). 
The organic layers were combined, dried over MgSO4 and evaporated in 
vacuo to afford a brown oil. The crude product was purified by column 
chromatography [Teledyne Isco CombiFlash Rf, RediSep prepacked columns, 
linear gradient of 0-94% (v/v) EtOAC in PE] to give a yellow solid (145 mg, 
58.0%). Rf = 0.30 [1:1 (v/v) PE:EtOAc]; [α]D20 0.0 (c 2.71 in CHCl3); melting 
point 47-49 °C; IR max/cm-1 3404 (OH), 1526 (N-O) and 1352 (N-O); δH 
(400.04 MHz; CDCl3) 8.71 (1 H, d, J = 2.8 Hz, Ar 3’-H), 8.40 (1 H, dd, J = 9.2, 
2.8 Hz, Ar 5’-H), 7.25 (1 H, d, J = 9.2 Hz, Ar 6’-H), 4.27-4.17 (2 H, m, 3-CH2), 
3.72 (1 H, dd, J = 10.8, 4.8 Hz, 1-CHa), 3.65 (1 H, dd, J = 10.8, 7.2 Hz, 1-CHb), 
2.35-2.17 (2 H, m, 2-CH and OH) and 1.05 (3 H, d, J = 6.8 Hz, 2-CH3); δC 
(100.59 MHz, CDCl3) 156.93 (Ar 1’-C), 139.86 (Ar 4’-C), 138.43 (Ar 2’-C), 
129.26 (Ar 5’-C), 121.92 (Ar 3’-C), 114.42 (Ar 6’-C), 72.82 (3-CH2), 64.34 (1-
CH2), 35.39 (2-CH) and 13.28 (2-CH3); ESI-MS m/z calcd. for 
[M+Na]+C10H12N2NaO6: 279.0593, found 279.0573.  
 
Attempted synthesis of (2R)-3-(2,4-dinitrophenoxy)-2-methylpropanoic 
acid (167)  
 
3-(2,4-Dinitrophenoxy)-2-methylpropan-1-ol 166 (130 mg, 0.51 mmol) in 
acetone (2.6 mL) was added over 1.5 h to CrO3 (2.7 M in H2SO4 aq, 0.36 mL, 
0.97 mmol) at 0 °C, and the resulting mixture was stirred at room temperature 
for 2 h. iso-Propanol (0.10 mL) was added to the mixture and stirred for 10 min 
to quench the reaction. The mixture was filtered through celite and washed 
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with DCM. The DCM layer was washed with water (3×20 mL), dried over 
MgSO4 and evaporated in vacuo to afford a pale yellow oil. The crude product 
was purified by column chromatography [silica, gradient elution with 2:1, 1.5:1 
(v/v) PE:EtOAc, 20:1 (v/v) DCM:MeOH] to give a white solid (39 mg, 28.3%) 
that eluted in 20:1 (v/v) DCM:MeOH. Rf = 0.19 [1:2 (v/v) PE:EtOAc]; [α]D20 0.0 
(c 0.78 in CHCl3); melting point 134-137 °C; IR max/cm-1 3085 (OH), 1698 
(C=O), 1526 (N-O) and 1354 (N-O); δH (500.13 MHz; CDCl3) 8.74 (1 H, d, J = 
3.0 Hz, Ar 3’-H), 8.43 (1 H, dd, J = 9.0, 3.0 Hz, Ar 5’-H), 7.23 (1 H, d, J = 9.0 
Hz, Ar 6’-H), 6.58 (1 H, br s, OH), 4.43 (1 H, dd, J = 9.0, 6.5 Hz, 3-CHa), 4.31 
(1 H, dd, J = 9.0, 6.0 Hz, 3-CHb), 3.14-3.04 (1 H, m, 2-CH) and 1.40 (3 H, d, J 
= 7.0 Hz, 2-CH3); δC (125.76 MHz, CDCl3) 178.39 (C=O), 156.27 (Ar 1’-C), 
140.38 (Ar 4’-C), 138.85 (Ar 2’-C), 129.13 (Ar 5’-C), 121.95 (Ar 3’-C), 114.53 
(Ar 6’-C), 71.44 (3-CH2), 39.21 (2-CH) and 13.59 (2-CH3); ESI-MS m/z calcd. 
for [M-H]-C10H9N2O7: 269.0410, found 269.0398. 
 
Methyl (R)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanoate (171) 
 
Compound 171 was prepared from (R)-3-hydroxy-2-methylpropionate (5.10 g, 
43.17 mmol) using the same procedure as for compound 163 to give a 
colourless oil (15.39 g, 100.0%). The oil was found to be ˃95% pure (by 1H 
NMR) and was used in next step without purification. Rf = 0.60 [10:1 (v/v) 
PE:EtOAc]; [α]D20 -17.0 (c 1.00 in CHCl3); lit. [α]D20 -17.8 (c 1.16 in CHCl3);250 
1H and 13C NMR spectra of the product were consistent with previously 
reported data.250 δH (400.04 MHz; CDCl3) 7.74-7.66 (4 H, m, Ar 2’-H), 7.50-
7.36 (6 H, m, Ar 3’-H and Ar 4’-H), 3.88 (1 H, dd, J = 10.0, 6.8 Hz, 3-CHa), 3.78 
(1 H, dd, J = 10.0, 6.0 Hz, 3-CHb), 3.71 (3 H, s, OCH3), 2.81-2.71 (1 H, m, 2-
CH), 1.20 (3 H, d, J = 7.2 Hz, 2-CH3) and 1.08 (9 H, s, (CH3)3); δC (100.59 
MHz, CDCl3) 175.33 (C=O), 135.51 (Ar 2’-C), 133.47 (Ar 1’-C), 133.41 (Ar 1’-
C), 129.62 (Ar 4’-C), 127.62 (Ar 3’-C), 65.87 (3-CH2), 51.47 (OCH3), 42.34 (2-
CH), 26.67 (C(CH3)3), 19.18 (SiC) and 13.41 (2-CH3); ESI-MS m/z calcd. for 





Compound 172 was prepared from methyl (R)-3-((tert-butyldiphenylsilyl)oxy)-
2-methylpropanoate 171 (10.28 g, 28.83 mmol) using the same procedure as 
for compound 164 to give a colourless oil (3.90 g, 41.2%). Rf = 0.24 [10:1 (v/v) 
PE:EtOAc]; [α]D20 -5.1 (c 0.99 in CHCl3); lit. [α]D20 -4.3 (c 1.15 in CHCl3);251 1H 
and 13C NMR spectra of the product were consistent with previously reported 
data.251 δH (400.04 MHz; CDCl3) 7.76-7.70 (4 H, m, Ar 2’-H), 7.50-7.40 (6 H, 
m, Ar 3’-H and Ar 4’-H), 3.77 (1 H, dd, J = 10.0, 4.4 Hz, 3-CHa), 3.74-3.67 (2 
H, m, 1-CH2), 3.65 (1 H, dd, J = 10.0, 7.6 Hz, 3-CHb), 2.75 (1 H, br s, OH), 
2.10-1.97 (1 H, m, 2-CH), 1.12 (9 H, s, (CH3)3) and 0.88 (3 H, d, J = 6.8 Hz, 2-
CH3); δC (100.59 MHz, CDCl3) 135.51 (Ar 2’-C), 135.50 (Ar 2’-C), 133.15 (Ar 
1’-C), 129.70 (Ar 4’-C), 127.68 (Ar 3’-C), 68.39 (3-CH2), 67.25 (1-CH2), 37.33 
(2-CH), 26.78 ((CH3)3), 19.08 (SiC) and 13.14 (2-CH3); ESI-MS m/z calcd. for 
[M+H]+ C20H29O2Si: 329.1937, found 329.1918. 
 
Attempted synthesis of (2S)-tert-butyl(3-(2,4-dinitrophenoxy)-2-
methylpropoxy)diphenylsilane (173) 
 
Compound 173 was prepared from (S)-3-((tert-butyldiphenylsilyl)oxy)-2-
methylpropan-1-ol 172 (10.28 g, 28.83 mmol) using the same procedure as 
for compound 165 to give a yellow oil (816 mg, 14.9%). Rf = 0.53 [5:1 (v/v) 
PE:EtOAc]; [α]D20 0.0 (c 1.10 in CHCl3); IR max/cm-1 1539 (N-O) and 1344 (N-
O); δH (400.04 MHz; CDCl3) 8.76 (1 H, d, J = 2.8 Hz, Ar 3’’-H), 8.40 (1 H, dd, 
J = 9.2, 2.8 Hz, Ar 5’’-H), 7.67-7.60 (4 H, m, Ar 2’-H), 7.45-7.31 (6 H, m, Ar 3’-
H and Ar 4’-H), 7.19 (1 H, d, J = 9.2 Hz, Ar 6’’-H), 4.28 (1 H, dd, J = 8.8, 5.6 
Hz, 3-CHa), 4.21 (1 H, dd, J = 8.8, 5.6 Hz, 3-CHb), 3.84 (1 H, dd, J = 10.0, 4.4 
Hz, 1-CHa), 3.73 (1 H, dd, J = 10.4, 6.8 Hz, 1-CHb), 2.35-2.24 (1 H, m, 2-CH), 
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1.11 (3 H, d, J = 7.2 Hz, 2-CH3) and 1.07 (9 H, s, (CH3)3); δC (100.59 MHz, 
CDCl3) 157.00 (Ar 1’’-C), 139.70 (Ar 4’’-C), 138.46 (Ar 2’’-C), 135.40 (Ar 2’-C), 
135.38 (Ar 2’-C), 133.31 (Ar 1’-C), 133.27 (Ar 1’-C), 129.63 (Ar 4’-C), 129.02 
(Ar 5’’-C), 127.59 (Ar 3’-C), 121.84 (Ar 3’’-C), 114.25 (Ar 6’’-C), 71.95 (3-CH2), 
64.50 (1-CH2), 35.63 (2-CH), 26.79 ((CH3)3), 19.20 (SiC) and 13.33 (2-CH3); 
ESI-MS m/z calcd. for [M+Na]+ C26H30N2NaO6Si: 517.1771, found 517.1756. 
 
Attempted synthesis of (2R)-3-(2,4-dinitrophenoxy)-2-methylpropan-1-ol 
(174)  
 
Compound 174 was prepared from tert-butyl(3-(2,4-dinitrophenoxy)-2-
methylpropoxy)diphenylsilane 173 (800 mg, 1.62 mmol) using the same 
procedure as for compound 166 to give a yellow solid (267 mg, 64.3%). Rf = 
0.32 [1:1 (v/v) PE:EtOAc]; [α]D20 0.0 (c 0.48 in CHCl3); melting point 47-49 °C; 
IR max/cm-1 3282 (OH), 1524 (N-O) and 1356 (N-O); δH (400.04 MHz; CDCl3) 
8.73 (1 H, d, J = 2.8 Hz, Ar 3’-H), 8.40 (1 H, dd, J = 9.2, 2.8 Hz, Ar 5’-H), 7.25 
(1 H, d, J = 9.2 Hz, Ar 6’-H), 4.27-4.18 (2 H, m, 3-CH2), 3.74 (1 H, dd, J = 10.8, 
4.8 Hz, 1-CHa), 3.66 (1 H, dd, J = 10.8, 7.2 Hz, 1-CHb), 2.32-2.20 (1 H, m, 2-
CH), 2.14 (1 H, br s, OH) and 1.06 (3 H, d, J = 7.2 Hz, 2-CH3); δC (100.59 MHz, 
CDCl3) 156.93 (Ar 1’-C), 139.91 (Ar 4’-C), 138.48 (Ar 2’-C), 129.26 (Ar 5’-C), 
121.95 (Ar 3’-C), 114.41 (Ar 6’-C), 72.83 (3-CH2), 64.38 (1-CH2), 35.41 (2-CH) 
and 13.30 (2-CH3); ESI-MS m/z calcd. for [M+Na]+C10H12N2NaO6: 279.0593, 
found 279.0569. 
 
Attempted synthesis of (2S)-3-(2,4-dinitrophenoxy)-2-methylpropanoic 
acid (175)  
 
Compound 175 was prepared from 3-(2,4-dinitrophenoxy)-2-methylpropan-1-
ol 174 (247 mg, 0.97 mmol) using the same procedure as for compound 167 
to give a white solid (120 mg, 46.1%). Rf = 0.20 [1:2 (v/v) PE:EtOAc]; [α]D20 
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0.0 (c 0.44 in CHCl3); melting point 135-138 °C; IR max/cm-1 3084 (OH), 1698 
(C=O), 1527 (N-O) and 1354 (N-O); δH (500.13 MHz; CDCl3) 8.74 (1 H, d, J = 
2.8 Hz, Ar 3’-H), 8.43 (1 H, dd, J = 9.0, 2.8 Hz, Ar 5’-H), 7.60 (1 H, br s, OH), 
7.23 (1 H, d, J = 9.0 Hz, Ar 6’-H), 4.43 (1 H, dd, J = 9.0, 6.5 Hz, 3-CHa), 4.31 
(1 H, dd, J = 9.0, 6.0 Hz, 3-CHb), 3.17-3.03 (1 H, m, 2-CH) and 1.40 (3 H, d, J 
= 7.0 Hz, 2-CH3); δC (125.76 MHz, CDCl3) 178.59 (C=O), 156.26 (Ar 1’-C), 
140.40 (Ar 4’-C), 138.86 (Ar 2’-C), 129.12 (Ar 5’-C), 121.96 (Ar 3’-C), 114.52 
(Ar 6’-C), 71.42 (3-CH2), 39.22 (2-CH) and 13.58 (2-CH3); ESI-MS m/z calcd. 
for [M-H]-C10H9N2O7: 269.0410, found 269.0411. 
 




Compound 135 was prepared from 3-(2,4-dinitrophenoxy)-2-methylpropanoic 
acid (30 mg, 0.11 mmol) using the same procedure as for compound 49 to 
give a white solid (36 mg). δH (500.13 MHz, 2H2O) 8.74 (1 H, s, Ar-H), 8.59 (1 
H, s, adenosine CH), 8.42 (1 H, dd, J = 9.5, 2.5 Hz, Ar-H), 8.34 (1 H, s, 
adenosine CH), 7.26 (1 H, d, J = 9.5 Hz, Ar-H), 6.15-6.06 (1 H, m, adenosine 
CH), 4.45-4.35 (2 H, m, CH2), 4.18 (2 H, br s, adenosine CH2), 3.96 (1 H, s, 
CoA(OHCH)), 3.85-3.74 (1 H, m, CoA(OCHa)), 3.55-3.48 (1 H, m, 
CoA(OCHb)), 3.40-3.25 (5 H, m, 2×CoA(CH2) and CH3CH), 2.99 (2 H, t, J = 
6.5 Hz, CoA(SCH2)), 2.33 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.22 (3 H, d, J = 7.0 
Hz, CHCH3), 0.86 (3 H, s, CoA(CH3)) and 0.72 (3 H, s, CoA(CH3)); ESI-MS 




6.33 Derivatisation of 2-methyldecanoic acid with a chiral amine 
(2R)-2-methyl-N-[(1S)-1-phenylethyl]decanamide (179) 
 
The amide 179 was synthesised using the protocol previously described.1 
Oxalyl chloride (31 μL, 0.37 mmol) and DMF (2 μL) were added to (2R)-2-
methyldecanoic acid 184 (16 mg, 0.08 mmol) in DCM (1 mL). The mixture was 
stirred at room temperature for 45 min before the solvent was evaporated in 
vacuo. S-1-Phenylethylamine (31 μL, 0.24 mmol) was added to a solution of 
the crude intermediate in DCM (1 mL). The mixture was stirred at room 
temperature for 45 min before it was washed with HCl aq. (1.0 M, 3×3 mL). The 
organic layer was evaporated in vacuo to give a colourless gum (19 mg, 
79.8%). The 1H NMR spectrum of the product was consistent with previously 
reported data.1 δH (500.13 MHz; CDCl3) 7.37-7.21 (5 H, m, Ar-H), 5.61 (1 H, 
br d, J = 7.5 Hz, NH), 5.20-5.10 (1 H, m, NHCH), 2.19-2.08 (1 H, m, 2-H), 1.70-
1.58 (1 H, m, 3-Ha), 1.48 (3 H, d, J = 7.0 Hz, ArCHCH3), 1.40-1.33 (1 H, m, 3-
Hb), 1.33-1.20 (12 H, m, 6×CH2),  1.10 (3 H, d, J = 7.0 Hz, 2-CH3) and 0.87 (3 
H, t, J = 6.5 Hz, 10-H); δC (125.76 MHz, CDCl3) 175.59 (C=O), 143.29 (Ar-C), 
128.65 (Ar-C), 127.30 (Ar-C), 126.16 (Ar-C), 48.34 (NHCH), 41.71 (2-C), 34.40 
(3-C), 31.85 (CH2), 29.61(CH2), 29.49 (CH2),  29.25 (CH2), 27.50 (CH2),  22.65 




Compound 180 was prepared from (2S)-2-methyldecanoic acid 187 (15 mg, 
0.08 mmol) using the same procedure as for compound 179 and as described 
by Darley et al.1 to give a colourless gum (17 mg, 76.1%). The 1H NMR 
spectrum of the product was consistent with previously reported data.1 δH 
(500.13 MHz; CDCl3) 7.35-7.21 (5 H, m, Ar-H), 5.62 (1 H, br d, J = 7.5 Hz, 
NH), 5.19-5.08 (1 H, m, NHCH), 2.19-2.09 (1 H, m, 2-H), 1.65-1.55 (1 H, m, 3-
Ha), 1.48 (3 H, d, J = 7.0 Hz, ArCHCH3), 1.39-1.31 (1 H, m, 3-Hb), 1.31-1.17 
(12 H, m, 6×CH2),  1.13 (3 H, d, J = 7.0 Hz, 2-CH3) and 0.86 (3 H, t, J = 6.5 
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Hz, 10-H); δC (125.76 MHz, CDCl3) 175.69 (C=O), 143.37 (Ar-C), 128.60 (Ar-
C), 127.27 (Ar-C), 126.15 (Ar-C), 48.35 (NHCH), 41.67 (2-C), 34.43 (3-C), 
31.85 (CH2), 29.57(CH2), 29.47 (CH2),  29.20 (CH2), 27.44 (CH2),  22.63 (CH2),  
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8.2 Appendix 2: Kinetic analyses of wild-type AMACR with R-2-
methyldecanoyl-CoA 44 
 





























































Direct Linear Plot 
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Substrate concentration (µM) 
256 
 
Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)     126.0946        22.6514 73.8592 to 178.3300 
 Km (µM)    150.4509     67.7755           -5.8431 to 306.7449 
 
 Goodness of Fit 
 Degrees of Freedom     8 
 AICc 58.214 
 R² 0.797 
 Sum of Squares 1,241.410 
 Sy.x  12.457 
 Runs Test p Value 0.256 
 
 Data 
 Number of x values     5 
 Number of replicates 2 
 Total number of values    10 





























Kinetic parameters from Direct Linear Plot: Km = 95 µM, Vmax = 108 nmol min-
1 mg-1 
 
































Direct Linear Plot 
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Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)     108.1721        8.4738 88.1344 to 128.2098 
 Km (µM)    84.4831     21.6391 33.3136 to 135.6527 
 
 
 Goodness of Fit 
 Degrees of Freedom     7 
 AICc 46.238 
 R² 0.885 
 Sum of Squares 461.656 
 Sy.x   8.121 
 Runs Test p Value 0.130 
 
 Data 
 Number of x values     5 
 Number of replicates 2 
 Total number of values     9 














































Apparent Km (µM) 


























8.5 Appendix 5: Kinetic analyses of wild-type AMACR with 3-(2,4-




Kinetic parameters from Direct Linear Plot: Km = 27 µM, Vmax = 274 nmol min-
1 mg-1, manually obtained from Direct Linear Plot as the data does not 
converge 
 









































Direct linear plot 



















































































Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)     283.7937        9.8534          263.3584 to 304.2288 
 Km (µM)    32.8497         3.3143               25.9761 to 39.7233 
 
 Goodness of Fit 
 Degrees of Freedom    22 
 AICc 125.687 
 R² 0.982 
 Sum of Squares 3,344.267 
 Sy.x  12.329 
 Runs Test p Value 0.042 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 
   Number of missing value       0  
264 
 
8.6 Appendix 6: Kinetic analyses of the H122L mutant with 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate 
 
 
Kinetic parameters from Direct Linear Plot: Km = 1.3 µM, Vmax = 1.5 nmol min-
1 mg-1. 
 

















Direct Linear Plot 








































































































Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error       95% Conf. Interval 
 Vmax (nmol min-1 mg-1)       1.7078          0.4764     0.7171   to   2.6985 
 Km (µM)   2.5984          3.7145            -5.1265   to   10.3232 
 
 Goodness of Fit 
 Degrees of Freedom    21 
 AICc 20.533 
 R² 5.784e-2 
 Sum of Squares 40.954 
 Sy.x   1.396 
 Runs Test p Value 0.188 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    23 






8.7 Appendix 7: Kinetic analyses of the D152N mutant with 3-(2,4-




Kinetic parameters from Direct Linear Plot: Km = 6.8 µM, Vmax = 1.9 nmol min-
1 mg-1 
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Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)     1.8156            0.2184              1.3568   to   2.2745 
 Km (µM)                           6.6551            3.2337              -0.1388  to  13.4490 
 
Goodness of Fit 
 Degrees of Freedom    18 
 AICc -24.188 
 R² 0.528 
 Sum of Squares  4.101 
 Sy.x   0.477 
 Runs Test p Value 0.323 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    20 






8.8 Appendix 8: Kinetic analyses of the M184A mutant with 3-(2,4-




Kinetic parameters from Direct Linear Plot: Km = 1.3 µM, Vmax = 0.3 nmol min-
1 mg-1 
 







































) Direct Linear Plot 









































































Substrate concentration (µM) 
272 
 
Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)     0.2510           0.003488             0.1785  to  0.3236 
 Km (µM)                           1.0899            1.0740              -1.1436   to   3.3234 
 
Goodness of Fit 
 Degrees of Freedom    21 
 AICc -94.517 
 R² 8.926e-2 
 Sum of Squares  0.275 
 Sy.x   0.115 
 Runs Test p Value 0.419 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    23 

























8.9 Appendix 9: Kinetic analyses of the E237A mutant with 3-(2,4-
dinitrophenoxy)-2-methylpropanoyl-CoA 135 substrate 
 
 
Kinetic parameters from Direct Linear Plot: Km = 0.2 µM, Vmax = 1.8 nmol min-
1 mg-1 
 















Direct Linear Plot 









































































































Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error         95% Conf. Interval 
 Vmax (nmol min-1 mg-1)      1.8450             0.1098           1.6166   to   2.0734 
 Km (µM)       0.6633      0.3738           -0.1141  to   1.4407 
 
Goodness of Fit 
 Degrees of Freedom    21 
 AICc -38.137 
 R² 0.182 
 Sum of Squares  3.195 
 Sy.x   0.390 
 Runs Test p Value 0.264 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    23 

























8.10 Appendix 10: Kinetic analyses of the E237Q mutant with 3-(2,4-




Kinetic parameters from Direct Linear Plot: Km = 2.0 µM, Vmax = 2.7 nmol min-
1 mg-1 
 














Direct Linear Plot 





































































































Substrate concentration (µM) 
278 
 
Kinetic parameters (Michaelis-Menten Plot) 
                  Value          ±Std. Error        95% Conf. Interval 
 Vmax (nmol min-1 mg-1)       2.9701            0.1740       2.6094   to   3.3309 
 Km (µM)  2.1647 0.7059      0.7006    to   3.6287 
 
Goodness of Fit 
 Degrees of Freedom    22 
 AICc -24.058 
 R² 0.570 
 Sum of Squares  6.525 
 Sy.x   0.545 
 Runs Test p Value 0.501 
 
 Data 
 Number of x values     8 
 Number of replicates 3 
 Total number of values    24 

























8.11 Appendix 11: List of presentations at conferences 
Oral presentations 
 11 November 2015: 12th CR@B (Cancer Research at Bath) 
symposium, the University of Bath 
 9 June 2015: Faculty of science graduate school afternoon of research 
presentations, the University of Bath (2-minute lightning talk and poster) 
 29 April 2015: 26th Society of Chemical Industry (SCI) postgraduate 
symposium, the University of Sheffield 
 21 November 2014: RSC’s protein and peptide science group (PPSG) 
early stage researcher meeting 2014, London 
 3 June 2014: Faculty of science graduate school afternoon of research 
presentations, the University of Bath 
 8 May 2013: Postgraduate 6-month research symposium, the 
University of Bath 
 
Poster presentations 
 28 June-3 July 2015: European school of medicinal chemistry, Urbino, 
Italy 
 19 May 2015: RSC Chemical biology and bioorganic chemistry 
postgraduate symposium, the University of Bristol 
 22 April 2015: 11th CR@B symposium, the University of Bath 
 9 March 2015: SET for Britain, House of Commons, Westminster 
 18 February 2015: RSC organic division south-west regional meeting, 
the University of Reading 
 25-29 January 2015: 12th Winter conference on medicinal and 
bioorganic chemistry, Colorado, the United States of America 
 21 November 2014: RSC’s PPSG early stage researcher meeting 
2014, London 
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